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Polycystic ovary syndrome (PCOS) is a common and complex endocrine condition with 
reproductive and metabolic complications, affecting up to 10% of reproductive-age women. 
Hyperandrogenemia, ovulatory dysfunction, and luteinising hormone hypersecretion are 
characteristic traits of PCOS however, it seems that the most concerning long-term key issues 
are metabolic problems associated with the syndrome, such as hyperinsulinemia, insulin 
resistance, obesity, dyslipidaemia and non-alcoholic liver disease.  
Despite the numerous studies on PCOS, its origin and pathophysiology are still not fully 
understood. However, there is increasing evidence that the adult PCOS phenotype is 
programmed in fetal life by androgen excess. Exposure to increased levels of testosterone in 
utero in rodents, sheep and monkeys result in adult reproductive and metabolic pathologies 
that parallel those seen in PCOS women. Since hyperandrogenemia is a hallmark of PCOS 
and daughters of PCOS mothers have elevated levels of androgens at birth, it is likely that 
prenatal androgenisation during early life predispose to the future development of PCOS.  
Animal models of PCOS provide an opportunity to examine the developmental aetiology and 
molecular mechanisms underlying the pathogenesis of this condition. Over last 10 years our 
lab has successfully utilised a well-established ovine model of PCOS, where pregnant ewes 
were treated with testosterone propionate (TP) through mid-gestation. From this model, we 
had a large sample bank of fixed and frozen tissues from the fetal, lamb and adolescent 
prenatally androgenised animals that allowed to carry a broad range of experiments. In 
addition, a new cohort of prenatally androgenised adult sheep enabled additional in vivo 
analysis. Past research documented that prenatal androgenisation result in hyperinsulinemia 
with altered pancreas structure and function, and early fatty liver without difference in body 
weight in adolescent sheep. This thesis examines the effects and consequences of increased in 
utero androgen exposure on metabolic dysregulation in adolescent and adult female sheep. 
During puberty, but not fetal or early life, there was decreased adipogenesis in subcutaneous 
adipose tissue (SAT), but not visceral adipose tissue (VAT), accompanied by decreased 
circulating concentrations of fibroblast growth factor 21 (FGF21), leptin and adiponectin, and 
increased concentrations of fasting free fatty acids (FFA) in prenatally androgenised sheep. 
This was countered by upregulated expression of FFA transporters in liver. As adults, TP-
exposed animals had increased body weight, elevated fasting insulin and FFA concentrations 
but normal FGF21, leptin and adiponectin levels.  Histological analysis revealed that adult TP-
exposed animals had SAT hypertrophy, which was associated with increased expression of 
 
iv 
inflammatory markers and correlated with increased fasting FFA. Therefore, it is likely that 
impaired preadipocyte differentiation in SAT during adolescence resulted in hypertrophy and 
inflammation of adult SAT. This consequently lowered capacity of SAT to safely store fat and 
potentially explains metabolic perturbations observed in PCOS-like female sheep.  
To further investigate potential causes of obesity in adult PCOS-like sheep postprandial 
thermogenesis (PPT), an important constituent of energy expenditure, was measured through 
implantation of datalogger thermometers into interscapular adipose tissue. Adult prenatally 
androgenised sheep had decreased amplitude of PPT, without difference in basal body 
temperature, despite receiving the same caloric intake, and independent of obesity. These 
findings indicate that adult PCOS-like sheep have reduced capacity for energy expenditure, 
which is mirrored in women with PCOS. This reduced capacity for postprandial thermogenesis 
was correlated with hyperinsulinemia decreased noradrenaline levels and reduced thermogenic 
potential of brown and/or beige adipose tissue. This suggests that women with PCOS might 
be prenatally programmed to become obese. 
In summary, findings documented in this thesis provide better understanding into the 
pathophysiology of PCOS from puberty to adulthood and give opportunities for early clinical 





Polycystic ovary syndrome (PCOS) is a common hormonal disorder with reproductive and 
metabolic complications, affecting up to 10% of reproductive-age women. The characteristic 
traits of the syndrome are increased level of male hormones, known as androgens, irregular 
menstruation, ovaries containing many small follicles, and difficulty getting pregnant as a 
result of irregular ovulation. However, it seems that the most concerning long-term key issues 
are metabolic problems associated with the syndrome, such as insensitivity to the action of 
insulin, resulting in compensatory increased production of insulin by pancreas, potentially 
resulting in type 2 diabetes, obesity, abnormal amount of lipids in the blood, and accumulation 
of fat in the liver and around internal organs, which might lead to further health complications.  
Despite the numerous studies on PCOS the exact cause of this syndrome is unknown. PCOS 
often runs in families and there is increasing evidence that this condition might result from 
exposure of the female fetus to increased levels of androgens during pregnancy. Studies 
demonstrated that exposure of experimental animals to increased levels of androgens in fetal 
life result in the same reproductive and metabolic problems in adult life, as in women with 
PCOS.  
Therefore, animal models of PCOS provide an opportunity to examine the cause and 
mechanisms underlying the development of this syndrome. Over past years our lab has 
successfully utilised a sheep model of PCOS, where pregnant sheep were treated with 
androgen through mid-pregnancy. Previous research by the members of our lab documented 
that females that were prenatally exposed to increased levels of androgens in fetal life had 
increased levels of insulin, and presence of fat deposits in the liver in adolescence. This thesis 
examines the effects and consequences of increased prenatal androgen exposure on metabolic 
dysregulation in adolescent and adult female sheep. 
Results demonstrated that in adolescence, sheep that were exposed to increased levels of 
androgens in fetal life, had decreased development of fat cells in subcutaneous adipose tissue 
(SAT), a fat tissue located beneath the skin. This led to decreased levels of beneficial proteins 
normally secreted from this fat tissue, leptin and adiponectin. Leptin and adiponectin regulate 
appetite and insulin sensitivity, thus decreased levels of those proteins could result in future 
insulin insensitivity and weigh gain. In addition, decreased development of fat cells in SAT 
indicated decreased capacity of that tissue to safely store any excess fat, which was reflected 
in increased levels of lipids in a blood. Further, this was countered by upregulated expression 
 
vi 
of proteins in the liver that transport fat into that organ, potentially explaining presence of fat 
deposits in that tissue, as previously detailed.  
As adults, androgen-exposed animals had increased body weight, elevated insulin and lipid 
concentration in blood however, normal leptin and adiponectin levels. Analysis of cells from 
SAT revealed that PCOS-like animals had significantly enlarged fat cells within this fat depot, 
which was associated with increased level of inflammatory markers. Therefore, it is likely that 
reduced adipocyte development during adolescence resulted in fat cell enlargement and 
inflammation of adult SAT.  
To further investigate potential causes of obesity in adult PCOS-like sheep postprandial 
thermogenesis, a heat production due to metabolism after a meal, was measured through 
implantation of datalogger thermometers into adipose tissue. Adult sheep prenatally exposed 
to increased levels of androgens had decreased maximal body temperature after a meal, 
without difference in basal body temperature, despite receiving the same caloric intake, and 
independent of obesity. These findings indicate that adult PCOS-like sheep have reduced 
ability to burn energy, which was also documented in women with PCOS. In addition, this 
reduced ability to burn energy was associated with increased insulin levels and reduced 
thermogenic potential of brown and/or beige adipose tissue, the tissue that is specialized in 
heat production and excess energy expenditure. This suggests that women with PCOS might 
be prenatally programmed to become obese. 
In summary, findings documented in this thesis provide better understanding into the 
mechanisms underlying PCOS from puberty to adulthood and give opportunities for early 
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1.1 Female reproductive function 
1.1.1 Mammalian reproductive development 
In mammals, sexual dimorphism has a genetic origin. The presence or absence of the Y 
chromosome, or precisely the sex-determining region of Y (SRY) gene, determines the 
genotypic sex (1,2). However, the development of the phenotype depends largely on endocrine 
induced differentiation. This hormonally induced phenotype is then a major determinant for 
further development of the individual and its capacity for reproduction, but also for sex-related 
differences in health and disease (3-5). Therefore, presence or absence of specific sex 
hormones early in fetal life, affects sexual differentiation in a permanent manner (5). 
The early development of the gonads is common in both sexes, and begins as paired 
thickenings of the coelomic epithelium that arise within the intermediate mesoderm, on either 
side of the central dorsal aorta (6). These genital ridge primordia develop at approximately the 
fifth week of gestation in humans, giving rise to bipotential gonads (6). This if followed by 
primordial germ cell (PGC) migration from the yolk sac into genital ridge primordia, which is 
completed by sixth week of gestation (6). Subsequently, PGCs start to cumulate and 
proliferate, maintaining their bipotentiality until differentiation (7,8). Correspondingly, a 
second group of cells, derived from the columnar coelomic epithelium, migrate in as columns 
forming primitive sex cords (9). The further development of these sex cords depends on 
presence, or absence, of SRY gene.  
In male fetuses, expression of the SRY gene in the somatic cells, which are precursors of 
Sertoli cells, initiates testicular cord formation, and enclosure of PGCs within the cords (9). In 
female fetuses, due to absence of SRY gene, and in the presence of genes such as wingless-
type mouse mammary tumour virus integration site family, member 4 (WNT4), follistatin 
(FST) and forkhead box L2 (FOXL2), sex cords condense cortically around PGCs (oogonia), 
initiating the formation of primordial ovarian follicles (10,11). Thus, in primordial ovarian 
follicles, the granulosa cells originate from condensing cord cells, while oogonia give rise to 
oocytes (11). From this point onwards, the gonads themselves direct sexual differentiation. In 
contrast to male gonads, which actively secrete androgens and anti-Müllerian hormone 
(AMH), endocrine activity of the ovaries is not essential for sexual differentiation (12). In 
female fetuses, in the absence of androgens and AMH, the Wolffian ducts regress 
spontaneously, whereas the Müllerian ducts persist, giving rise to oviducts, uterus, cervix and 
upper vagina (13). Furthermore, the lack of androgens in female fetuses permits formation of 
female external genitalia from, common for both sexes, bipotential primordia of the external 
Chapter 1 Literature Review 
3 
genitalia. In males however, androgens maintain the Wolffian ducts, which consequently 
develop into epididymis, vas deferens and seminal vesicles, whereas AMH provokes 
regression of Müllerian ducts (14). In addition, the presence of androgens in male fetuses 
results in the formation of male external genitalia.  Therefore, the differentiation process is 
highly androgen-dependent. The exposure of female fetuses to high levels of androgen in utero 
causes masculinisation of external genitalia. In congenital adrenal hyperplasia (CAH), due to 
congenital defect in corticosteroid synthesising enzymes, the fetal adrenal glands secrete large 
quantities of androgens, which in turn, stimulate development of male external genitalia in 
females (15,16). Moreover, some female patients with CAH demonstrate behavioural traits 
typically associated with male behaviour (15,16).  
1.1.2 The hypothalamic-pituitary-ovarian axis 
The reproductive cycle is regulated by the hypothalamic-pituitary-ovarian (HPO) axis. 
Signalling is initiated in the hypothalamus, a small region at the base of the brain. 
Hypothalamus comprises of numerous nuclei that control neuroendocrine, behavioural and 
autonomic functions. The pituitary gland is located just below hypothalamus, and consists of 
two main lobes, the anterior lobe, connected to hypothalamus through portal capillary system, 
and posterior lobe, connected with the hypothalamus through magnocellular neurons (17). The 
anterior lobe of the pituitary consists of various cell types, including the gonadotrophs, 
basophilic cells that synthesise, store and secrete the gonadotrophins, luteinising hormone 
(LH) and follicle stimulating hormone (FSH), controlled upon pulsatile stimulation of 
hypothalamic gonadotrophin-releasing hormone (GnRH) that binds to GnRH receptors 
(GnRHR) located on the gonadotroph (17). Therefore, the changes in FSH and LH secretion 
could be attributed to alterations in amplitude and frequency of the GnRH pulses or by 
modulating the actual response of gonadotrophs to GnRH pulses. Conversely, 
kisppeptin/neurokinin B/dynorphin pathway (KNDy neurons) play a key role in regulating 
GnRH secretion (18,19). Kisspeptin, through binding to kisspeptin receptors, expressed on 
GnRH neurons, directly controls GnRH pulsatility. Kisspeptin neurones, which are located in 
close proximity to GnRH neurons, also co-express neurokinin B and dynorphin, which, in turn, 
via neurokinin B receptor and kappa opioid peptide receptor, regulate pulsatile kisspeptin 
secretion, with neurokinin B being stimulatory and dynorphin inhibitory (19). There is also a 
dynamic relationship between ovary and pituitary. Estrogen and progesterone secreted from 
the ovary through the negative feedback mechanism control GnRH, FSH and LH secretion 
through action on both hypothalamus and anterior pituitary. It has been shown that kisspeptin 
neurons express both estrogen and progesterone receptors and that kisspeptin, neurokinin B 
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and dynorphin activity, and subsequently GnRH and LH secretion, is modulated by sex 
steroids (19). In addition, significant elevation in the plasma concentrations of estrogen during 
the late follicular phase of the ovarian cycle, through positive feedback mechanism, can induce 
LH and FSH secretion. There is evidence suggesting that kisspeptin might be also involved in 
mediating the positive estrogenic feedback (20). 
1.1.3 Folliculogenesis 
Throughout fetal life, ovaries grow slowly and assume a pelvic location, while ovarian germ 
cells undergo major changes. Formation of follicles starts shortly after sexual differentiation 
(21).  At approximately day 45 in the ovine fetus and 7 to 9 weeks of gestation in the human, 
mitotically active oogonia interact with adjacent mesonephric cells to form the ovigerous 
cords, the oogonia-pregranulosa cell complexes surrounded by a basal lamina (21). During 
mid-gestation, the maximum number of germ cells is achieved, with approximately 6 million 
present in the fetal human ovary (22). After day 75 of gestation in sheep and 20 weeks of 
gestation in humans first follicles start to form through breakdown of germ cell clusters and 
subsequent interaction with pre-granulosa cells, which form a single layer around each oocyte 
(23). Oogonial germ cells enter first meiotic division, and arrest their progress at first meiotic 
prophase, thereby becoming primary oocytes (23). The majority of germ cells undergo atresia 
before birth (11), with an average of 1 million follicles present at birth in the human ovary 
however, at the time of puberty this number may be reduced further (22,24). Throughout 
reproductive life there is a further depletion of number of follicles and, as the result of ovarian 
follicle exhaustion, menopause occurs on average at about 51 years of age (24). An existing 
dogma states, that mammalian females are born with a total pool of non-renewing primordial 
follicles that they will have throughout reproductive life span. However, an existence of 
mitotically active germ cells in human and mice ovaries has been reported (25,26).  
After a primordial follicle is activated it growths through stages of development, primary 
(preantral), secondary (antral), and tertiary (preovulatory). Throughout the neonatal and pre-
pubertal life follicles can grow as far as the early antral phase however, only after puberty 
follicles can be activated to progress to the large antral, dominant and ovulatory stage. It has 
been estimated that the entire growth phase of a follicle from primordial to antral stage is much 
greater than 220 days or eight ovarian cycles (24,27). 
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In the preantral phase of follicular growth, the follicle increases in size, due to growth of oocyte 
and proliferation of granulosa cells, which become several layers thick. In addition, zona 
pellucida is formed, a layer of glycoproteins, which separates the oocyte from granulosa cells, 
and condensation of ovarian cells on the outer membrana propria will eventually become theca 
cells (24,27). 
In the antral phase, granulosa and theca cells further proliferate and increase in size and a 
follicular antrum is formed. This is a collection of fluid within the follicle mainly secreted 
from growing granulosa cells. Theca cells divide into two layers, the outer theca externa and 
the inner theca interna. As follicular antrum expands, the oocyte become suspended in 
follicular fluid and is left surrounded only by the cumulus oophorus, a dense mass of granulosa 
cells encompassing the oocyte (28).  
Whereas follicular development from primordial to early antral stage is independent of 
gonadotrophic regulation, further progression requires the action of FSH and LH from the 
anterior pituitary (24). In the absence of external signals from the pituitary, atresia of antral 
follicles occurs (29). FSH binds to FSH receptors, distributed in granulosa cells, while LH 
binds to LH receptors located on theca interna cells (30). Under the stimulation of LH, the 
theca interna cells synthesise androgens, mainly androstenedione, although testosterone is also 
produced to lesser extent, which are then aromatised into estrogen in granulosa cells, under 
the control of FSH (30). Fig. 1.1 summarises the two cell, two gonadotrophin, model of 
follicular steroidogenesis. In addition, androgens from theca cells, stimulate aromatase 
activity, and together with FSH stimulate the proliferation of granulosa cells, therefore 
increasing the thecal output of androgens, resulting in a matched increase in estrogens, which 
further stimulates the proliferation of granulosa cells (31). Finally, estrogen, together with 
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Figure 1.1. The two cell, two gonadotrophin, model. The image illustrates mechanism of estradiol 
production in the preovulatory follicle.  
Adapted from Catalano et al. (32) 
1.1.4 Female puberty 
Puberty, a process of transition, involves physiological, morphological and behavioural 
changes that lead to gain of reproductive capability.  In pre-pubertal girls, the HPO axis is 
suppressed, the ovary is quiescent, and consequently circulating gonadototrophin and sex 
hormones are at low levels (33). Approximately 2-4 years before puberty, adrenarche and 
gonadarche take place, an increase in sex steroids from the adrenal glands and the gonads 
respectively (33). Puberty is triggered by the activation of hypothalamic GnRH secretion, 
which is associated with increased pulse frequency of kisspeptin and sensitization of GnRH 
neurons to kisspeptin. This subsequently results in increase in the magnitude and frequency of 
nocturnal LH pulses and is associated with a growth spurt, and development of secondary 
sexual characteristics, such as maturation of the genitalia, development of breast tissue and the 
growth of pubic and axillary hair (18,33). Menarche follows 1-2 years later and is correlated 
with body fat mass. Observational studies reported that a threshold weight of 46 kg, or more 
precisely 22% total body fat content, is required to initiate menarche (34,35). An adipokine, 
leptin, has been indicated as a permissive signal in the progression into puberty and the 
maintenance of normal hypothalamic-pituitary-gonadal function thereafter (36). That is why, 
the increasing prevalence of obesity in children was highlighted as a potential cause of growing 
incidence of precocious puberty in children. 
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1.1.5 Human ovarian cycle 
The human ovarian cycle lasts on average 28 days, although it can be highly variable, ranging 
from 25 to 30 days, and begins with the first day of menstruation (17). Menstruation, the 
external measure of cyclicity in women, ensues at the end of the luteal and the beginning of 
the follicular phase, and on average, lasts for 3–6 days (37). The ovarian cycle is composed of 
two distinct phases, which are separated by ovulation on day 14 of the cycle, the follicular 
phase and the luteal phase, each usually lasting 14 days (Fig 1.2). Irregularity in cycle length 
is mostly attributed to variability in the duration of the follicular phase of the cycle (38). The 
ovarian cycle is tightly controlled by endocrine, autocrine and paracrine factors regulating 
follicular development, ovulation, luteinisation and luteolysis. 
1.1.5.1 The follicular phase 
In regularly cycling women during the luteal–follicular transition, on average four days before 
menstruation, levels of estrogen and progesterone begin to decline resulting in an increase in 
FSH and LH (39), due to decreased negative feedback. This rise in FSH resumes growth of 
multiple antral follicles, accompanied by an increase in ovarian estrogen and androgen 
secretion. This, in turn, gradually re-establishes a negative feedback, resulting in temporary 
decrease of FSH level and steady levels of LH. The selection of the dominant follicle, by 
upregulating LH-receptor and downregulating FSH-receptor expression on its granulosa cells, 
results in a further estrogen surge (40). This turn, through a positive feedback effect, triggers 
a rapid increase in LH and FSH, which consequently initiates ovulation (38). The resulting 
follicular collapse and formation of corpus luteum, means levels of estrogen decrease again, 
together with FSH and LH, whereas levels of progesterone increase (24,38).  
1.1.5.2 The luteal phase 
The luteal phase of the cycle is characterised by rising concentrations of plasma progesterone 
and estrogen, which peak 6-8 days after ovulation, which through negative feedback, and other 
luteal peptide hormones such as inhibin A, suppresses circulating gonadotrophins (17). The 
low level of FSH suppresses the growth of antral follicles. The increasing estrogen from the 
corpus luteum does not induce an LH surge because of the increased levels of progesterone at 
the same time (38). At the end of luteal phase, if conception has not occurred, levels of 
progesterone and estrogen decline, during luteolysis, decreasing in negative feedback, and 
FSH and LH start to rise again, thereby resuming antral growth and initiating another cycle. 
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Figure 1.2. The hormonal profile over the human ovarian cycle. The ovarian cycle is composed of two 
distinct phases, which are separated by ovulation on day 14 of the cycle, the follicular phase and the 
luteal phase, each usually lasting 14 days. 
Adapted from Johnson 2007 (17) 
 
1.1.6 Ovarian steroidogenesis 
In adult females, the ovary is a major source of steroid hormones. During the follicular phase 
of the ovulatory cycle, ovary predominantly secretes estrogens and androgens, whereas during 
the luteal phase mainly progestogens, with additional estrogens and androgens. The 
steroidogenic pathway begins with transport of free cytoplasmic cholesterol across the 
mitochondrial membrane by steroidogenic acute regulatory protein (StAR), encoded by STAR 
gene (17). Then, two main classes of enzymes, the cytochrome (CYP) P450 enzymes and the 
hydroxysteroid dehydrogenases (HSD), modulate the consecutive conversion of cholesterol 
(41). The conversion of cholesterol to pregnenolone marks the first step in the formation of 
the major steroid hormones is rate-limiting and is controlled by  cytochrome P450 side chain 
cleavage enzyme (P450scc), encoded by  CYP11A1 gene (42). Pregnenolone is then 
transported to smooth endoplasmic reticulum. Pregnenolone can be converted to progesterone 
through action of 3β-HSD type 2 (3β-HSD2), encoded by HSD3B2 gene. Biosynthesis of 
androgens is controlled by an additional critical cytochrome enzyme: 17α-hydroxylase, 
encoded by  CYP17A1 that regulates two consecutive catalytic reactions, leading to the 
formation of androgenic precursors, dehydroepiandrosterone (DHEA) and androstenedione 
(A4) (42). DHEA is then converted to A4 by the action of 3β-HSD2, whereas 17β-HSD type 
3 (17β-HSD3), encoded by HSD17B3 gene, converts A4 to testosterone (T) (43). Biosynthesis 
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of estrogens requires action of aromatase, encoded by CYP19A1 gene, which converts 
androgenic substrates, A4 into estrone, and T into estradiol (42). In addition, estrone can be 
converted to estradiol by the action of 17β-HSD type 1 (17β-HSD1), encoded by HSD17B1 
gene. 17α-hydroxylase is found in theca cells, while aromatase is located in granulosa cells, 
however, both theca and preovulatory granulosa cells express StAR, P450scc, and 3β-HSD2 
(42). This indicates that both, theca and preovulatory granulosa cells, are therefore capable of 
making pregnenolone and progesterone from cholesterol. However, in follicular phase, there 
is no direct blood supply to granulosa cells therefore, these cells have limited access to 
cholesterol, which result in low synthesis level of progestagens. In contrast, in the luteal phase, 
due to formation of the corpus luteum, these cells have an abundant blood supply and access 
to cholesterol, and synthesise large amounts of progesterone (41). Figure 1.3 summarises 
ovarian and adrenal steroidogenesis. 
1.1.7 Adrenal steroidogenesis 
The adrenal glands are another source of steroid hormones, and are composed of the inner 
medullary region, which controls the secretion of catecholamines, adrenaline and 
noradrenaline, and the outer cortical region, cortex, secreting corticosteroids, 
mineralocorticoids and sex steroids. The cortex consists of three zones, responsible for the 
secretion of hormones. Androgens, DHEA, DHEA sulfate (DHEAS), A4 and T are synthesised 
in the zona reticularis; glucocorticoids, cortisol and corticosterone, in the zona fasciculatis; the 
mineralocorticoid, aldosterone, is synthetised in the zona glomerulosa (42). Androgens are 
synthesised, like in ovary from conversion of cholesterol by the action of P450scc, 17α-
hydroxylase, 3β-HSD2, and 17β-HSD3. The conversion of the androgen DHEA into DHEAS 
is catalysed by DHEA sulfotransferase 2A1 (DHEA-ST), encoded by SULT2A1 gene (17). 
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Figure 1.3 Ovarian and adrenal steroidogenesis. In black/grey common pathway; in blue adrenal 
specific; in red ovarian specific.  
 
1.1.8 Ovarian and adrenal androgens in adult females 
Androgens are 19 carbon steroids that are synthesised from cholesterol as the substrate or via 
conversion from other androgens or precursor steroids. Quantitatively, women secrete more 
androgens than estrogens (43). The main circulating androgens in adult females, in descending 
order of concentration in a serum, are DHEAS (1–4 µg/mL), DHEA (1-10 ng/ml), A4 (0.5-
2ng/ml), T (0.2-0.7ng/ml), and 5α-dihydrotestosterone (DHT) with a concentration of 
0.02ng/ml (43).  However, only T and DHT bind to the androgen receptor, whereas DHEAS, 
DHEA and A4 can be viewed as pro-androgens, as they need to be converted to T, to induce 
a biological action (43). In normal adult women, A4 is derived in approximately equal amounts 
from the ovarian theca cells and the adrenal zona fasciculata however, it shows circadian level 
variation and peak concentrations during the middle of ovarian cycle. Testosterone is derived 
25% from the ovaries, 25% from the adrenals, and 50% from peripheral conversion of A4. The 
concentration of T varies throughout the ovarian cycle, with T concentrations being the lowest 
at early follicular phase, followed by a pre-ovulatory increase, and relatively higher 
concentration in luteal phase as compared to the beginning of the cycle. Testosterone shows 
circadian variation, with the highest concentration in the morning. In the circulation, 
approximately 65-75% of T is carried bound to sex-hormone binding globulin (SHBG), and 
25-35% bound to albumin, with estimated of only 1–2% of T being free or biologically 
available (43). A free androgen index (FAI), ratio of total T to SHBG multiplied by 100, is a 
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method of calculating bioavailable testosterone. It has been demonstrated that T concentrations 
do not change significantly during menopausal transition, but rather decrease with age (44), 
however, there is significant decrease in SHBG during menopause, therefore an increased 
concentrations of free T is observed across during this transition (45). DHT is a potent, non-
aromatisable androgen, almost exclusively derived from peripheral conversion of T by the 
action of 5α-reductase, although small quantity is secreted from the adrenals (43). DHEA and 
DHEAS are mainly secreted from adrenal zona reticularis, with approximately 80% of DHEA 
and 90% of DHEAS produced in the adrenals (46). Serum concentrations of DHEAS and 
DHEA increase from adrenarche, peak in third decade of life, followed by a steady decline 
with age (47). There is no significant fluctuation of both DHEAS and DHEA during ovarian 
cycle. The regulation of androgen secretion involves stimulation by adrenocorticotropic 
hormone (ACTH) in adrenal and LH in ovary together with intraglandular paracrine and 
autocrine mechanisms (46). Liver, adipose tissue, and skin express 3β-HSD, 17β-HSD, 
aromatase and steroid sulfatase, and thus can catalyse conversion of androgenic precursors 
into androgen and estrogen (48). Therefore, substantial androgen production originates from 
conversion of circulating DHEAS in target tissues. 
There is increasing evidence for widespread anatomical distribution of androgen receptors in 
women, in areas as diverse as breast, bone and brain (44). Therefore, it is likely that androgens 
and their metabolites may have an important role not only in sexual differentiation, growth 
and metabolism, but also in other biological processes (49). Our current knowledge of 
androgen action is still primarily based on measuring serum levels of these hormones and their 
metabolites however, the specific intracellular actions of these hormones is less well 
understood but is likely to be of critical importance to their biological significance. Studies on 
rhesus monkeys demonstrated widespread tissue distribution of the steroidogenic enzymes, 
3β-HSD, 17β-HSD, steroid sulfatase, 5α-reductase  and aromatase, suggesting that all that 
tissue, 114 out of 132 sites studied, could possibly form biologically active sex steroids (50). 
Therefore, this could indicate that the active androgens and estrogens synthesised in peripheral 
tissues could exert their activity in the cells of origin, without diffusing into the circulation 
(48). 
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1.1.9 Ovarian and adrenal androgens in adolescent girls 
Before adrenarche, circulating levels of androgens are similar in male and female children. 
During puberty, plasma levels of DHEA and DHEAS reach adult levels first, followed by A4 
and T (43,51). The pattern of increase in DHEA and DHEAS is comparable in boys and girls, 
and coincides with the development of the zona reticularis in the adrenal glands however, this 
is not mirrored by an increase in ACTH  (51).  
1.1.10 Reproduction in sheep 
Sheep are seasonal breeders as their HPO axis, and thus reproductive function, is controlled 
by the hours of light to which the ewe is exposed. As pregnancy in sheep lasts on average 147 
days, fertility has evolved to ensure that lambs are born in the spring, when warmer weather 
and ample access to food safeguard lamb survival and growth (52). Prolonged melatonin 
secretion from pineal gland during the hours of darkness, directly signals to the hypothalamus 
and activates the HPO axis. Thus, in temperate zones, in autumn, when daylight to darkness 
ratio decreases, the hypothalamic GnRH pulses are activated and estrus cycle commence, 
while in springtime, as nights becoming shorter, secretion of melatonin decreases, estrus 
cycling ends, and the ewes enter anestrus.  
Reproductive cyclicity in sheep and other non-primate mammals, is termed the estrus cycle. 
The estrus cycle of the ewe is fundamentally analogous to the ovarian cycles of women, with 
the comparable neuroendocrine mechanisms controlling both cycles, however, there are some 
differences (52). In the estrus cycle menstruation does not occur, and cycle consists of four 
different stages, estrus, metaestrus, di-estrus and pro-estrus (53). In ewes, the estrus cycle lasts 
usually 17 days, with short follicular phase, taking 2-3 days, and pro-longed luteal phase 
lasting approximately 15 days, although environmental stressors, such as poor nutrition and 
severe weather, may disrupt cycle regularity (54,55). Estrus, is a period of 24-36 hours, in 
which the ewe is receptive to the ram. Preovulatory LH surge occurs at the start of estrus, so 
that ovulation occurs, on average, 24–30 hours after the onset of estrus behaviour (53). Luteal 
phase consists of metaestrus, with the formation of the corpus luteum and increase in 
progesterone levels, di-estrus in which progesterone reaches peak levels and pro-estrus, when 
the corpus luteum regresses and progesterone levels decline (53). In the estrus cycle, tonic LH 
secretion in pulsatile manner occurs throughout the cycle, regulated by the negative feedback 
actions of ovarian hormones, and the LH surge is triggered by high circulating concentrations 
of estradiol, which induces ovulation and formation of the corpus luteum. FSH concentrations 
decrease at the beginning of the follicular phase, and increase together with LH surge. After 
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ovulation, FSH level, analogous to LH concentration, decline again however, unlike LH, FSH 
increases again, 20–28 hours after the LH surge, followed by a sharp drop (53). A gradual rise 
in FSH concentration is frequently observed between fourth and sixth day of the luteal phase, 
which correlates with waves of antral follicle development, as unlike in women, the corpus 
luteum does not produce estradiol and inhibin A, and therefore FSH is not suppressed and 
follicular development can occur in the luteal phase (53). 
1.1.11 Regulation of pubertal transition in sheep 
At birth, the lambs are well developed and have similar birth weight to newborn humans, on 
average 3.5-4.5 kg, depending on the breed (56), however, lambs grow much more rapidly. 
By 30 weeks of age lambs can increase their birthweight up to ten times, while human infants 
only double their birthweight (56,57). Like in other organisms, sufficient growth is necessary 
to gain reproductive function therefore, sheep, due to their fast growth, enter puberty on 
average between 6 and 12 months. In the developing sheep there is strong correlation between 
weight with GnRH and LH pulsatility, which could indicate a potential role of adipose tissue 
and leptin in regulating timing of puberty (57). It was demonstrated that leptin can stimulate 
LH secretion in prepubertal males, but not females, indicating potential sex differences in 
factors controlling timing of the pubertal increase in GnRH secretion (58,59). However, it 
seems that one of the most important factors contributing to pubertal transition in female sheep 
is sensitivity to photoperiod and action of melatonin, as lambs can enter puberty only during 
breeding season, regardless of the month of birth, with the exception of females born in the 
autumn.  
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1.2 Role of adipose tissue in metabolism 
White adipose tissue (WAT) is a specialised loose connective tissue, consisting of several 
distinct anatomical depots (60). WAT has mainly been considered as an energy storage depot, 
thermal insulator, and mechanical cushion however, it is now recognised as an endocrine organ 
(61). The mass of adipose tissue in humans is highly variable, ranging from 5% to 60% of total 
body weight (62) and is influenced by many factors, including sex and hormones, age, diet, 
physical activity level, and drugs (61). Subcutaneous adipose tissues (SAT), an adipose tissue 
layer found between the dermis and the aponeuroses and fasciae of the muscles, includes 
abdominal, gluteal and femoral compartments, and stores approximately 80% of total body fat 
in the body (63). Conversely, visceral adipose tissue (VAT), which is associated with internal 
organs, and include omental, mesenteric and retroperitoneal fat, represent 10–20% of total 
body fat in men, and 5–10% in women (63). There are also smaller depots of adipose tissue 
surrounding heart (epi/pericardial) and kidneys (perirenal), as well as intermuscular fat (60). 
In other large mammals, such as sheep, the location and relative size of these principal depots 
are comparable.  
 
Figure 1.4 Major white adipose tissue depots in humans. Subcutaneous adipose tissue (sc) include 
abdominal, gluteal and femoral depots. Visceral adipose tissue is associated with internal organs, 
including stomach (omental), intestine (mesenteric), perinephric (kidneys) and retroperitoneal fat in 
retroperitoneal compartment.  
Taken from Lee et al. (62) 
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WAT is a heterogeneous organ, consisting of adipocytes, macrophages, fibroblasts, stromal 
cells, monocytes and preadipocytes, with an estimated 1–2 million adipocytes and 4–6 million 
other cells, per gram of WAT (62). Adipocytes constitute approximately 90% of the WAT 
volume, due to their relatively large cell size, ranging from 20 to 200 µm, in which 95% of the 
cell volume is occupied by a unilocular lipid droplet (62). There are some sex dependent 
differences in adipocyte size. Women tend to have smaller adipocytes in VAT than in SAT, 
while in men and extremely obese individuals, adipocyte size is comparable in both adipose 
depots. In addition, there is higher number of preadipocytes in SAT, as compared with VAT 
(64).  
1.2.1 Adipocyte development and growth 
In humans, preadipocyte differentiation into adipocytes occurs between the 14th and the 16th 
weeks of gestation (65), likewise in sheep it ensues in third month of gestation (66). In rodents, 
however, majority of adipose tissue is formed after birth (67). In humans, adipocyte 
proliferation tends to decrease in late gestation, and adiposity is increased primarily by filling 
of predetermined adipocytes until puberty, after which another intensified proliferation of 
adipocytes occurs (68). Therefore, the adolescent period sets the total number of adipocytes 
that the individual will have as an adult, although, the differentiation potential of preadipocytes 
into mature adipocytes is present throughout life, and depends on the body energy status and 
the storage needs. However, in adult life, the capacity of preadipocytes to become fully 
functional mature adipocytes declines (69,70). There is a constant turnover of adipocytes, with 
an estimated 8% of adipocytes per year in humans, and 0.6% per day in mice, being replaced 
(68). This stage of accelerated adipocyte proliferation in adolescence is paralleled by higher 
expression of peroxisome proliferator activated receptor gamma (PPARG), the master 
regulator of adipogenesis (71). It has been demonstrated, that diminished expression of 
PPARG results in reduced mitochondrial function and accumulation of lipids in nonadipose 
tissues, due to the decreased storage capacity of WAT, which consequently leads to 
lipotoxicity and metabolic perturbations (72,73). Therefore, inability of an individual to 
increase adipose cell number results in the development of hypertrophic adipocytes, which 
might increase risk of metabolic diseases (74).  
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1.2.2 Lipolysis and triglyceride formation 
The main role of WAT is to store free fatty acids (FFA) in form of triglycerides (TG) during 
times of energy abundance and to release them back during periods of energy shortage, by the 
integration of several biochemical pathways. In adipocytes, TG are synthesised from 
esterification of FFA, which are mainly delivered through breakdown of circulating TG 
through lipoprotein lipase (LPL), although the direct uptake of circulating FFA also 
contributes (62). Lipolysis is defined as hydrolysis of TG into FFA and glycerol. Adipose 
triglyceride lipase (ATGL), hydrolyses TG into diacylglycerol and fatty acids, which are 
further broken down to FFA and glycerol by hormone sensitive lipase (HSL) and 
monoglyceride lipase (MGL) (73). Lipolysis occurs during fasting, under the control of 
glucagon and catecholamines, which stimulate various lipases in adipocytes, resulting in 
secretion of FFA from the adipocyte to the circulation. FFA are then bound to albumin and are 
transported to muscle, liver, heart and other tissues for their oxidation or re-esterification (75). 
In the fed state, increased insulin concentrations inhibit lipolytic enzymes, thus decreasing 
lipid mobilisation from adipose tissue. 
1.2.3 WAT as an endocrine organ 
WAT has previously been considered as a metabolically inert tissue however, there is now 
significant evidence that WAT is also a dynamic endocrine organ, regulating metabolism and 
energy homeostasis, in an endocrine, paracrine and autocrine manner, through the secretion of 
adipokines (73). Furthermore, as adipose tissue is also involved in additional processes such 
as steroid metabolism, angiogenesis and the immune response, it is therefore vital that WAT 
maintains its functionality, which is lost in obesity (73). 
The number of identified adipokines is constantly increasing. Leptin, adiponectin, resistin, 
serpin, retinol binding protein 4 (RBP4), vaspin, visfatin, omentin, apelin, and chemerin are 
only some of them. In addition, there are number of cytokines and chemokines, that exert 
inflammatory response and cell migration, including tumour necrosis factor alpha (TNFα) and 
interleukin 6 (IL6) as well as monocyte-chemoattractant protein 1 (MCP1) however, for the 
purpose of this thesis only leptin and adiponectin will be reviewed in the section below. 
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1.2.3.1 Leptin 
In 1994 the first adipocyte-secreted protein was identified by Friedman and colleagues and 
was named leptin, from the Greek word leptos, meaning thin (76). Leptin, is a protein coded 
by LEP (OB) gene and is considered a metabolic signal of energy sufficiency (76,77). Leptin 
is secreted mainly by white adipose tissue, and its expression and concentration directly 
reflects the volume of body fat, and thus the amount of energy stored (78), however, it can 
also indicate acute changes in caloric intake (79). Leptin acts on the central nervous system to 
adjust food intake, through activation of anorexigenic (appetite-diminishing) and orexigenic 
(appetite-stimulating) neuropeptides, according to the needs of the body (77). In addition, there 
is some evidence showing that in mice, leptin can regulate energy expenditure, through 
elevating sympathetic nerve activity (80) and activation of thermogenesis in brown adipose 
tissue (81). Leptin also plays a critical function as neuroendocrine integrator linking the 
magnitude of body energy stores with the reproductive system. Leptin is an vital factor in the 
metabolic control of puberty and fertility, having a stimulatory/permissive effect on the 
hypothalamic-pituitary-gonadal (HPG) axis (82,83). Moreover, the presence of leptin 
receptors on ovarian theca and granulosa cells has been documented, however, in contrary to 
the role of leptin on the HPG axis, there is evidence showing that leptin can have an inhibitory 
effect on ovarian steroidogenesis (84,85) and act as inhibitor of ovarian follicle development 
(86). 
Leptin induces its effects by binding to specific leptin receptors (LEPR) expressed in the brain 
and in peripheral tissues, including liver, skeletal muscle, pancreas, kidney, heart, adrenal 
glands, ovaries and testes (87). Alternative splicing generates several isoforms of LEPR. The 
long LEPR isoform mediates complete signal transduction initiated by leptin, and it is 
associated with energy homeostasis and neuroendocrine function, while the short LEPR 
isoform is thought to play an important role in transporting leptin across the blood–brain-
barrier (77). Downstream of the LEPR, leptin activates numerous signal transduction 
pathways, including Janus kinase signal transducer and activator of transcription 3 (JAK-
STAT3), which is important for regulation of energy homeostasis (88), and 
phosphatidylinositol 3-kinase (PI3K), which is important in regulation appetite and glucose 
homeostasis (89). Leptin deficiency or resistance, resulting from LEP or LEPR gene mutation, 
results in severe obesity in humans and transgenic animals (90,91). Leptin replacement 
therapy, in patients with leptin deficiency, causes reduced food intake and enhanced response 
to satiety signals (92), which consequently results in decreased body weight (93). Likewise, 
lipodystrophy is associated with hypoleptinemia, thus leptin treatment in patients with 
lipodystrophy has been shown to decrease insulin resistance and hyperlipidemia, and to 
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reverse hepatic steatosis (94,95). Interestingly, in women with lipoatrophy and features of the 
PCOS, leptin treatment restored menstrual cycles, decreased T, and increased SHBG levels 
(96). However, majority of obese humans have high levels of circulating leptin, which reflect 
increased levels of adiposity, but are leptin resistant (78). The proposed mechanism underlying 
leptin resistance include defects in downstream signalling of LEPR in hypothalamus or 
changes in the leptin transport across the blood–brain barrier (97). 
1.3.2.2 Adiponectin  
Adiponectin was first identified by Scherer and colleagues in 1995, as an adipocyte secretory 
protein (98) however, since it was discovered independently by several laboratories at around 
the same time, it has few different names such as, adipocyte related complement protein 
(Acrp30), adipose most abundant gene transcript 1 (apM1), adipose-specific gene (ADIPOQ), 
and gelatin-binding protein of 28 kDa (GBP28) (99).  
Adiponectin is the protein product of the ADIPOQ gene transcript, and is secreted exclusively 
from adipose tissue, in the form of a trimer as the low-molecular-weight (LMW) form, a 
combination of two trimers as a middle-molecular-weight (MMW) form, or as six trimers as 
a high-molecular-weight (HMW) form. Adiponectin is one of the most abundantly secreted 
adipokines, constituting 0.05% of the total serum proteins, and circulates either as a trimer or 
an oligomer. Adiponectin mediates its effects through two receptors ADIPOR1 and ADIPOR2 
(100). Downstream of its receptors, adiponectin stimulates the phosphorylation and 
subsequent activation of adenosine monophosphate activated protein kinase (AMPK) and 
peroxisome proliferators activated receptors (PPARs), thereby regulating both glucose and 
lipid metabolism, in skeletal muscle and the liver (100). ADIPOR1 is highly expressed in 
skeletal muscle, while ADIPOR2 is particularly abundant in liver. Expression of adipocyte 
receptors in insulin target organs, is upregulated during fasting and suppressed during 
postprandial states. 
Adiponectin is an insulin sensitising adipokine. Levels of mRNA and circulating adiponectin 
are significantly decreased in obese and lipodystrophic humans, as well as in animal models 
of obesity and type 2 diabetes mellitus (T2DM) (101,102). Administration of recombinant 
adiponectin restores insulin sensitivity, decreases levels of glucose, FFA, TG, and reduces 
body weight (103-105). Studies demonstrated that adiponectin decreases insulin resistance by 
reducing TG content in muscle and liver, through increasing FFA oxidation and energy 
dissipation. In addition, adiponectin has been shown to suppress gluconeogenesis in liver (106) 
and increase glucose uptake in muscle and adipose tissue (107,108). Therefore, it has been 
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postulated that decreased adiponectin level contribute to the development of insulin resistance, 
metabolic syndrome, T2DM and atherosclerosis (99,109). 
A role for adiponectin in reproduction has also been investigated. Both adiponectin receptors 
were detected in human pituitary and hypothalamus neurons (110,111), suggesting potential 
impact of this adipokine on the central reproductive endocrine axis. Adiponectin has been 
shown to acutely reduce basal and GnRH-stimulated LH secretion through increased 
phosphorylation of AMPK, with no impact on FSH levels (112), therefore, low levels of 
adiponectin can lead to increased LH concentrations. Adiponectin receptors have been also 
detected in ovarian granulosa and theca cells (113,114), and it was found that adiponectin 
reduced steroidogenesis in theca cells. Conversely, testosterone has been shown to selectively 
reduce adiponectin levels by inhibiting its secretion from adipocytes (115) and a negative 
correlation between circulating adiponectin and testosterone has been reported (116), which 
might indicate a potential role of adiponectin in the pathophysiology of PCOS. 
1.2.4 Adipose tissue depot differences between SAT and VAT 
There is strong evidence showing differences between SAT and VAT biology, including 
adipokine secretion and rates of lipolysis and TG synthesis (117). Two mechanisms have been 
proposed to explain this phenomenon, which are not mutually exclusive. Firstly, differences 
resulting from distinctive innervation and links with the circulatory system, such as, the direct 
venous drainage of VAT into the portal circulation, resulting in hepatic exposure to by-
products of fat metabolism and adipokines. Secondly, the cell-autonomous depot-specific 
differences in adipocyte physiology, such as distinct gene expression in VAT and SAT 
preadipocytes, even after isolation and prolonged passage under identical conditions (68,118). 
Further, experimental studies demonstrated that transplantation of VAT into a subcutaneous 
position has minor effects while, transplanting SAT to the visceral compartment results in 
overall reduced adiposity and improvement in glucose homeostasis (119). It has been 
demonstrated that adipocytes in the VAT depot exhibit increased lipolysis when stimulated 
with adrenergic agonists, mainly due to decreased expression of antilipolytic α2-adrenergic 
receptors (ADR) and increased expression of lipolytic β3-ADR. In addition, there is evidence 
showing that adipocytes in VAT are less sensitive to the antilipolytic effects of insulin 
therefore, in the states of increased circulating insulin, the contribution of VAT-derived FFA 
may become more significant, up to 40%. In addition, it has been demonstrated that, FFA 
release from VAT to the hepatic portal vein is paralleled by increasing VAT, thus, individuals 
with central (visceral) obesity are more likely to have altered hepatic function (120). On the 
contrary, VAT is not significant contributor of FFA in the systemic peripheral circulation as 
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studies show that only 6% to 13% of total FFA in circulation originate from VAT. In addition, 
some studies demonstrated that in VAT macrophages are more prevalent and the production 
of proinflammatory cytokines is higher, therefore, this could also contribute to hepatic 
pathology in obesity, although these results are not consistent (121,122). These results indicate 
that there are intrinsic differences between depots and also imply that subcutaneous fat may 
have beneficial effects on metabolism. 
1.2.5 Central obesity 
Central obesity, so called apple or android fat distribution, refers mainly to increased visceral 
adiposity, however, it also includes fat accumulation in abdominal SAT, is considered a 
significant risk for metabolic complications (123,124). In contrast preferential fat 
accumulation in the gluteofemoral region and leg, namely pear-shaped or gynoid fat 
distribution, is believed to be associated with lower risk, or as some authors suggested, it may 
be protective. Therefore, it has been proposed that calculating waist-to-hip ratio (WHR) is a 
better determinant than body weight in estimating a risk for developing metabolic 
complications in obese individuals.  
1.2.6 Obesity and WAT 
Obesity is characterised by increased storage of FFA and subsequent expansion of adipose 
tissue, mainly through hypertrophy. It has been demonstrated that, in times of energy excess, 
adipose cells expand first by hypertrophy until they reach a critical threshold of 0.7–0.8 
µg/cell, after which signals are secreted that induce the proliferation and/or differentiation of 
preadipocytes (125). Overfeeding for several months caused increase in cell size but not cell 
number (126), however, a study by Tchoukalova et al. reported that overnutrition induces 
hypertrophy in upper-body SAT but hyperplasia in depots below the waist (127). Nevertheless, 
once adipocytes are gained, they are hard to lose, as even significant weight loss is associated 
with a reduction in adipocyte volume, but not number (128). Increase in fat mass is 
accompanied by changes in blood flow and hypoxia of the adipose tissue, with activation of 
the hypoxia-inducible factor 1 alpha (HIF1α), which in turn, may lead to metabolic 
dysfunction (129). When the expansion capacity is saturated, either due to decreased 
expandability of adipose cells, decreased recruitment of fat cell progenitors or augmented 
differentiation to new adipocytes, adipose cells start to release their lipid content. This starts 
an inflammatory process, with increased macrophage infiltration and pro-inflammatory 
cytokine production, such TNFα and IL6 as well as MCP1 (130). Conversely, elevated MCP1, 
can promote the recruitment of circulating monocytes, while upregulated expression of TNFα 
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and IL6 can impair insulin signalling and FFA oxidation in hepatocytes, skeletal muscles and 
adipose tissue (131). Histologically, macrophages can be observed as crown-like structures 
surrounding adipocytes, with tendency to cluster around dead or dying adipocytes, which 
underlie their irregular distribution in the WAT (68). Furthermore, this pathological process 
deregulates secretion of adipokines, such as leptin and adiponectin, which leads to further 
increased caloric consumption and reduced energy expenditure as well as decreased insulin 
sensitivity in peripheral tissue and ectopic lipid accumulation. Figure 1.5 summarizes 
pathological changes in WAT resulting from expansion of adipose tissue in obesity. 
 
Figure 1.5 Pathological obesity-induced changes in white adipose tissue resulting in enhanced 
production of pro-inflammatory cytokines and macrophage infiltration, increased release of free fatty 
acids, altered secretion of adipokines and insulin resistance. On the systemic level, dysregulated 
adipokine secretion may lead to increased food intake, decreased energy expenditure and reduced 
insulin sensitivity as well as ectopic lipid deposition and inflammation.  
              Adapted from Choe et al. (132) 
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1.2.7 Role of brown adipose tissue in energy homeostasis 
Brown adipose tissue (BAT), discovered recently in adult humans, is a highly vascularised 
oxidative tissue containing multilocular fat cells with abundant mitochondria. Myogenic factor 
5 (Myf5) positive cells are common progenitors for brown adipocytes and myocytes in skeletal 
muscle (133). In humans BAT is mostly localised to the supraclavicular and neck regions 
(134). It is specialised in heat production and energy expenditure through the capacity of 
brown adipocytes to dissipate energy from glucose and lipids via uncoupling protein 1 (UCP1) 
(135). Therefore, BAT might play a role in protecting against obesity and obesity-associated 
metabolic alterations, since reduced BAT activity in obesity was reported (136). Recently an 
endocrine role of BAT was also put forward, showing that BAT releases factors that can act 
in autocrine and paracrine manner (135). 
There is also growing evidence for presence of cells exhibiting a brown adipocyte thermogenic 
phenotype (including UCP1 expression), named ‘beige’ or ‘brite’ (brown-in-white), in WAT, 
after thermogenic activation (137). These cells are predominantly present in SAT depots (133). 
Stimulation of adipocyte receptors such as β3-ADR and PPARG can induce activation of beige 
adipocytes within WAT. There are two possible sources of beige adipocytes in WAT, 
conversion of mature white adipocytes or de novo generation from distinct progenitor cells 
(133). As shown in rodent models, beige adipocyte activation can have protective effects 
against obesity and improve glucose homeostasis in T2DM (138). 
 
Figure 1.6 Differentiation of white and brown adipocytes. WAT adipocyte precursors derive from both 
MYF5- and MYF5+ mesenchymal precursor cells while BAT adipocyte precursors derive exclusively 
from MYF5+ mesenchymal precursor cells. Beige adipocytes can derive from WAT adipocyte 
precursors and potentially directly from mature white adipocytes.  
             Taken from Peirce et al. (139) 
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1.2.8 Adipose tissue and sexual dimorphism 
Body fat distribution patterns are sexually dimorphic. In general, women are characterised by 
a higher body fat percentage than men, with a greater proportion of adipose tissue in gluteal 
and femoral regions, while men tend to have more adipose tissue accumulated in the abdominal 
region (140). However, in both sexes, a large accumulation of visceral fat (omental, mesenteric 
and retroperitoneal) is associated with metabolic syndrome (141). Sex hormones play an 
important role in the regulation of body fat distribution. However, to fully understand 
relationship between sex steroids and adipose tissue the role of steroid-converting enzymes 
needs to be recognized (140). This may be particular important with regards to androgens, 
which modulate adipocyte function and affect the size and distribution of adipose tissue (142). 
An inhibitory effect of testosterone on lipoprotein lipase in adipose tissue was reported, which 
supports an inhibitory effect of androgens on lipid accumulation. Furthermore, it was 
described that androgens can inhibit preadipocyte differentiation (142).  
In men, low plasma testosterone is linked to abdominal obesity (143). Conversely, androgen 
treatment in female-to-male transsexuals results in increased visceral fat accumulation and 
insulin resistance (144). In women increased levels of androgens are thought to be associated 
with abdominal obesity. This idea is largely based on the observation that hyperandrogenism 
seen in PCOS patients is often accompanied by abdominal obesity and hyperinsulinemia (145).  
Besides the well-known impact of sex hormones on WAT distribution, there is some evidence 
that there is also sexual dimorphism in distribution and function of BAT. Women have been 
found to have greater volume of BAT, than men (146,147). Further, studies on rodents 
demonstrated that, there is sex-specific composition of lipids in BAT (148), mitochondrial 
function and sensitivity of BAT to adrenergic stimulation (149). Female mice are more 
responsive to browning of WAT during β-adrenergic stimulation than males (150), and have 
higher UCP1 expression in BAT (151). 
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1.3 Clinical features and diagnostic criteria of PCOS  
PCOS was first described in 1935 by Irving Stein and Michael Leventhal, in report entitled 
“Amenorrhea associated with polycystic ovaries”, where the authors described seven patients 
with enlarged ovaries, detected using radiologic techniques, amenorrhea, sterility, pain, and 
hirsutism (152). Since then more than 30,000 scientific reports on this topic have been 
published, and this clinical triad of polycystic ovaries, hyperandrogenism, and 
oligo/amenorrhea, has been the foundation for diagnostic criteria of PCOS in different 
guidelines (153). 
However, PCOS is a heterogenous syndrome and the clinical presentation of PCOS varies 
broadly. Polycystic ovaries (PCO) are common findings in patients with PCOS, hence the 
name of the syndrome. PCO are defined as an ovarian volume of greater than 10 millilitres 
and/or presence of 12 or more follicles measuring 2–9 mm in diameter in each ovary (154). It 
is estimated that PCO are present more than 75% of patients with PCOS (155) however, 20% 
of women in general population also have PCO (156). Menstrual disturbances associated with 
PCOS include oligomenorrhea, amenorrhea, and prolonged erratic menstrual bleeding, yet 
nearly one third of patients have a normal menstrual cycle (157). Increased androgen plasma 
concentrations (hyperandrogenaemia), and its clinical manifestation (hyperandrogenism) of 
hirsutism and/or acne is another common presentation in PCOS. In the large study of patients 
presenting with clinically evident androgen excess, it was found that 82% had PCOS (158). 
Excess hair growth is reported in 50-70% of PCOS women (158-160), while acne and alopecia 
are less prevalent, with 15-30%, and 22%, respectively of adult women affected 
(158,161,162). Further, 40-60% women with PCOS have elevated LH levels (163,164). 
Infertility is also a common complication in patients with PCOS. PCOS is considered most 
frequent cause of anovulatory infertility and it accounts for 90% of patients attending infertility 
clinics with anovulation, yet 60% of women with PCOS are fertile (165). 
The diagnosis of PCOS requires the exclusion of other ovarian, pituitary and adrenal causes 
of androgen excess in reproductive-age women. Until now three different diagnostic criteria 
have been proposed, as summarised in Table 1. In 1990, the National Institutes of Health (NIH) 
established definition of the disorder and diagnostic criteria, which advised that clinical or 
biochemical presence of hyperandrogenism (HA) and chronic oligo-anovulation (OA) were 
needed to diagnose PCOS (166). In 2003, during a consensus workshop in Rotterdam, new 
diagnostic criteria were proposed by the European Society for Human Reproduction and 
Embryology/American Society for Reproductive Medicine (ESHRE/ASRM), which included, 
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in addition to previous guidelines, presence of polycystic ovaries on ultrasound, as a diagnostic 
criterion for the syndrome (154). Expansion of PCOS classification, to include women who 
either had PCO in combination with HA and/or OA, resulted in a significant increase in the 
number of patients diagnosed with PCOS, and extended the heterogeneity of PCOS 
phenotypes as compared with the NIH guidelines (167). Recently, a novel phenotypic 
approach to classifying PCOS has been introduced by a panel of specialists during the NIH 
Evidence-based Methodology Workshop, recommending use of the following phenotype 
classification: phenotype A: HA+OA+PCO; phenotype B: HA+OA; phenotype C: HA+PCO; 
and phenotype D: OA+PCO, with phenotypes A and B being the highest risk for metabolic 
dysfunction (168-170). Finally, in 2006, The Androgen Excess Society (AES) issued new 
recommendations, which stated that PCOS should be primarily considered a disorder of 
androgen excess and that diagnosis of PCOS should be based on the presence of clinical or 
biochemical HA in combination with OA and/or PCO, therefore excluding a non-
hyperandrogenic phenotype, which was proposed in the 2003 Rotterdam criteria (155). The 
rationale for proposing these new criteria was based on the that evidence that HA seemed to 
be the most robust determinant of the PCOS pathophysiology and a central factor contributing 
to the associated metabolic dysfunction (167,171). Interestingly, some studies demonstrated 
that with age, women with PCOS, may regain menstrual cyclicity (172) and present with 
decrease in ovarian volume and number of follicles (173,174) however, their androgen levels 
remain elevated when compared with age matched controls (175).  
NIH 1990 ESHRE/ASRM 2003 AES 2006 NIH 2012 
Exclusion of other ovarian, pituitary and adrenal causes of androgen excess in reproductive-age women 
All criteria required Two of three criteria 
required 













Table 1.1 Criteria for diagnosis of PCOS according to different guidelines. HA: hyperandrogenism, OA: 
oligo-anovulation, PCO: polycystic ovaries. Adapted from Lizneva et al. 2016 (167). 
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1.3.1 Clinical features and diagnostic criteria of PCOS in adolescent 
girls 
In general, the diagnostic criteria for PCOS in adolescent girls follows the guidelines outlined 
for adult women however, hormonal and reproductive differences associated with pubertal 
transition need to be taken into consideration. Irregular menstrual cycles are frequent in 
adolescent girls, with up to 85% anovulatory cycles during the first year after menarche (176). 
PCO is also very common, with up to 40% of the adolescent girls demonstrating PCO 
morphology two years after menarche as documented in ultrasonographic studies (177). 
Premature pubarche, the appearance of sexual hair before the age of 8 years in girls, is 
considered a potential predictor of PCOS in future life, as it has been demonstrated that girls 
with premature pubarche have a risk of developing PCOS (178). In turn, premature pubarche 
is a sign of premature adrenarche and increased adrenal androgens, which might be the first 
manifestation of steroidogenic dysregulation in girls with PCOS (179-181). HA has been 
found to be the strongest predictor of PCOS in adolescent girls (176). That is why, all three 
diagnostic criteria (HA+OA+PCO) should be present in adolescent girls to identify PCOS, 
with OA present for at least 2 years after menarche, according the ESHRE/ASRM consensus 
from 2010 (160).  
1.3.2 Prevalence of PCOS 
PCOS is the most common endocrine disorder among women of reproductive age (182). The 
global prevalence of PCOS and its different phenotypes varies greatly based on geographical 
location, ethnicity and diagnostic criteria used with worldwide occurrence ranging from 4% 
to 21% (182). Depending on diagnostic criteria applied, the prevalence oscillates between 5% 
to 10% with NIH 1990 guidelines; from 10% to 15% according to the AES 2006 
recommendations, and from 6% to 21% with ESHRE/ASRM 2003 criteria (167). Higher 
prevalence of PCOS with the ESHRE/ASRM 2003 and AES 2006 criteria can be mainly 
attributed to their broader definition with inclusion of additional phenotypes. The prevalence 
of specific phenotype among women with PCOS was recently evaluated, with phenotype A 
(HA+OA+PCO) accounting for 66%, phenotype B (HA+OA) for 13%, phenotype C 
(HA+PCO) for 11% and phenotype D (OA+PCO) for 9% (167). The estimated prevalence of 
PCOS in adolescent girls varies between 0.81-5% however, it is likely to be underdiagnosed 
in this population (183-186). 
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1.3.3 Metabolic characteristics of adult women with PCOS 
1.3.3.1 Insulin resistance 
PCOS is clearly a reproductive disorder however, it seems that metabolic comorbidities 
associated with the syndrome have more pronounced implications across the lifespan and pose 
a significant health and economic burden. It was estimated that 40% of total PCOS health care 
costs were attributed to diabetes associated with the syndrome (187). Although not diagnostic 
criteria, insulin resistance (IR) and associated hyperinsulinemia are the most common 
metabolic complications in PCOS. Insulin resistance is defined as pathological state, in which 
there is diminished cellular response to the insulin, and as a consequence, an increased amount 
of insulin is required to stimulate the biological response (188). Increased insulin secretion by 
pancreatic β-cells is the physiological compensatory mechanism and as long as 
hyperinsulinemia overcomes insulin resistance, glucose levels remain normal. However, when 
ability of β-cells to secrete insulin deteriorates, relative or absolute insulin insufficiency 
develops, with impaired glucose tolerance (IGT) and T2DM (188). Women with PCOS have 
increased frequency of IR than age- and body mass index (BMI)-matched controls, and obesity 
has disproportionately greater impact on IR in PCOS than in general population (189). In a 
recent meta-analysis of 28 published euglycemic–hyperinsulinemic clamp studies, it was 
found, that women with PCOS have 27% worse insulin sensitivity than controls, independent 
of BMI, age or diagnostic criteria (189). It is estimated that 50-70% of PCOS patients are IR 
(190) however, a recent cross-sectional study reported  that 75% of lean and 95% of 
overweight women with PCOS had decreased insulin sensitivity (191). IR is more pronounced 
in the classic PCOS phenotypes, phenotype A and B, compared with PCOS patients who have 
either normal androgen levels or regular menstrual cycles (189). It has been suggested that 
PCOS patients manifest intrinsic insulin hypersecretion, elevated β-cell function together with 
decreased insulin clearance and insulin signalling abnormalities, which in consequence lead 
to IR, which is further exacerbated by increased body weight and adiposity (192-195). IR and 
hyperinsulinemia are the key pathophysiological features of PCOS contributing to 
reproductive, endocrine and metabolic disturbances. 
1.3.3.2 Type 2 diabetes mellitus 
T2DM is a metabolic disorder characterised by hyperglycaemia and a distorted lipid profile 
caused by pancreatic β cells being unable to secrete adequate insulin to overcome insulin 
resistance. In turn, chronic hyperglycaemia and hyperlipidaemia, through glucotoxic and 
lipotoxic mechanisms, including rough endoplasmic reticulum (RER) stress, accelerate β-cell 
failure, which might result in the need for insulin therapy (196). T2DM is a significant risk 
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factor for heart disease and stroke, end-stage renal failure, non-traumatic lower-limb 
amputations, and is the leading cause of blindness among adults aged 20–74 years (196). 
Women with PCOS are at increased risk of developing T2DM and have higher conversion rate 
from IGT to T2DM than general female population (197,198). PCOS has been identified as a 
significant non-modifiable risk factor for T2DM by the International Diabetes Federation 
(199). Legro et al. estimated that PCOS patients contribute to 20% of IGT and 40% of T2DM 
cases in reproductive-aged women in US (200). Moreover, women with PCOS are at increased 
risk of developing gestational diabetes mellitus (GDM) (201,202). A large prospective cohort 
study documented a remarkably high incidence (22%) of GDM in PCOS women (203), 
compared to 7% in general female population (204). GDM, in turn, is a significant lifetime 
risk for developing T2DM, with 35%- 60% of women with GDM progressing to T2DM within 
10 years postpartum (205,206)  
1.3.3.3 Obesity 
Epidemiological studies provide a clear evidence for the close link between PCOS and obesity, 
showing that 38%–88% women with PCOS are overweight or obese (207), and conversely, 
that the prevalence of PCOS is high in unselected obese female population, with up to 28% of 
all cases (208,209). Therefore, considering the high prevalence of obesity in PCOS, some 
authors postulated that women with PCOS might have a unique predisposition to obesity, and 
that these women might face additional barriers to effective weight management (210). Indeed, 
decreased basal metabolic rate (BMR) (211) and reduced postprandial thermogenesis (212) 
have been reported in women with PCOS. However, as not every obese woman develops 
PCOS, it should be noted that, obesity does not cause PCOS but rather exacerbates its 
symptoms. It has been demonstrated that obesity can further increase prevalence of irregular 
menstrual cycles, amplify androgen concentrations and elevate risk for pregnancy 
complications (213). Obesity is also inked to a reduced response to infertility treatment (213). 
Conversely, even modest weight loss in obese PCOS women can significantly improve 
reproductive and metabolic characteristics of the syndrome (207).  
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1.3.3.4 Adipose tissue dysfunction 
Numerous studies demonstrated that there is a strong relationship between fat mass and the 
severity of PCOS phenotype however, the mechanisms underlying this association are not 
completely understood. Increased abdominal (visceral) adiposity is thought to be correlated 
with adverse metabolic profile, mainly due to its proximity to hepatic portal vein, and thus 
direct effects of FFA and cytokines released from this depot on liver, while subcutaneous 
adipose tissue is believed to be inert, or even protective (214,215). Previous studies indicated 
that overweight/obese women with PCOS have increased abdominal adiposity when compared 
with BMI-matched controls (216,217). This hypothesis has gained wide acceptance, as it 
explained increased frequency of metabolic disturbances in women with PCOS, as compared 
with women in general population (218). However, more recent studies, using magnetic 
resonance imaging (MRI) techniques, has challenged this assumption, showing that there is 
no difference in adipose tissue distribution between PCOS and BMI-matched controls (219). 
Moreover, Barber and colleagues demonstrated that women with PCOS remained more insulin 
resistant than control women, thus indicating that increased insulin resistance in PCOS women 
is unlikely to emerge from increased visceral adiposity (219). Interestingly, in a study by 
Dolfing et al., again employing MRI imaging, it was found that lean PCOS women had less 
visceral fat than the control women (220), while Horejsi et al. reported that young, lean PCOS 
patients had significantly decreased SAT volume, especially on the legs, when compared with 
age- and BMI- matched controls (145). Moreover, there is evidence showing link between 
partial lipodystrophy and PCOS (221-226). Lipodystrophy is a clinical disorder characterised 
by adipocyte malfunction, resulting in maldistribution of body fat, with a partial lack of 
adipose tissue (lipoatrophy) in certain body areas, with excess of adipose tissue 
(lipohypertophy) elsewhere, with resulting hyperinsulinemia, insulin resistance, and 
abnormalities of glucose homeostasis (222). Therefore, aforementioned evidence might 
indicate potential role of the intrinsic adipocyte dysfunction in the development of PCOS. 
Indeed, there are increasing numbers of reports showing that women with PCOS have adipose 
tissue dysfunction, independent of obesity. Insulin and androgens, both main culprits in PCOS, 
affect adipose tissue function, however, insulin and androgens have opposing regulatory 
effects on the differentiation of preadipocytes to adipocytes. There is evidence that insulin 
stimulate adipogenesis (227), while androgens inhibit preadipocyte differentiation (228), thus 
hormonal and metabolic derangements are likely to play an important role in adipose tissue 
function in PCOS. Wang et al. documented that in subcutaneous adipocytes from PCOS 
patients, expression of testosterone synthesising enzymes was higher, while expression of 
aromatase was decreased, suggesting increased local androgen action (229). It has been 
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reported, that adipocytes in SAT of women with PCOS are hypertrophic (230). Conversely, 
adipocyte hypertrophy is strongly associated with insulin resistance and increased 
inflammation. Furthermore, a decrease in hormone-sensitive lipase expression and activity and 
catecholamine-induced lipolysis in SAT, and an increase in the VAT, in PCOS women, was 
also reported (231,232), which might partially elucidate adipocyte hypertrophy in the SAT 
depot. Moreover, an increase in the expression of CD36, a FFA transporter, in adipocytes from 
women with PCOS, was also described (233). In addition, PCOS women were found to have 
decreased adiponectin levels, independent of BMI, which can further contribute to metabolic 
perturbations in those females, considering the insulin sensitising properties of adiponectin 
(230,234-236). There is evidence showing that adiponectin can suppress theca cell androgen 
synthesis, and therefore decreased levels of adiponectin in PCOS may contribute to enhanced 
ovarian androgen production (237). In PCOS, there is also evidence of a low-grade chronic 
inflammation of adipose tissue, with increased secretion of pro-inflammatory mediators, such 
as TNFα and IL6, which might be a consequence of adipocyte hypertrophy (238). These 
inflammatory cytokines can in turn exacerbate the metabolic and ovarian dysfunctions of the 
syndrome, such as insulin resistance, T2DM, cardiovascular disease (CVD), 
hyperandrogenism and disordered ovarian cyclicity (238).  
1.3.3.5 Metabolic syndrome 
Metabolic syndrome (MetS), also known as syndrome X, the insulin resistance syndrome, and 
the deadly quartet, is a cluster of metabolic abnormalities, which occur together more often 
than by chance alone. They include insulin resistance, (central) obesity, dyslipidaemia, and 
hypertension, and are well documented risk factors for both T2DM and CVD (239). In fact, 
MetS poses a 5-fold increased risk for developing T2DM and a 2-fold risk for CVD (240). 
There are different definitions of MetS, however, these definitions agree on the main 
components of the syndrome, glucose intolerance, obesity, hypertension, and dyslipidaemia 
(239). Insulin resistance is accepted as the central factor in the pathophysiology of MetS (239). 
It leads to decreased suppression of lipolysis in WAT and therefore, elevated FFA in 
circulation. Conversely, a major contributor to the development of IR is an excess of 
circulating FFA, which alter the downstream signalling of insulin in peripheral tissue, with 
decreased glucose uptake in skeletal muscle and WAT (239), and impair a pancreatic 𝛽-cell 
function (241). In addition, with increased FFA flux to the liver, there is amplified production 
of triglycerides, and apoB-containing triglyceride-rich very low density lipoproteins (VLDL), 
resulting in dyslipidaemia and non-alcoholic fatty liver disease (NAFLD)  (239). 
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MetS is common in reproductive-age women with PCOS, with an estimated prevalence of 35-
45% (242-246) compared to 6% in females age 20–29, and 15% in females age 30–39, in the 
general population (247). Therefore, it has been suggested that PCOS is an ovarian 
manifestation of MetS, and that the name ‘PCOS’ should be changed to ‘female metabolic 
syndrome’ or ‘syndrome XX’, to mirror its strong link with cardio-metabolic abnormalities 
(248). Interestingly, hyperandrogenic sisters of women with PCOS, and women with increased 
androgens, but no PCOS, also have an increased prevalence of MetS (249,250). The 
prevalence of MetS was twofold higher in the PCOS population with hyperandrogenism 
compared with PCOS with normal androgen levels and control groups, supporting hypothesis 
that androgens may play a role in the adverse metabolic profile seen in PCOS (251). Indeed, 
free testosterone and fasting insulin levels were found to be a strong predictors of MetS in 
women with PCOS (245,246) supporting the common aetiological role of insulin resistance in 
both PCOS and the metabolic syndrome.  
1.3.3.6 Non-alcoholic fatty liver disease 
NAFLD is the most common chronic liver disorder in Western countries, with estimated 
prevalence of 20-30% in general population (252). NAFLD and is often considered the hepatic 
manifestation of MetS, with incidence as high as 75-95% in the morbidly obese population 
(253-255). NAFLD refers to the accumulation of fat in the liver of subjects who drink little or 
no alcohol, and comprises of spectrum of hepatic manifestations, ranging from simple hepatic 
steatosis to non-alcoholic steatohepatitis (NASH), associated with hepatic inflammation and 
fibrosis  (252). An increased incidence of NAFLD and NASH in women with PCOS was 
reported, with an estimated 39-69% of women affected, independent of BMI, depending on 
ethnicity and diagnostic criteria used (256,257). PCOS and NAFLD have common risk factors, 
including insulin resistance and obesity however, the increased prevalence of NAFLD in 
PCOS patients, especially lean ones, is not fully understood. 
1.3.3.7 Dyslipidaemia 
Dyslipidaemia is a spectrum of qualitative lipid abnormalities reflecting perturbations in the 
structure, metabolism, and biological activities of both atherogenic lipoproteins, including 
increased levels of  apolipoprotein B, TGs, VLDL and low density lipoprotein (LDL) 
cholesterol, and decreased level of anti-atherogenic high density lipoprotein (HDL) cholesterol 
(258). Dyslipidaemia is another common finding in PCOS, independent of BMI and insulin 
resistance and obesity can further exacerbate lipid disorders (259-261). It is estimated that 
70% of PCOS patients exhibit abnormal serum lipid levels (262). Women with PCOS often 
display increased TGs and LDL cholesterol levels combined with decreased HDL cholesterol 
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(259-262). Moreover, in women younger than 40 years, PCOS might be the main cause of 
dyslipidaemia (259). In addition, PCOS patients were reported to have elevated levels of FFA 
(263,264). Both, IR and increased androgen levels, have been indicated as possible causes of 
dyslipidaemia in PCOS (265). Conversely, FFA have been demonstrated to increase adrenal 
androgen precursors in vivo (266) and exacerbate both insulin resistance and hyperinsulinemia, 
mainly due to interfering with insulin signalling, inhibiting insulin-stimulated glucose uptake, 
glucose oxidation and glycogen synthesis in skeletal muscle and liver (267,268). Increased 
FFA have also been demonstrated to directly stimulate pancreatic insulin secretion (269). 
1.3.3.8 Cardiovascular disease 
Life-long metabolic dysfunctions in women with PCOS, such as IR, T2DM, obesity and 
dyslipidaemia, exaggerate the risk for CVD (270). This is significant, since CVD is the leading 
cause of mortality in women (271). Patients with PCOS have increased early clinical and 
subclinical markers of vascular dysfunction and atherosclerosis and elevated blood pressure, 
when compared with general female population, however, cardiovascular risk profiles may 
vary with PCOS phenotype, age, ethnicity and BMI (251,270,272). Furthermore, PCOS 
patients were found to have elevated markers of low-grade chronic inflammation, which have 
also been implicated in the pathogenesis of CVD, including C reactive protein (CRP), 
fibrinogen and white blood cell count (273). In addition, PCOS patients were documented to 
have elevated risk of ischaemic stroke, ischaemic heart disease and overall mortality 
(274,275). Increased androgen levels might contribute to overall risk of CVD in women with 
PCOS. It has been demonstrated that in females high testosterone levels contribute to 
atherosclerosis and CVD development independently of age, adiposity, ovarian function, and 
smoking (276,277). Particularly, androgens have been demonstrated to stimulate inflammation 
and oxidative stress (OS) in vascular endothelium, as well as induce renal reabsorption of 
sodium and water, contributing to development of atherosclerosis and hypertension,  
respectively (278). 
1.3.4 Metabolic characteristics of adolescent girls with PCOS 
1.3.4.1 Insulin resistance 
Impaired glucose metabolism, insulin resistance and hyperinsulinemia are common metabolic 
dysregulations in adolescent PCOS girls, across the spectrum of BMI, and may be a central 
factor underlying the pathogenesis of PCOS (279). It was reported that the prevalence of IR 
among adolescent girls with PCOS was 69.4%, independent of age and BMI (181,279-282). 
Increased body weight and adiposity, like in adult women with PCOS, further exacerbate 
insulin resistance. Obese girls with PCOS, when compared with BMI-matched controls, were 
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reported to have a 50% reduction in peripheral tissue insulin sensitivity, evidence of hepatic 
insulin resistance, and compensatory hyperinsulinemia (283). Interestingly, a study by Kent et 
al. demonstrated that daughters in the latter stages of puberty, but not sons, of PCOS women 
had significantly increased levels of insulin during a two hour oral glucose tolerance test 
(OGTT), when compared with BMI-matched control girls (284). However, authors did not 
find evidence of increased androgen levels in those girls, although testosterone levels were 
elevated in the sons of PCOS mothers (285). Comparable results were reported by Sir-
Petermann et al., showing that pre-pubertal and pubertal daughters of PCOS mothers had 
increased insulin levels after a two hour OGTT, when compared with controls (286). In 
addition, it was demonstrated that although androgen levels were normal in pre-pubertal girls, 
they were elevated during puberty. These findings suggest that hyperinsulinemia might 
precede reproductive perturbations in girls at increased risk of developing PCOS (286). 
1.3.4.2 Obesity 
Obesity frequently co-exist with PCOS and there is a correlation between incidence of PCOS 
in adolescent girls and elevated BMI, however, population studies are scarce. One study found 
that the overall prevalence of PCOS in 137,502 adolescent girls aged 15-19 years was 1.14%, 
however, compared with normal and underweight girls, the odds ratios for confirmed PCOS 
diagnosis were 3.85 for overweight, 10.25 for moderately obese, and 23.10 for extremely 
obese adolescents (185). However, authors also noted that the association between PCOS and 
obesity was lost when a subset of girls with suspected PCOS, based on medical records, were 
included into analysis, suggesting that obese girls are more likely to seek medical help and 
receive a diagnosis of PCOS, leading to a potential bias and overestimation of the association 
of PCOS with obesity (185). Moreover, longitudinal, population-based studies found that 
pubertal obesity and weight gain after adolescence was associated with an increased risk of 
having symptoms of PCOS in later life (287,288). In addition, a prospective study on 244 
randomly selected postmenarchal girls reported PCO morphology in 61.1% of the obese girls, 
36.2% in overweight girls, and 32.1% in the normal weight girls, indicating that obesity might 
be a contributing factor (183). Obesity often exaggerate hyperandrogenemia and 
hyperinsulinemia in normal pre-pubertal and pubertal girls, which might further accelerate 
development of PCOS in predisposed girls (289,290). Conversely, hyperandrogenemia can 
increase adiposity and alter adipose tissue distribution towards visceral fat, which in turn 
further contributes to the metabolic and endocrine disturbances in PCOS. 
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1.3.4.3 Metabolic syndrome 
Childhood and adolescent MetS might predict adult morbidity and premature mortality (291-
293). The increased prevalence of MetS, and its individual components, in girls with PCOS 
has been reported in numerous studies (294-299). In a retrospective study of 205 teenage girls, 
it was found that 10.8% of adolescent girls with PCOS had MetS, defined as presence of three 
or more risk factors, compared with 1.7% in those without PCOS (297). However, since girls 
in control group in this study had a medical history of irregular menses or hyperandrogenemia, 
but not PCOS, it can be speculated that the difference in the prevalence of MetS in adolescent 
PCOS, when compared with pubertal girls in the general population, might be even higher. 
Adolescents with PCOS were reported to have increased BMI, blood pressure, TG, and 
decreased HDL (297), therefore, it could be argued that obesity is the major factor contributing 
to the elevated risk of MetS in girls with PCOS. However, it was found that adolescent girls 
with PCOS had a 4.5 times higher prevalence of MetS, than age- and BMI-matched girls from 
the general adolescent population (294). Interestingly, in this study, hyperandrogenemia was 
reported to be the strongest predictor of MetS in adolescent PCOS girls, independent of obesity 
and insulin resistance (294). Adolescent girls with PCOS were also reported to have persistent 
elevations of FFA, hyperinsulinemia, and elevated cardiovascular disease risk markers, such 
as arterial stiffening and atherogenic lipoprotein lipid profiles  (294,298,300). 
 
Table 1.2 Summary of main clinical manifestations of PCOS across the life course. Adapted from 
National Institutes of Health Evidence-Based Methodology Workshop on PCOS, 2012 (301).  
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1.3.5 Pathophysiology of PCOS  
The pathophysiology of PCOS is complex and despite over 80 years of research, remains 
elusive. However, it is widely accepted that androgens and insulin play central role in the 
pathogenesis of PCOS.  
In a normal ovary, androgens are synthesised from cholesterol in the theca cell layer of the 
ovarian follicle, under the stimulation of LH secreted from the anterior pituitary gland, which 
bind to LH receptors located on theca interna cells (302). Subsequently, androgens are 
converted into estrogen in the granulosa cells, under the regulation of FSH, by the action of 
the aromatase enzyme (302). In addition, in normal ovary, inhibin promotes androgen 
synthesis, whereas androgens, in turn, stimulate inhibin production. Activin opposes the 
effects of inhibin (302). Women with PCOS have elevated LH serum concentration (163) and 
increased LH pulse amplitude and frequency (303,304), but normal FSH levels, which in turn, 
lead to LH:FSH imbalance and elevated androgen synthesis (303,304). However, some women 
with PCOS have normal levels of LH, but remain hyperandrogenic, which point to additional 
mechanisms underlying hormonal dysregulation. Indeed, it was demonstrated that theca cells 
of PCOS women have intrinsic steroidogenic defect, and are hyper-responsive to 
gonadotrophins, thus secrete excess androgens even under normal LH levels, which might be 
further potentiated by increased LH and insulin concentrations (305,306). As indicated in in 
vitro studies, the enhanced steroidogenic potential of PCOS theca cells resides in the increased 
enzyme activities of P450scc, 17α-hydroxylase, and 3β-HSD and increased  expression of the 
transcription factor GATA-6, which regulates the promoter activity of CYP11A and CYP17A1 
(305,306,307). 
Conversely, increased androgen levels may decrease the sensitivity of the hypothalamic GnRH 
pulse generator to steroid inhibition resulting in enhanced LH secretion (308). Further, women 
with PCOS have increased serum concentrations of inhibin B, which in turn, might lead to 
decreased levels of FSH, and thus decreased stimulation of aromatase by FSH, consequently 
resulting in the reduced conversion of androgen to estrogen, further aggravating the ovarian 
androgen excess (309,310). This also could perpetuate the vicious cycle of increased 
androgens in PCOS women (309,310). It has been demonstrated that androgens stimulate the 
development of smaller antral follicles, but inhibit the growth of larger antral follicles 
(302,311,312). In consequence, increased androgen levels in PCOS patients cause the 
development of a polycystic ovary, an ovary with many small antral follicles.  
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Although the ovaries are the primary source of androgen excess in PCOS, there is some 
evidence that women with PCOS frequently also display increased adrenal androgen 
production (313). This adrenal androgen excess, defined by high circulating levels of the 
metabolite DHEAS, is present in 20-30% of women with PCOS, and it is likely to be intrinsic 
(313). As there is no evidence of increased ACTH levels in patients with PCOS, this might be 
due to aberrant adrenocortical biosynthesis or increased sensitivity to ACTH (314,315).  
Elevated insulin, as a potential consequence of insulin resistance, acts synergistically with LH 
to increase the generation and release of androgens from ovarian theca cells, through activation 
of 17α-hydroxylase, a key enzyme in ovarian androgen biosynthesis (316). Moreover, insulin 
suppresses hepatic production of SHBG, further enhancing the concentrations of free, 
biologically available, testosterone. In addition, insulin promotes the arrest of preantral follicle 
development, thus leading to both hyperandrogenemia and menstrual disturbance. 
Experimental studies demonstrated that insulin can increase LH pulse amplitude in pituitary 
tissue and adrenal androgen production, by enhancing adrenal sensitivity to ACTH, further 
exacerbating hyperandrogenemia (316,317). Considering insulin resistance, the action of 
insulin might seem paradoxical however, it has been demonstrated that insulin, downstream 
of its cellular receptor, acts via two key pathways, phosphatidylinositol 3-kinase (PI3K), which 
include insulin receptor substrates (IRS), IRS1 and IRS2, and mitogen-activated protein kinase 
(MAPK) pathways (318). In general, metabolic action of insulin is mediated through the PI3K 
pathway, whereas mitogenic and steroidogenic effects via MAPK pathway (318). In insulin 
resistant patients, including T2DM and PCOS, PI3K pathway deteriorates however, the 
MAPK pathway remains relatively intact, therefore the selective insulin resistance in women 
with PCOS results in defects in insulin-mediated glucose metabolism, but continued high 
insulin levels lead to upregulated steroidogenesis (319). Conversely, a decrease in insulin 
levels, resulting from improvement in insulin sensitivity in PCOS, achieved through either 
weight loss or drug therapy, leads to improved ovulatory function, menstrual cyclicity and 
fertility. 
Insulin resistance in women with PCOS has been attributed to impaired insulin stimulated 
glucose uptake and post-receptor defects of the insulin-signalling system in adipose tissue and 
skeletal muscles. Impaired insulin stimulated tyrosine phosphorylation of IRS1 has been 
postulated as one of the mechanism leading to insulin resistance in PCOS women. 
Furthermore, decreased expression of the insulin-regulated glucose transporter 4 (GLUT4), 
encoded by SLC2A4 gene, was shown in adipocytes of PCOS women (320). Interestingly, in 
vitro experimentation showed that testosterone can directly induce insulin resistance in SAT, 
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via androgen receptor (AR), selective for metabolic signalling pathways, independent of PI3K 
pathway (319). In skeletal muscle, reduced insulin receptor (INSR) tyrosine kinase activity 
due to increased serine phosphorylation was indicated as a potential cause for insulin 
resistance in PCOS. 
It has been demonstrated that women with PCOS have decreased levels of circulating 
adiponectin, an insulin-sensitising adipokine, regardless of their level of adiposity, which 
positively correlated with IR and negatively with testosterone and FAI (321-322). Adiponectin 
in turn, has been shown to reduce the synthesis of androgens from ovarian theca cells (321-
322), therefore, enhanced ovarian androgen production in women with PCOS could be also 
attributed to reduced adiponectin.  
Obesity with associated increased adiposity further exacerbate the hormonal imbalance in 
PCOS patients. Obesity aggravates insulin resistance and hyperinsulinemia, but also 
hyperandrogenemia. Numerous studies report a positive relationship between BMI and 
androgens in both the paediatric and adult female population, opposite to what is observed in 
males (142,143). Although typically, women with PCOS were thought to have primarily 
increased visceral adiposity when compared with BMI-matched controls, employment of more 
sensitive imaging techniques revealed that there is no difference in volume of visceral, 
abdominal and gluteal subcutaneous adipose tissue depots between obese  PCOS and weighed 
matched controls (219). Interestingly, one study reported decreased visceral adiposity in 
young, lean PCOS women when compared with BMI- matched controls (220). Therefore, it 
seems that women with PCOS appear to manifest global adiposity, with similar distribution to 
BMI-matched control women.  
Nevertheless, excessive adiposity, and particularly android versus gynoid body fat 
distribution, has been suggested as an important factor in hyperandrogenemia. Android 
distribution, with increased VAT, was associated with decreased SHBG and increased free 
and total T concentrations, when compared with the gynoid distribution. The different 
distribution of steroidogenic enzymes, with increased 17β-HSD, converting A4 to T, in VAT 
versus increased aromatase, catalysing conversion of androgens to estrogens in SAT, has been 
proposed as a potential mechanism underlying different body fat distribution and elevated 
androgens levels in females with central adiposity. Conversely, increased expression of AR in 
VAT depots, as compared with the SAT was documented. In addition, obesity leads to 
dysfunction of adipose tissue, resulting in altered levels of circulating adipokines and 
Chapter 1 Literature Review 
38 
increased pro-inflammatory cytokines, which can further impair insulin resistance and 
stimulate steroidogenic enzymes in the ovary, accelerating androgen synthesis (130). 
1.3.6 Management of PCOS 
The complex pathophysiology and the broad clinical spectrum of PCOS entails a 
multidimensional therapeutic approach, however, lifestyle modification leading to sustained 
reduction of body weight remain central in improving the clinical, metabolic and hormonal 
characteristics of PCOS. Weight loss, through combination of balanced diet and regular 
exercise, should be undoubtedly encouraged in obese and overweight women, however, 
evidence has shown that even lean PCOS women can benefit from employing healthier life 
choices (323,324). It has been shown that even modest weight loss, by 10% of initial body 
weight, can increase frequency of ovulation, and improve the hormonal and metabolic profile, 
even if the women remain obese (325-328).  
1.3.6.1 Insulin sensitisers 
Insulin sensitisers, metformin and thiazolidinediones (TZDs) are commonly prescribed to 
women with PCOS, as evidence has shown that these pharmaceuticals can be beneficial in the 
management of this syndrome. Metformin is a biguanide generally used as an 
antihyperglycaemic agent, however, it has been also extensively evaluated as a potential 
treatment of infertility in PCOS. Metformin primarily improves insulin sensitivity, inhibits 
hepatic glucose production, and decreases intestinal glucose uptake, but also facilitates weight 
loss, reduces visceral adiposity and hyperandrogenemia, partially through direct action on 
ovarian theca cells, overall resulting in more favourable metabolic and hormonal profile (329-
333). In addition, studies have shown that metformin improved ovulation rate, likely due to 
reducing insulin levels and altering the effect of insulin on ovarian androgen biosynthesis 
(329). 
TZDs, namely rosiglitazone and pioglitazone, have also been found to be useful in decreasing 
IR and hyperandrogenemia, as well as restoring ovulation in PCOS. A study on the effects of 
six months of rosiglitazone treatment on obese and insulin-resistant PCOS women, 
demonstrated a decline in T and  DHEAS levels, an increase in insulin sensitivity and SHBG, 
and the number of ovulatory cycles, without changes in body weight (334). Studies comparing 
TZDs and metformin did not find differences in their insulin-sensitising effects however, 
TZDs have more side effects and treatment with metformin is preferable (332). Interestingly, 
TZDs have a variety of beneficial effects in adipose tissue, including insulin sensitisation, 
induction of browning, and anti-inflammation. Unfortunately, the clinical utility of TZDs has 
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been limited by their unfavourable side effect profile, including fluid retention, osteoporosis, 
and (possibly) increased risk of cardiovascular events.  
1.3.6.2 Oral contraceptives 
If pregnancy is not desired, the combined oral contraceptive pill (COCP), might be prescribed 
to regulate menstrual cyclicity and to attenuate the clinical signs of hyperandrogenism in 
PCOS. Treatment with COCP lowers both, LH and FSH and additionally, increases the hepatic 
production of SHBG, decreases adrenal androgen secretion, and reduces the risk of 
endometrial hyperplasia, which is associated with chronic anovulation (333). However, since 
PCOS is associated with metabolic comorbidities, treatment with COCP might not be 
sufficient. Some studies raise concerns that treatment with COCP might actually result in the 
deterioration of insulin sensitivity, glucose tolerance and lipid profile, especially in obese 
PCOS patients. 
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1.4 Aetiology of PCOS 
1.4.1 Heritability of PCOS 
Despite the numerous studies on PCOS, its origin is still not fully understood. It has been 
suggested that this syndrome has a heterogeneous aetiology, developing from a mixture of 
genetic and environmental factors, additionally modified by sexual maturation and ageing. 
The PCOS phenotype shows familial clustering and appears to be transmitted between 
generations with hyperandrogenemia and insulin resistance being the most common 
characteristics (335-340). It is estimated that 20-40% of first-degree female relatives of women 
with PCOS are also affected by this syndrome (335-340). Sisters of PCOS women have 
increased frequency of hyperandrogenemia and PCO morphology, higher LH and plasma 
insulin concentrations, decreased insulin sensitivity, and  greater incidence of obesity than 
women in the general population (341). In addition, male siblings or sons of PCOS women 
were found to have increased metabolic and hormonal perturbations, including IR and 
hyperinsulinemia, greater TG and cholesterol levels, elevated LH and FSH responses to GnRH 
agonist stimulation and higher DHEAS concentrations (342-346). Moreover, it has been 
documented that monozygotic twins shared twice as many features of PCOS than dizygotic 
twins, thus potentially supporting the hypothesis of a genetically inherited origin of PCOS 
(347). Although, since monozygotic twins are more likely to be exposed to an identical 
intrauterine environment than dizygotic twins, it could be argued that this could equally 
support the hypothesis of developmental programming of PCOS. Nevertheless, numerous 
studies have tried to ascertain the genetic basis of the syndrome, however, a robust genotype 
has not been identified.   
1.4.2 Genetics of PCOS 
Over than 100 PCOS-related candidate genes have been examined through candidate gene 
association studies. In this method, relationship of a genetic variation of candidate genes, 
usually a frequency of single-nucleotide polymorphism (SNP), with trait or disease, is 
investigated in case-control studies (348). More recently, the genome-wide association study 
(GWAS) technique was employed, in which an extensive number of SNPs are tested for 
association with a disease in a large number of selected individuals (349) 
The main categories of candidate-genes studied in PCOS included, genes involved in the 
biosynthesis and the action of androgens, genes related to metabolism, and genes correlated 
with inflammatory cytokines.  
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Several studies investigated link of specific alleles of CYP11A1 and CYP17A1 genes, key 
regulators in androgen biosynthesis, with PCOS however, results are contradictory. While 
some reported a positive association of CYP11A1 and CYP17A1 with hyperandrogenemia in 
PCOS (350-352), others did not confirm these findings (353-357). Polymorphisms in androgen 
receptors and their potential links with PCOS were also studied.  In a study by Ibanez et al., 
shorter CAG trinucleotide repeat length in the AR gene was found to be an indicative of 
increased androgen sensitivity and elevated risks for precocious pubarche, and subsequent 
ovarian hyperandrogenism in postpubertal girls (358), and women with PCOS (359). 
Furthermore, it has been demonstrated that polymorphisms of short CAG repeats in AR can 
impact the positive association between insulin resistance and free testosterone in women with 
PCOS (359). However, the results are inconsistent (360-363). 
Since PCOS is also strongly correlated with insulin resistance and metabolic syndrome, genes 
closely related with insulin signalling and obesity were also assessed. INSR is considered as 
an important candidate gene for PCOS, as  number of different nucleotide polymorphism of 
the INSR gene has been found to be associated with this syndrome (364-367). However, a 
recent meta-analysis of studies on polymorphism of INSR and PCOS found no significant 
evidence for association with PCOS (368). Insulin receptor substrates are critical downstream 
factors involved in insulin signalling, therefore, these were also considered plausible 
candidates for PCOS susceptibility. Several studies on polymorphisms of IRSs have been 
conducted but the results are inconclusive. A week correlation between polymorphisms in 
IRS1, but not IRS2, and PCOS was found (369,370). However, there was no correlation 
between IRS1 polymorphisms and the characteristic features of PCOS (369,370).  
An obesity-associated gene, FTO, has been identified as a strong candidate gene for PCOS. It 
was found that a FTO polymorphism is associated with PCOS (371), which correlated with 
hyperandrogenism (370,371), and insulin resistance (372). While the majority of the studies 
found that the FTO polymorphism was a strong predictor of obesity and adiposity in PCOS 
(371-374), one study reported that this association was independent of BMI (375). 
PCOS is associated with low grade inflammation, therefore it was speculated that genes 
associated with chronic inflammation, such as TNF and IL6, might contribute to the incidence 
of PCOS, although this may be secondary to hyperandrogenism, insulin resistance and obesity. 
Although some studies reported link between PCOS and  polymorphisms in TNF (376) and 
IL6 genes (377), a more recent meta-analysis did not confirm those findings (378). 
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To date, five GWAS studies were conducted on women with PCOS with different ethnicity, 
including Han Chinese (378,379), Korean (378,379) and European ancestry populations (380). 
From these studies, 15 risk loci have been identified, with genes associated with gonadotrophin 
action, folliculogenesis, ovulation, T2DM, T1DM and cell proliferation, and although these 
studies provided new clues for understanding the genetic components and cellular pathways 
in PCOS, we are still far from understanding its pathogenetic mechanisms. This is likely due 
to PCOS being a polygenic condition with a cluster of different molecular pathologies and 
clinical complications. 
1.4.3 Prenatal programming of PCOS 
As postulated by Barker et al. the maternal–fetal environment plays an important role in the 
developmental programming of adult disease by epigenetic modifications of genetic 
susceptibility (382-384). There is growing evidence that perturbed intrauterine environment 
during critical periods of development can permanently alter the trajectory of the growing fetus 
and predispose to adult chronic disease. Well known examples of insults resulting in 
developmental programming include maternal under- and overnutrition (385-387), smoking 
(388), stress (389), and hormonal imbalance. One of the most recognised studies on 
developmental programming is the Dutch famine study, documenting long-term metabolic 
effects in people born during or after the Dutch hunger winter of 1944-45 (390-391). Prenatal 
undernutrition resulted in a low-birth weight in offspring, and in adult life this cohort of people 
had significantly increased frequency of diabetes, cardiovascular and pulmonary disease, 
obesity and cancers (390,391).  
Although the molecular mechanism of developmental programming of adult disease are still 
largely unknown, epigenetic changes induced by an altered intrauterine environment are 
likely. Epigenetics refers to molecular mechanisms regulating gene expression not caused by 
DNA sequence variation, including DNA methylation, histone modification and other changes 
in chromatin structures  together with transcriptional and post-transcriptional regulations by 
noncoding RNAs (392).  
There is increasing evidence that the adult PCOS phenotype is programmed in fetal life by 
androgen excess. It is widely known, that women exposed to increased androgen levels in 
utero, due to congenital adrenal hyperplasia or virilising tumours, have increased risk of 
developing a PCOS-like syndrome in adult life, even after eliminating the hyperandrogenemia 
with postnatal therapies (393,394). Furthermore, testosterone levels in pregnant women with 
PCOS are higher than in normal pregnant controls throughout pregnancy and a particular 
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increase in testosterone concentrations in PCOS women was observed from the second 
trimester of pregnancy (395-397). In daughters of PCOS mothers testosterone levels in the 
amniotic fluid are elevated (395-397), which is further mirrored in increased testosterone 
concentrations in the umbilical vein at birth, as compared with control girls (398,399).  In 
addition, it was demonstrated that maternal circulating total testosterone level, within normal 
physiological range in unselected population, was significantly correlated with early follicular-
phase circulating AMH, a marker of  enhanced follicular development, in female adolescent 
offspring (398,399). Likewise, it was reported that three-month old and prepubertal daughters 
of PCOS mothers had elevated AMH concentrations, suggesting an altered follicular 
development during infancy and childhood (400,401). Interestingly, Crisosto et al. 
demonstrated that treatment of pregnant PCOS women with metformin, which reduced insulin 
and androgen levels in those women, reduced AMH levels in their newborns, as compared 
with the daughters of untreated PCOS women and comparable to levels seen in offspring from 
normal mothers (400,401).  In a retrospective study by Bridges et al. it was reported that most 
women diagnosed with PCOS in adulthood already had polycystic ovaries during childhood 
and puberty (402).  
Yet, despite this evidence, the hypothesis of prenatal androgenisation as an aetiological factor 
in PCOS was questioned for many years, as the human fetus is protected from the effects of 
excessive maternal androgens by a combination of high level of placental aromatase activity, 
which metabolises androgens to estrogens, and increased concentrations of plasma binding 
proteins, which decrease free testosterone in the circulation (403).  However, there is data 
demonstrating that placenta from PCOS women show macroscopic and microscopic 
alterations, as compared to healthy controls (404), and increased activity of placental 3β-HSD1 
and decreased placental aromatase, which could induce an accumulation of androgenic 
substrates (404). Further, although mechanisms underlying changes in placental activity of 
steroidogenic enzymes are not understood, potentially some of them could be attributed to 
increased insulin levels, as frequently reported in pregnant PCOS females (395,405), as it was 
demonstrated that in human placental cytotrophoblasts insulin inhibits aromatase activity 
(406), and promotes 3β-HSD1 activity (407). Conversely, disorders associated with impaired 
insulin sensitivity and hyperinsulinemia, such as gestational diabetes and preeclampsia, have 
been linked with decreased placental aromatase activity and increased AR levels (408). 
Interestingly, it was also found that in women with gestational diabetes there was a 
significantly higher concentrations of T and DHT in the amniotic fluid, in both male and 
female fetuses, when compared with those of their respective gender controls (409). Therefore, 
it cannot be excluded that fetal hyperandrogenism comes directly from increased fetal 
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production of androgens, ovarian and/or adrenal, as result of maternal and fetal 
hyperinsulinemia, which can stimulate androgen hypersecretion.   
Therefore, it is likely that combination of increased maternal androgens, decreased placental 
aromatase activity, and possibly elevated insulin levels, change the fetal environment, which 
predisposes female fetuses to the future development of PCOS. Animal models of PCOS 
provide further evidence supporting this hypothesis, which will be discussed in the next 
section. 
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1.5 Animal models of PCOS 
Animal models of PCOS provide an opportunity to examine the developmental aetiology and 
molecular mechanisms underlying the pathogenesis of this condition. However, the 
applicability of rodent models in understanding PCOS is restricted, due to the different patterns 
of in utero development, ovarian development and structure, the presence of several ovulations 
in any normal estrous cycle and therefore, naturally occurring multi-follicular ovaries (410). 
In non-rodent animal models however, prenatal androgen exposure of female primate and 
sheep fetuses clearly leads to a disrupted reproductive phenotype, with altered metabolism and 
ovarian morphology, neuroendocrine defects, hyperandrogenism and LH excess in adult life, 
resembling that of women with PCOS (411-416). 
1.5.1 Non-human primate model 
Female rhesus monkeys have been used as a non-human primate model of PCOS. Rhesus 
monkeys’ genome has a 93% similarity to that of humans, and their reproductive biology and 
metabolic physiology is analogous to humans. Thus, studies using this model of PCOS deliver 
the greatest translational relevance for human (417). Numerous studies demonstrated that 
prenatal exposure to testosterone yields a comprehensive adult PCOS-like phenotype in female 
rhesus monkeys (418-421). It was reported that prenatally androgenised females exhibited 
ovarian hyperandrogenism and higher levels of circulating testosterone (414), adrenal 
hyperandrogenism (420) and  LH excess (422). What is more, those females had 50% less 
menstrual cycles then control females and 40% exhibited polyfollicular ovaries (414). 
Interestingly, prenatally androgenised female rhesus monkeys also displayed metabolic traits 
of PCOS, namely: impaired insulin sensitivity and glucose intolerance, T2DM, increased 
abdominal adiposity and dyslipidaemia (414,418,419). These data provide strong evidence for 
the role of increased prenatal androgens in the programming of adult PCOS. Unfortunately, as 
monkeys are very expensive, with poor availability and a long lead-time to adulthood they are 
not the ideal pre-clinical model. 
1.5.2 Ovine model 
Sheep have many developmental and reproductive characteristics comparable with humans 
(423). In sheep, as in humans, ovarian differentiation is completed in utero and lambs are well 
developed at birth. Furthermore, sheep are mono- or bi-ovulatory therefore, compared to poly-
ovulatory rodents, are better animal model for studying the reproductive aspects of PCOS. In 
addition, their adult size is similar to adult humans, thus providing greater opportunity for 
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detailed and repetitive hormonal and metabolic profiling, and in consequence investigating 
aspects of metabolism, but also energy expenditure. Sheep are domesticated species therefore, 
can be kept in their natural environment for most of the time, free from stress associated with 
caging. Moreover, in comparison with rhesus monkeys, sheep are more cost-effective as an 
experimental research model. In addition, in comparison to rodents they are outbread with 
natural variability in phenotypes, like women. 
The ovine model of PCOS, like the rhesus monkey model, strongly supports the hypothesis of 
prenatal programming of PCOS. Numerous studies provided evidence that prenatal androgen 
exposure of female sheep, both with T and DHT, disrupts reproductive cyclicity and various 
aspects of metabolism (423). However, the severity of perturbations depends on the treatment 
window, with prenatal androgenisation from fetal day 30, of 147 day of gestation, causing 
masculinisation of female external genitalia and increased aggressive behaviour, while 
treatment from fetal day 60 to 90 results in less severe phenotype with normal external 
genitalia (423). 
Regardless of window treatment however, prenatally androgenised sheep have been shown to 
have altered cyclicity (424,425), with progressive deterioration of the reproductive phenotype 
with aging, and postnatal overfeeding (426,427). Moreover, prenatally androgenised ewes 
were reported to have elevated GnRH-induced LH response, leading to LH hypersecretion and 
acyclicity in adulthood (428), PCO morphology (429), increased androgenic capacity and 
altered gene expression of theca cells (412) and reduced fertility (430). In addition, these sheep 
were found to have decreased insulin sensitivity (411,426), altered pancreas morphology, with 
increased β-cell number (431), increased circulating FFA (423) and fatty liver (411).  
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1.6 The objectives of this thesis 
As discussed in the introduction of this thesis, PCOS is a complex condition with reproductive, 
endocrine and metabolic complications, however it seems that metabolic problems associated 
with the syndrome, such as obesity, insulin resistance and NAFLD, are the most concerning 
long-term issues. The ovine model of PCOS will be used. Previous research utilising this 
clinically realistic model of PCOS reported hyperinsulinemia and early fatty liver changes, 
with no difference in body weight and adiposity, in adolescence. This thesis will principally 
focus on the effects of prenatal androgen exposure on metabolic health, mainly in adolescent 
and adult female sheep, although data from fetal and juvenile animals will also be included in 
selected chapters.  
Chapter 3 will investigate the role of prenatally increased androgens on the development and 
function of adipose tissue depots, VAT and SAT, in fetal, juvenile, adolescent and adult 
PCOS-like sheep. Particularly, this chapter will examine expression of genes associated with 
adipocyte differentiation, insulin sensitivity and inflammation in SAT and VAT. In addition, 
this chapter will provide results of morphometric analysis of adipocytes from SAT and VAT 
in adult animals. In addition, the effects of direct treatment with steroids in utero on the 
development of SAT in adolescent females will be assessed.  
Chapter 4 will determine the role of postprandial thermogenesis, an important constituent of 
energy expenditure, in the development of obesity in adult PCOS-like sheep. In addition, this 
chapter will evaluate the expression of thermogenic genes in different depots of adipose tissue, 
in both adolescent and adult animals. Finally, noradrenaline levels in the adipose tissue depots 
in adult animals will be evaluated. 
Chapter 5 will investigate the causes and consequences of presence of fatty liver in adolescent 
PCOS-like sheep. Further, this chapter will evaluate fat liver content in adult animals and 
hepatic expression of genes associated with fatty acid uptake and processing.  
Finally, chapter 6, will determine potential role of novel metabolic regulators, fibroblast 
growth factor 21 (FGF21) and irisin in metabolic phenotype of adolescent and adult PCOS-
like sheep. 
The results presented in this thesis provide better understanding into the metabolic 
pathophysiology of PCOS from puberty to adulthood and give opportunities for early clinical 
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2.1 Introduction 
This chapter will list the general materials and methods that were utilised in this thesis, while 
more detailed methods will be described in the individual results chapters. Any work that was 
not carried out directly by author of this thesis will be acknowledged in the appropriate 
sections. All reagents and chemicals were obtained from Merc, former Sigma-Aldrich 
(Gillingham, Dorset, UK), unless otherwise stated. 
2.2 Animal husbandry 
Scottish Greyface ewes were used for these studies and housed and cared for at the Marshall 
Building, Roslin, East Lothian. All experiments were conducted under a UK Home Office 
project licence (PPL60/4401) after local ethical committee approval.  
2.2.1 Mating and pregnant ewe husbandry 
Prior to mating, ewes were assessed by body condition score and only those with a good score 
of 2-3 were chosen. To obtain a similar time of pregnancy across the cohort, estrous cycles of 
previously selected ewes were synchronised with Chronogest CR sponges infused with 20mg 
flugestone acetate, a synthetic progesterone (Intervet UK Ltd., Buckinghamshire, UK), which 
was implanted vaginally for 10-12 days. After the withdrawal of the sponges, to terminate 
luteal phase, 0.5ml of prostaglandin estrumate (Schering Plough Animal Health, Welwyn 
Garden City, UK) was administered intramuscularly (IM). Approximately 48h later, ewes 
came into heat, and the Scottish Greyface ewes were mated with Texel rams, marked with 
raddle crayons, under natural seasonal breeding conditions from November to January. Ewes 
that were not mated, as indicated by the lack of a reference paint on their hind, were returned 
for mating a second time. Pregnancies and number of fetuses per pregnancy were confirmed 
by ultrasound scan, and pregnant ewes with single, twin (or rarely) triplet pregnancies were 
evenly divided amongst treatment groups. Pregnant ewes were housed in groups in spacious 
enclosures, unless dominant ewes prevented smaller ewes from feeding, in which case smaller 
ewes were housed separately. Animals were fed hay ad libitum, supplemented with Excel Ewe 
Nuts (0.5-1.0kg/day; Carrs Billington, Lancashire, UK) and Crystalyx Extra High Energy Lick 
(Caltech Solway Mills, Cumbria, UK). To prevent Clostridial diseases and Pasteurellosis, 4-6 
weeks before lambing ewes received Heptavac P Plus (Intervet UK Ltd.).  
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2.2.2 Pregnant ewe treatment 
Treatment methods used for this thesis include maternal treatment and fetal treatment. When 
a twin pregnancy resulted in two female offspring or fetuses only one from each pregnancy 
was included in the analysis to avoid any possibility of genetic bias. 
2.2.2.1 Maternal Injections 
In the maternal injection (MI) cohort, pregnant sheep were treated intra-muscularly with 
100mg testosterone propionate (TP) (AMS Biotechnology (Europe) Ltd., Abingdon, UK), 
dissolved in 5% ethanol and added to vegetable oil (Sainsburys’s SO organic range) under 
aseptic conditions to achieve a final volume of 1ml, and stored in an incubator at 37°C until 
use, to prevent steroid precipitate formation. Control (C) ewes were treated with the 1ml of 
vehicle only, containing same proportion of 5% ethanol and vegetable oil, and stored in an 
incubator at 37°C. To avoid masculinisation of external genitalia, seen in animals treated from 
day 30 of gestation, treatment was started at day 62 of gestation. Animals were treated twice 
weekly from day 62 until day 102 of gestation, with pregnancy lasting on average 147 days. 
The dose and method of testosterone treatment were selected based on published data, with 
regards to postnatal reproductive disruptions.  
2.2.2.2 Fetal Injections 
In the fetal injection (FI) cohort, on day 62 and day 82 of gestation, mothers were anesthetised 
by initial sedation with Xylazine, 10mg; IM, (Rompun; Bayer PLC Animal Health Division, 
Berkshire, UK), followed by Ketamine, 2mg/kg; intravenously (IV), (Ketaset; Fort Dodge 
Animal Health, Southampton, UK). All subsequent procedures were conducted under surgical 
aseptic conditions. Fetuses were injected via ultrasound guidance using a vaginal probe into 
the fetal flank with 20G Quincke spinal needle (BD Biosciences, Oxford, UK) with following 
according to treatment group: C, 0.2ml vehicle (5% ethanol in vegetable oil); TP, 20mg TP in 
0.2ml vehicle; 50µg diethylstilbestrol (DES) in 0.2ml vehicle, or 100µg dexamethasone 
(DEX) in 0.2ml vehicle (Table 2.1).  Immediately after surgical procedure all treated ewes 
received prophylactic antibiotics (1ml/25kg of Streptacare, Animalcare Ltd, UK) and were 
then monitored during recovery; no significant adverse effects of these procedures were 
observed. The fetal injection commenced on the same day of pregnancy as maternal injections 
and were carried 20 days apart to best replicate the length of fetal exposure in maternal 
injection cohort. When twin pregnancy was involved, both fetuses were injected with the same 
compound. Ultrasound was performed by Prof. Colin Duncan, while Prof. Alan McNeilly, 
Prof. Mick Rae, Dr Kirsten Hogg and Dr Fiona Connolly carried out the fetal injection, in 
accordance with personal licences issued by the UK Home Office. 
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2.2.3 Non-pregnant treatment 
In addition, non-pregnant ewes were treated intra-muscularly with 100mg TP (AMS 
Biotechnology (Europe) Ltd., Abingdon, UK), in 1 ml vegetable oil, twice weekly for two 
weeks. Controls (C) were treated with the same volume of vehicle only. 
 
Maternal Treatment 
Treatment Period Collection Stage Treatment Sample Size 
D62- sacrifice D70 fetus C 3 
TP 6 
D62- sacrifice D90 fetus C 6 
TP 8 
D62-102 D112 fetus C 9 
TP 4 
D62-102 11 weeks lambs C 8 
TP 8 
D62-102 11 months ewes C 5 
TP 9 
D62-102 30 months ewes C 11 
TP 4 
Fetal treatment 





Contemporary androgen treatment 
2 weeks 30 months ewes C 5 
TP 5 
Table 2.1 Table of treatments and animal numbers used in studies documented in this thesis. 
 
2.2.4 Husbandry of offspring 
Lambs were suckled or fed with powdered lamb milk substitute (Shepherdess, SCA Mill, 
North Yorkshire, UK), then gradually weaned at 3 months, and fed hay or grass ad libitum, 
until sacrifice. Lambs were vaccinated with Heptavac P Plus (Intervet UK Ltd.) at 3 and 7 
weeks of age. 
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2.2.5 Animal sacrifice and specimen collection 
2.2.5.1 Animal sacrifice 
In pregnancies where fetal tissue was collected, ewes were sacrificed on either D70, D90 or 
D112 of gestation with sodium pentobarbital, 150mg/kg; IV, (Euthatal; Merial Animal Health 
Ltd., Essex, UK).  The gravid uterus was immediately removed, fetal sex and weight recorded, 
and tissue collected. In pregnancies carried to term, females were sacrificed and tissue 
collected at 11 weeks, 11 months, and 30 months of age. For 11 months old sheep, since 
animals were collected during breeding season, prior to euthanasia, sheep estrous cycles were 
synchronized with two injections of prostaglandin estrumate, 125mg (0.5ml); IM, (Schering 
Plough Animal Health) 11 days apart to ensure that all cycles were aligned. Adult, 30 months 
old ewes were sacrificed in non-breeding season. Euthanasia was performed with single lethal 
injection of sodium pentobarbital, 150mg/kg; IV (Euthetal; Medial Animal Health Ltd., Essex, 
UK), in accordance with the regulatory guideline of Schedule 1: Appropriate Methods of 
Humane Killing of Animals (Scientific Procedures) Act 1986.  
2.2.5.2 Tissue and plasma collection 
Prior to euthanasia, animals were fasted overnight and Intravenous Glucose Tolerance Test 
(IVGTT) was performed. Peripheral basal blood was sampled, followed by intravenous 
administration of bolus glucose (500mg/ml in 20ml) followed by another blood sample 
collection at 15 min. Blood was collected into heparinised tubes, centrifuged at 1200g at 4°C 
for 15 min and the plasma stored at -20°C. Animals were immediately sacrificed and tissue 
collected. Tissues (listed in Table 2.2) were fixed in Bouins solution for 24h, to prevent tissue 
degradation, and then transferred to 70% ethanol, before processing and embedding in paraffin 
wax, and/or snap frozen, to prevent RNA degradation, and stored at -80°C. In addition, liver 
samples were collected from adolescent and adult animals and embedded in cassettes 
containing OCT compound, (VWR International, Leicestershire, UK), snap frozen and stored 
at -80°C. Omental fat from each adolescent and adult animal was removed and weighed.   
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Tissue Collection Stage 
Fetal 
d70/90/112 
11 weeks 11 months 30 months 
Adrenal ✓  ✓ ✓ ✓ 
Cerebellum     ✓ 
Fat marrow     ✓ 
Fat scapular ✓    ✓ 
Fat supraclavicular     ✓ 
Fat subcutaneous ✓* ✓* ✓* ✓ 
Fat visceral ✓* ✓* ✓* ✓ 
Frontal cortex     ✓ 
Heart ✓    ✓ 
Hypothalamus ✓ ✓ ✓ ✓ 
Kidney ✓   ✓ 
Liver  ✓ ✓ ✓ ✓ 
Lung ✓   ✓ 
Mammary gland ✓ ✓ ✓ ✓ 
Muscle ✓ ✓ ✓ ✓ 
Ovary ✓ ✓ ✓ ✓ 
Pancreas ✓ ✓** ✓** ✓** 
Pituitary ✓ ✓ ✓ ✓ 
Spleen ✓   ✓ 
Thyroid ✓ ✓ ✓ ✓ 
Uterus ✓ ✓  ✓ ✓ 
Table 2.2 Ovine tissue collected at the time of sacrifice from different cohorts of animals.  →* Tissue 
frozen only; →**Tissue fixed only. Only selected tissue from the list above was studied in this thesis. 
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2.3 Histology  
2.3.1 Tissue Processing 
To preserve tissue morphology and antigenicity, at the time of collection, tissue samples were 
fixed in Bouins solution for 24h, and then transferred to 70% ethanol. Samples were processed 
and embedded in heated liquid paraffin wax and cooled into blocks for long term storage by 
Prof. Mick Rae. Tissue blocks were sectioned on microtome (Leica, UK) at the thickness of 
5µm, and wax ribbons were transferred to a pre-heated to 45°C water bath, mounted on poly-
L-lysine-coated microscope slides (Leica Biosystems, Peterborough, UK) and incubated at 
50°C for 24h to dry. 
2.3.2 De-waxing and rehydration 
Prior to any tissue staining protocol, slides were dewaxed in xylene for two separate 5 min 
incubations, to remove the hydrophobic paraffin wax from the tissue, and next rehydrated in 
gradient alcohol, 1 min each, in the following concentrations of alcohol 2x 100%, 90%, 80% 
and 75% and completed with incubation in distilled water (dH2O).     
2.3.3 Haematoxylin and Eosin Staining  
For the evaluation of gross tissue morphology haematoxylin and eosin (H&E) staining was 
utilised. Haematoxylin solution, a mixture of hematein and aluminium ions, has an overall 
positive charge and binds to negatively charged chromatic material in the cell nucleus, staining 
cell nuclei with blue/purple colour. Eosin, a negatively charged dye, binds to a positively 
charged proteins in the cytoplasm, resulting in a pink stain. After the de-waxing and 
rehydration process in gradient alcohol tissue slides were immersed in haematoxylin for 5 min 
and washed in dH2O. Next, tissue was very briefly rinsed in acid alcohol (1% HCL in 70% 
ethanol), to remove excess background stain, and again rinsed in dH2O. Slides were placed in 
Scott’s tap water for 30 sec, an alkaline bluing agent, to enhance contrast of the H&E stain. 
Slides were than washed in dH2O and immersed in eosin for 30 sec and rinsed again in dH2O. 
The tissue slides were subsequently thoroughly dried before undergoing dehydration in 
increasing grades of alcohol; 75%, 80%, 90% and 2 x 100% and cleared in xylene for 10 min. 
Slides were than mount with a cover slips using Pertex mounting media (Cell Path, UK) and 
allowed to dry in a fume hood for 24h.  
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2.3.4 Immunohistochemistry 
Immunohistochemistry (IHC), is a method that allows visualisation of the distribution and 
localisation of specific antigens, proteins or cellular components in a tissue sections, through 
utilising a principle of antibody-antigen interaction in a tissue. In a direct method of IHC, a 
primary antibody, with attached reporter molecule, binds directly to antigen however, this 
method, due to low abundance of binding, can yield a low signal. To further increase binding 
and intensify signal, an indirect protocol is often applied, where a secondary antibody 
conjugated to biotin, specific to primary antibody, i.e. raised against the host species of the 
primary antibody, is added. The avidin-biotin-peroxidase tertiary complex (ABC), is than 
utilised to bind the biotinylated portion of the secondary antibody through the high binding 
affinity of avidin for biotin. The final step of visualisation of the complex is achieved through 
addition of compound that reacts with the tertiary complex resulting in a stain, usually 3,3'-
diaminobenzidine (DAB) which yields brown coloured deposits. 
2.3.5 Antigen Retrieval 
Antigen retrieval step is often included in IHC protocol to expose the antigen epitopes which 
could be otherwise masked by fixation process due to protein cross linking, thus potentially 
obstructing the binding of the primary antibody to its target. Different antigen retrieval 
strategies exist with heat, digestive enzymes or detergents being widely used. In the 
experiments detailed in this thesis removing of cross-links was achieved through heating tissue 
slides in a citrate buffer. Following de-waxing and rehydration (Section 2.4.2), slides were 
submerged in a container of citrate buffer (0.05M, pH 6), which was then placed in a pressure 
cooker. Slides were pressured cooked for 5 min and then cooled for 20 min. After removing 
from pressure cooker slides were rinsed in dH2O and washed in phosphate buffered saline 
(PBS) twice for 5 min. 
2.3.6 Blocking  
In IHC protocols that utilise peroxidases and biotin for the amplification or enzymatic 
detection of target antigens, it is essential to reduce or mask endogenous forms of these 
proteins to prevent false positives and high background staining.  
To reduce endogenous peroxidase activity, and consequently a non-specific brown staining of 
DAB, after antigen retrieval (section 2.4.5) slides were immersed in 3% hydrogen peroxide 
(H2O2) diluted with dH2O for 10 min. Slides were than washed twice in PBS for 5 min each 
time. To block endogenous biotin activity and therefore, a non-specific staining, an 
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avidin/biotin kit was used (Vector Laboratories, Peterborough, UK). First, slides were treated 
with avidin for 15 min at room temperature to block endogenous biotin, washed with PBS for 
2 min, treated with biotin for 15 min to saturate any remaining biotin binding sites on avidin, 
and washed again for 2 min with PBS. Slides were quickly wiped with tissue to remove excess 
liquid, a water repellent barrier was drawn around tissues with a wax pen, to ensure any added 
solution would remain on tissue, thus preventing dehydration. Next, to prevent any non-
specific binding, tissue was incubated for 1h at room temperature in humidity chamber with 
serum matching the host species of the secondary antibody diluted in 5% bovine serum 
albumin (BSA). 
2.3.7 Incubation with Primary and Secondary Antibody 
After incubation, excess serum was removed from slides and primary antibody, diluted in 
blocking serum, was applied. An optimal concentration of primary antibody was tested prior 
to experiment. Tissue covered in blocking serum without primary antibody and non-specific 
matched immunoglobulins of equivalent concentrations served as negative controls. Details of 
primary and secondary antibodies used in this thesis can be found in the appropriate 
experimental chapters. Slides were placed in a humidity chamber and stored at 4°C overnight. 
Following incubation with the primary antibody, slides were washed in PBS supplemented 
with 1% Tween 20 (PBST), twice for 5 min. Subsequently, slides were incubated for 1 hour 
at room temperature with secondary biotinylated antibody, diluted 1 in 500 in blocking serum.  
2.3.8 Detection and Counterstaining 
After incubation with the secondary antibody, slides were washed twice for 5 minutes in PBST 
and incubated with the ABC Elite Complex (Vector Laboratories, Peterborough, UL), as per 
the manufacturer’s protocol, for 1 hour at room temperature. Subsequently, slides were washed 
twice in PBS before colourimetric detection with DAB substrate (Vector Laboratories), as per 
the manufacturer’s instructions, with the same exposure time for each sample, usually lasting 
for 30 sec to 1 min. The enzymatic reaction was stopped with slides immersion in dH2O. Slides 
were washed twice in dH2O and excess water was removed before adding to haematoxylin for 
1 minute for counterstaining. Slides were washed briefly in dH2O, excess water was removed. 
Next, slides were added to Scott’s Tap water and acid alcohol, and were dehydrated and 
mounted as described in Section 2.4.3.  
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2.3.9 Imaging 
Images of protein immunolocalisation were captured using the Olympus Provis BX2 
microscope (Olympus America Inc., Center Valley, PA, USA) with attached a Canon EOS 
30D Microcam camera (Canon Inc. Headquaters, Tokyo, Japan) using Axiovert v4.8 software 
(Carl Zeiss Ltd., Welwyn Garden City, UK). 
2.4 Western Blotting 
Western blotting is a method used in research to separate and identify proteins of interest, 
through antibody probing, in tissues or cells. In this technique, proteins are extracted from 
samples and separated, based on molecular weight, through gel electrophoresis. These proteins 
are subsequently transferred to a membrane, using an electric current, generating a band for 
each protein. Following protein transfer, membranes are blocked in an appropriate blocking 
buffer preventing nonspecific binding of detecting antibodies, therefore minimising 
background noise. The membrane is then incubated with primary antibodies specific to the 
proteins of interest. Several washing steps ensure that the unbound antibodies are washed off, 
leaving only the bound antibody to the protein of interest. The bound antibodies are then 
detected, using various methods. In this thesis, secondary fluorescent antibodies were utilised 
to visualise proteins of interest.  
2.4.1 Protein Extraction 
Protein extraction was carried using radioimmunoprecipitation assay (RIPA) buffer 
(ab156034, Abcam, Cambridge, UK). Briefly, a small piece of tissue (approximately 30mg) 
was cut over dry ice and samples were immediately transferred to 2ml eppendorf tubes 
containing 500µl of RIPA buffer, supplemented with 5µl of HaltTM Protease Inhibitor 
Cocktail and 5µl of HaltTM Phosphatase Inhibitor Cocktail (Thermo Scientific Pierce, 
Rockford, USA). Samples were kept on ice for the subsequent steps. Samples were sonicated 
with Soniprep 150 ultrasonic disintegrator (MSE, London, UK) for 15 sec with alternating 
cooling on ice, until homogenous mixture was obtained. Samples were then centrifuged at 
17500g at 4°C for 10 min to pellet unwanted cellular material. Supernatants were transferred 
to fresh eppendorf tubes and stored at -20°C.  
2.4.2 Protein Quantification  
Protein concentration was quantified using the Bradford assay, a colourimetric assay based on 
the binding of Coomassie dye to proteins (430). The assay principle is based on the colour 
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change from brown to blue upon binding of proteins to Coomassie dye under acidic conditions, 
represented by increased absorbance at 595nm proportional to the amount of protein present 
in the sample. The Bradford assay was performed by Dr Forbes Howie using the Cobas Fara 
centrifugal analyser (Roche Diagnostics, Welwyn Garden City, UK). The protein 
concentration was measured in 25µl of samples diluted with 50µl dH2O. A standard curve, 
created from serial dilutions of BSA in dH2O ranging from 0-100mg/l, was utilised to estimate 
sample concentration, ensuring all samples read on the linear portion of the obtained standard 
curve.  
2.4.3 Western Blotting Protocol 
Protein samples were diluted to given concentration in RIPA buffer and combined with equal 
volume of 1X Laemmli buffer (0.1M Tris-HCl pH 6.8, 20% glycerol, 2% (w/v) SDS, 0.16% 
(w/v) bromophenol blue and 3% β-mercaptoethanol (β-ME). Proteins were denatured at 99°C 
for 6 min and the samples loaded onto 4-20% Tris-HEPES-SDS Precast Polyacrylamide Mini 
Gels (Thermo Scientific Pierce, Rockford, USA). A full-range PageRulerTM Plus Prestained 
Protein Ladder (Thermo Scientific Pierce, Rockford, USA) was additionally loaded to one 
well per gel. Gels were submerged in a 1X Tris-HEPES-SDS Running Buffer (Thermo 
Scientific Pierce, Rockford, USA) and electrophoresed in Bio-Rad tanks (BioRad Laboratories 
Ltd.) at 100V at room temperature for 1h. Before proteins were transferred to a PVDF 
membrane (IPFL00010; Immobilon-FL PVDF; Merck Millipore, Darmstadt, Germany) using 
fast semi-dry blotter (Thermo Scientific Pierce, Rockford, USA) at 25V for 9 min, the 
membrane was submerged in methanol for 30 sec and subsequently the gel, membrane and 
filter papers were soaked in Western Blot Transfer Buffer (Thermo Scientific Pierce, 
Rockford, USA). Membranes were blocked in Odyssey Blocking Buffer (Li-Cor Biosciences, 
Ltd., UK) overnight at 4°C. The membranes were then incubated with a primary antibody for 
a housekeeping protein (loading control) diluted in Odyssey Blocking Buffer/PBS with 0.1% 
(w/v) Tween 20 (PBST20) for 2h at room temperature. Immunoblots were washed 4 times for 
5 min with PBST20 and incubated with the primary antibody of interest diluted in Odyssey 
Blocking Buffer/PBST20 for 4h at room temperature. Subsequently membranes were washed 
in PBST20 4 times for 5 min and incubated with two different fluorescently-labelled secondary 
antibodies diluted in Odyssey Blocking Buffer/PBST20/0.01% (w/v) SDS for 1h at room 
temperature. Finally immunoblots were washed in PBST20 4 times for 5 min and rinsed with 
PBS to remove residual Tween 20. Membranes were visualised on the Odyssey Imager (Li-
Cor Biosciences, Ltd., UK). The size of the visualised protein band was confirmed with 
reference to the molecular weight markers. Protein densitometry was analysed with Image 
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Studio Lite Software (Li-Cor Biosciences, Ltd., UK) with housekeeping protein levels used as 
an internal reference. 
2.5 ELISA 
Enzyme-linked immunosorbent assay (ELISA) is a plate-based assay technique, typically 
performed in 96-well polystyrene plates, designed for detecting and quantifying substances 
such as proteins, in a solution. The detection principle is based on a highly specific antibody-
antigen interaction. In an ELISA, the surface of the plate wells is coated with a capture 
antibody. In a competitive ELISA, competition for antibody binding sites between labelled 
antigen and sample antigen takes place, therefore the signal yielded is inversely proportional 
to the amount of the antigen in a tested sample. Conversely, in a sandwich ELISA, the sample 
antigen added to the plate binds directly to the capture antibody, and a second detection 
antibody is added, which binds the antigen. If the primary antibody is not conjugated, an 
addition of a secondary antibody conjugated to an enzyme is necessary. An addition of a 
colourimetric substrate results in a reaction, yielding a measurable product (signal). In a 
sandwich ELISA signal intensity is directly proportional to the amount of antigen present in 
sample. The reaction is stopped with the addition of stop solution and detection is 
accomplished spectrophotometrically, usually at 450 nm (ThermoMax Microplate Reader; 
Molecular Devices, CA, USA). Sample concentration was calculated based on standard curve 
of analytes with known concentration after subtracting background values of set of blanks.  
2.6 Multiplex immunoassay 
Multiplex immunoassays utilise the same principle of highly specific antigen-antibody 
interaction as the sandwich ELISA, however, they allow for detection of multiple analytes of 
interest in biological samples in a single experiment. These immunoassays utilise an xMAP 
bead-based technology, with a distinctly coloured bead sets created by the use of two 
fluorescent dyes at distinct ratios and conjugated with a specific capture antibody attached to 
beads. These colour-coded beads are used to identify the bound capture antibodies, and a 
sandwich assay with labelled detector antibodies is than used to measure protein levels. 
Subsequently, beads are read using a specialised flow cytometer and samples are decoded 
using a specialised software. 
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2.7 Gene expression 
2.7.1 RNA extraction  
RNA extraction from frozen tissue was performed using the RNeasy Kit (Qiagen Ltd., West 
Sussex, UK) however, depending on the tissue type different kits were used. 
2.7.1.1 RNA extraction from liver tissue 
RNA from liver tissue was isolated using the Qiagen RNeasy Mini Kit. A representative 3mm 
cube of tissue was cut over dry ice, to prevent tissue thawing and thus RNA degradation, and 
transferred immediately to 2ml safe-lock eppendorf tube with an autoclaved metal bead 
(Qiagen Ltd.), containing 600µl RLT lysis buffer with 1% v/v β-ME, to denature proteins and 
inactivate RNases, that could otherwise degrade RNA. Tissue samples were disrupted and 
homogenised using a TissueLyser (Qiagen Ltd.) at 25Hz for total of 4 min, with position 
change of TissueLyser racks after 2 min, to ensure even homogenisation of all samples. 
Samples were then centrifuged at 11500g for 3 minutes to remove precipitated proteins and 
cellular debris. The resulting supernatant was transferred to a fresh 1.5ml eppendorf tube and 
mixed with 600µl of 70% ethanol, diluted with nuclease-free (NF) H2O. Next, samples were 
transferred to an RNeasy spin column, centrifuged at 11500g, and the flow-through was 
discarded. Subsequently, columns were washed RW1 buffer, and an additional on column 
DNA digestion with DNase-1 (Qiagen Ltd.) was then performed to remove residual genomic 
DNA. Following a 15 min incubation with DNase at room temperature, spin columns were 
washed with RW1 and RPE buffers, as per the manufacturer’s instructions. Total RNA was 
eluted with 30µl NF H2O through centrifugation of collection tubes at 1150 g for 1 min and 
stored at -80°C. 
2.7.1.2 RNA extraction from adipose tissue 
To extract RNA from adipose tissue, a combination of TRI reagent, a monophasic solution of 
phenol and guanidinium isothiocyanate that simultaneously solubilises biological material and 
denatures protein, with Qiagen RNeasy Mini Kit was used. A 50mg sample of adipose tissue 
was cut on dry ice and transferred to 2ml Eppendorf tubess with metal beads, containing 1.5ml 
TRI reagent. Samples were homogenised using the Qiagen TissueLyser for 6 min at 25Hz and 
rested for 5 min at room temperature, to promote dissociation of nucleoprotein complexes. 
Lysates were transferred into new eppendorf tubes, and phase separated with addition of 0.3ml 
chloroform, to partition RNA into aqueous supernatant for separation, and vigorous mixing 
for 15 sec. Samples were incubated for additional 5 min at room temperature and centrifuged 
at 15000g at 4°C for 30 min. The upper aqueous phase containing RNA was collected and 
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mixed with the same volume of 70% ethanol. Following this step RNA was extracted as per 
the manufacturer’s instruction, eluted in 30μl NF H2O and stored at -80°C.  
2.7.1.3 RNA extraction from skeletal muscle 
RNA extraction from skeletal muscles was performed using Qiagen RNeasy Fibrous Tissue 
Mini Kit as per manufacturer’s instruction. A representative 3mm cube of tissue was cut over 
dry ice and transferred immediately to a 2ml safe-lock eppendorf tube with autoclaved metal 
bead (Qiagen Ltd.), containing 300µl RLT lysis buffer with 1% v/v β-ME, to denature proteins 
and inactivate RNases that could otherwise degrade RNA.  Tissue samples were disrupted and 
homogenised using a TissueLyser (Qiagen Ltd.) at 25Hz for total of 4 min, with position 
change of TissueLyser racks after 2 min, to ensure even homogenisation of all samples, 
Subsequently, Samples were transferred to new eppendorf tubes and 590µl of NF H2O and 
10µl of proteinase K solution (Qiagen Ltd.) was added, and mixed thoroughly by pipetting. 
Samples were incubated at 55°C for 10 min and centrifuged at room temperature at 10,000g 
to pellet down any tissue debris. Supernatants were transferred into new 1.5ml eppendorf tubes 
and 100% molecular grade ethanol was added (half volume of that of supernatant). Samples 
were then transferred onto spin columns. Following this step RNA was extracted as described 
previously, eluted in 30μl NF H2O and stored at -80°C.  
2.7.2 Measurement of RNA concentration 
RNA concentration and purity was assessed using a NanoDrop 1000 spectrophotometer 
(Thermo Fisher Scientific, UK). Samples were kept on ice, 1µl of sample was pipetted onto 
the lower measurement pedestal, sampling arm was closed and the absorbance was measured 
at 260nm to calculate RNA concentration. In addition, a ratio at 260nm/280nm was calculated, 
to estimate RNA purity. Sampling pedestal and arm were wiped with laboratory tissue in 
between measurement of consecutive samples, to prevent carryover and inaccurate readings. 
2.7.3 Complementary DNA synthesis 
Complementary DNA (cDNA) was synthesised from RNA template, via reverse transcription. 
Reverse transcriptase (RT) use an RNA template and a short primer complementary to the 3' 
end of the RNA to direct the synthesis of the first strand cDNA, which can be used in 
subsequent downstream quantitative real-time polymerase chain reactions (qRT-PCR), 
allowing the detection of low abundance RNAs in a sample. Complementary DNA was 
synthetised using TaqMan RT reagents kit (Applied Biosystems, UK) as per the 
manufacturer’s instruction. In each new set of cDNA samples prepared, a control omitting 
reverse transcriptase (RT) and reaction replacing cDNA with NF H2O, were included. Samples 
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were prepared in 0.2ml PCR tubes (Axygen Inc, Glasgow, UK). Reagents, volumes and end 
concentrations are displayed in Table 2.3. The cDNA was prepared on G-storm gradient PCR 
thermocycler (G-Storm GS1, GRI Ltd., Essex, UK) with 1h incubation of samples at 42°C 
followed by an enzyme inactivation step of 95°C for 10 minutes. Samples are then stored at -
20°C for further use.  
Reagent Volume (µl) 
Final 
Concentration 
RT Buffer 5 1X 
dNTP's mix 10 2mM 




RNase Inhibitor 5 1.0U/µl 
MultiScribe RT 5 2.5U/µl 
RNA (100ng/µl) 5 10ng/µl 
NF H2O 11.5  
Total volume 50µL  
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2.7.4 Quantitative Real-Time Polymerase Chain Reaction  
The Polymerase Chain Reaction (PCR) allows for specific sequences within a DNA or cDNA 
template to be amplified, using sequence specific primers, heat stable DNA polymerase, and 
thermal cycling. PCR reaction consists of three steps: denaturation, primer hybridisation and 
extension. First, a high temperature, approximately 94°C-95°C, is applied to denature double 
stranded DNA into single stranded DNA, or loosen secondary structures in single-stranded 
DNA. Next, temperature is lowered to approximately 60°C permitting binding of primers to 
the gene of interest on the single stranded DNA. Subsequently, the temperature is raised to 
72°C, which is an optimal for DNA polymerase activity, and primer extension occurs. 
Following the extension step, cycle is repeated, resulting in denaturation of the newly created 
double strand and creation of new complementary strand resulting in exponential amplification 
of the target DNA. Quantitative Real-Time PCR (qRT-PCR), unlike ‘traditional’ end-point 
PCR, in which detection and quantification of amplified sequences are performed at the end 
of last PCR cycle through gel electrophoresis and image analysis, permits the monitoring of 
each PCR cycle and allows for determining of the initial quantity of the amplified sequences. 
This is achieved through increase in fluorescence signal, emitted by fluorescence probes or 
DNA-binding dyes, measured by PCR instrument, which corresponds to gene amplification.  
2.7.5 SYBR Green DNA-binding dye 
SYBR Green dye is a fluorescent DNA-binding dye, which binds to the minor groove of any 
double-stranded DNA. The unbound SYBR Green dye produces little fluorescent signal, while 
a strong fluorescent signal is emitted during PCR amplification, due to binding to increasing 
copies of double-stranded DNA. Therefore, the fluorescent signal increases with the number 
of amplifications and is directly proportional to the number of amplified copies of double 
stranded DNA. The cycle threshold (Ct) value, representing the cycle number at which the 
fluorescent signal of the reaction crosses the threshold above background signal during the 
exponential phase of the reaction, is used to calculate the initial DNA copy number. However, 
as SYBR Green can be bound to any amplified product, target and non-target, therefore, testing 
the specificity of an assay is essential. It is normally performed by the analysis of the 
dissociation curve, a readout of gradual melting of the PCR products after the PCR cycling is 
completed. This is based on principle that one defined genetic sequence has specific melting 
temperature, therefore, only one sharp peak, representing denaturation of double-stranded 
DNA and thus dissociation of SYBR dye, should be present in the melting curve. Occurrence 
of any additional peaks indicates a non-specific amplification.  
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2.7.6 SYBR Green protocol and analysis 
Real-time quantitative amplification was performed on 384-well plate format (Applied 
Biosystems), with all samples run in duplicate and housekeeping control genes included in 
each run, using the ABI 7900HT Fast Real Time PCR system instrument (Applied 
Biosystems). A 10µl volume of final reaction mix was prepared with 5µl PowerSYBR Green 
PCR Master Mix (Applied Biosystems), 0.5µl primer pairs, 1µl cDNA, and 3.5µl NF H2O. 
The qRT-PCR cycling program consisted of an initial denaturation (95°C for 10 min), 
combined annealing and extension step (95°C for 15 sec, 60°C for 1 min), repeated 40 times, 
and a final dissociation step (95°C, 60°C, and 95°C, 15 sec each). Negative controls were 
included for each gene and consisted of RT negative (cDNA master mix without RT enzyme), 
H2O negative (cDNA master mix with RNA substituted for NF H2O) and PCR negative (PCR 
master mix with cDNA substituted for NF H2O) samples. Ct values were collated using the 
ABI 7900HT v2.3 software and exported to an Excel file. Ct values of sample duplicates were 
checked to verify accuracy and the melting curve was assessed to confirm the specificity of 
PCR product. The expression of the target gene relative to the housekeeping genes, as an 
internal control determined by geNorm assay of housekeeping genes (Primerdesign Ltd, 
Southampton, UK) was quantified using the ∆∆Ct method (432), as follows: 
Δ Ct = mean Ct of gene of interest – mean Ct of housekeeping genes 
Δ Ct calculated for both control and treatment samples 
ΔΔ Ct = Δ Ct treatment sample – mean of all Δ Ct control samples 
Gene expression = 2^- (ΔΔ Ct) 
  
Chapter 2 Materials and Methods 
66 
2.7.7 The selection of the optimal reference genes using geNorm 
In the qRT-PCR studies a normalisation step is essential. The use of reference (housekeeping) 
genes is the most effective method however, selection of genes with the most stable expression 
level unaffected by experimental treatments is critical to ensure the accuracy of qRT-PCR 
results. Therefore, to select the most stable house-keeping genes in ovine liver and adipose 
tissue, the geNorm Reference Gene Selection Kit with 12 candidate genes (Primerdesign Ltd, 
Southampton, UK) was carried as per the manufacturer’s instructions. Four samples per each 
treatment group were included in the assay. The analysis of the data using the provided 
geNorm software was performed by Grace Cathal. Table 2.4 summarises the most stable, with 
high reference target stability (geNorm M ≤ 0.5) housekeeping genes in selected ovine tissues.  





ACTB ATCGAGGACAGGATGCAGAA CCAATCCACACGGAGTACTTG 101 
MDH1 TTATCTCCGATGGCAACTCC GGGAGACCTTCAACAACTTTCC 100 
Visceral 
adipose tissue 
RPS26 CAAGGTAGTCAGGAATCGCTCT TTACATGGGCTTTGGTGGAG 106 
18S CAACTTTCGATGGTAGTCG   CCTTCCTTGGATGTGGTA   110 
Subcutaneous 
adipose tissue 
ACTB ATCGAGGACAGGATGCAGAA CCAATCCACACGGAGTACTTG 101 
MDH1 TTATCTCCGATGGCAACTCC GGGAGACCTTCAACAACTTTCC 100 
Table 2.4 Reference genes used in qRT-PCR studies. 
 
2.7.8 Primer Design 
Forward and reverse primers were designed for amplification of the gene of interest by qRT-
PCR using Primer3Plus online software (http://www.bioinformatics.nl/cgi-
bin/primer3plus/primer3plus.cgi), from DNA sequence obtained at Ensembl Genome Browser 
(http://www.ensembl.org/index.html). Primer regions were selected so that the forward and 
reverse sequence was intron spanning, primer length was 18-22 bp, primer melting 
temperature 52-65°C, and primer GC content 50-60%. Primer sequences were further assessed 
for likelihood of obtaining other similarly sized products using the Basic Local Alignment 
Search Tool (BLAST) provided by the National Center for Biotechnology Information 
(NCBI). 
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Primers were synthetised by Eurofins MWG Operon, Germany. Standard PCR was performed 
for validation of authenticity of the gene product. Standard PCR was performed on G-storm 
gradient PCR thermal cycler (Labcare Ltd, UK) using GoTaq Flexi DNA polymerase 
(Promega Ltd, UK). The PCR thermocycle consisted of an initial denaturation at 95°C for 5 
min, combined annealing and extension step (95°C for 30 sec, 60°C for 45 sec and 72°C for 
45 sec), repeated 35 times, and a final extension step at 72°C for 10 min. PCR products were 
visualised on a 2% agarose gel with 0.5% gel red prepared in 1X TAE buffer (0.04M tris 
acetate buffer, 0.001M EDTA), run alongside a 1000 bp ladder. Gel electrophoresis was 
carried out at 100V for 45 min and bands subsequently visualised in an ultraviolet light box 
Primer efficiency was assessed by generating standard curves in qRT-PCR, constructed using 
double dilution (1:2) of an representative cDNA template, and by using LinRegPCR software 
(433) whereas primer binding specificity by including a dissociation (melting) curve post qRT-
PCR-cycling, during each run. A linear standard curve generating a straight line with an R2 
value near to 1.0 and a slope of -3.33, and a single high peak in a dissociation curve implicated 
suitable primers.  
2.8 Statistical analysis 
Most of the analysis presented in this thesis involved a comparison between C and TP treated 
groups. The data was subject to Shapiro-Wilk normality test to assess if the values come from 
a Gaussian distribution. For comparing means of two treatment groups with equal variances, 
an unpaired, two-tailed Student’s t test was used, unless otherwise stated. If data was not 
normally distributed, a Mann Whitney test was utilised. To compare multiple sets of data a 
one-way analysis of variance (1 way-ANOVA) was used. Log transformation was used to 
approximate the normal distribution for parametric analysis when necessary. Each section 
provides details of statistical analysis utilised. GraphPad Prism 6.0 (GraphPad Prism Software, 
San Diego, CA, USA) was used to analyse data. A P value of <0.05 was considered as 
statistically significant. Results are presented as mean + S.E.M, where * signifies a P<0.05, ** 
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3.1 Introduction 
PCOS is a complex condition with reproductive, endocrine and metabolic characteristics, 
however, it seems that the most concerning long term key issues are metabolic problems 
associated with the syndrome, such as hyperinsulinemia, insulin resistance, obesity and 
dyslipidaemia  (434-436). Obesity and increased visceral obesity are considered key factors 
contributing to metabolic dysfunction in PCOS (437-440). Accumulation of VAT is correlated 
with pathologic inflammation and insulin resistance whereas SAT is thought to be protective 
or at least inert (441-447). Recently our group reported that midgestational androgenisation of 
female sheep resulted in hyperinsulinemia and early signs of NAFLD, independent of body 
weight or central obesity in adolescent, 11 months old PCOS-like sheep (411). These pubertal 
prenatally androgenised animals had no differences in ovulation rate, when compared to 
controls, during their first breeding season. They did not have a significant increase in basal 
circulating testosterone, but there was enhanced capacity for androgen synthesis in theca cells 
and adrenal glands (412) and circulating androgens were increased during adrenal stimulation 
testing. Interestingly similar results were described in adolescent daughters of PCOS mothers, 
showing that those girls are hyperinsulinemic without difference in body weight or adiposity 
and have increased testosterone levels in late puberty (448).  
WAT is the body’s primary long-term energy store, but it is also an important endocrine organ 
producing many adipokines and cytokines regulating energy homeostasis, insulin sensitivity 
and inflammation, therefore, functional WAT is essential in maintaining body homeostasis 
(73,449-451). WAT has a maximal expansion capacity, which is determined on an individual 
basis by environmental and genetic factors (452). When the capacity to safely store fat is 
saturated, lipid overflow occurs. Excess FFA are then deposited in non-adipose tissue such as 
liver and muscle, causing inflammation and insulin resistance by a lipotoxic mechanisms 
(453). We therefore hypothesised that altered adipose tissue morphology and function may be 
a central factor contributing to early metabolic disturbances in PCOS including IR and the 
early detection of NAFLD. 
Adipocytes derive from multipotent mesenchymal stem cells. There are two main phases of 
adipogenesis, determination and terminal differentiation. During the determination phase 
commitment of a pluripotent stem cell to the adipocyte lineage occurs, resulting in pre-
adipocyte formation. Morphologically preadipocytes cannot be distinguished from the stem 
cells however, those cells, in contrast to stem cells, do not possess ability to differentiate into 
different cell types. During terminal differentiation, preadipocytes gain characteristic traits of 
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mature adipocytes, including ability for lipid transport and synthesis, insulin responsiveness 
and production, and secretion, of adipokines.  Numerous transcription factors are involved in 
establishing the mature white adipocyte phenotype, however, PPARG and family of 
CCAAT/enhancer binding protein transcription factors (C/EBP) play a main role in controlling 
the entire terminal differentiation process (454-456). PPARG is a member of a nuclear-
receptor superfamily, and it has been demonstrated to be essential and sufficient for adipocyte 
differentiation. Studies have demonstrated that this gene is sufficient to induce adipocyte 
differentiation in fibroblasts and that adipogenesis cannot occur without presence of PPARG. 
In addition, it has been demonstrated that other pro-adipogenic factors, such as C/EBPs, induce 
PPARG promoters. Moreover, it has been shown that PPARG is also necessary to maintain 
the fully differentiated state of mature white adipocytes. In vivo experiments demonstrated that 
the knockout of PPARG in differentiated adipocytes leads to adipocyte death followed by the 
generation of new adipocytes. We hence aimed to: 
1. examine the expression of molecular markers of adipogenesis and mature adipocytes 
in adipose tissue of PCOS-like sheep during different stages of development; 
2. establish effect of different steroid classes on adipocyte differentiation; 
3. characterise the adult metabolic phenotype of PCOS-like sheep; 
4. perform morphological analysis of adult WAT. 
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3.2 Materials and Methods 
3.2.1 Experimental animals 
The ovine model, the animals used, their husbandry and treatments have been described 
previously (Section 2.2). The female animals assessed in this chapter are detailed in Table 3.1. 








Lambs 11 weeks old C=8, TP=8 
Adolescent 
Maternal Injection 
D62-102 Ewes 11 months old 
C=5, TP=9 
Fetal Injection 
D62 and D82 





Ewes 30 months old C=11, TP=4 
Contemporary Injections 
2 weeks 
Ewes 30 months old C=5, TP=5 
Table 3.1 Treatment regime, age and corresponding sample numbers of experimental animals discussed 
in this chapter.  
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3.2.2 Gene expression analysis using qRT-PCR  
Extraction of RNA from fetal and postnatal adipose tissue was performed using the 
combination of TRI reagent and Qiagen RNeasy Mini Kit (Qiagen Ltd., West Sussex, UK), as 
described in section 2.8.1. Protocols for cDNA synthesis and qRT-PCR are described in 
section 2.8.3. and 2.8.4, respectively. Forward and reverse primers were designed and 
validated as stated in section 2.8.6 and primer sequences analysed in this chapter are listed in 
Table 3.2.  
Gene Forward Sequence Reverse Sequence 
Product 
Size (bp) 
PPARG TGCAGTGGGGATGTCTCATA CAGCGGGAAGGACTTTATGT 172 
CEBPA GTGGACAAGAACAGCAACGA CGCAGTGTGTCCAGTTCG 185 
CEBPB GACAAGCACAGCGACGAGTA AGCTGCTCCACCTTCTTCTG 158 
CEBPD CGAGTACCGGCAGCGAC GTCGCGCAGTCCGGC 172 
LEP ATCTCACACACGCAGTCCGT CCAGCAGGTGGAGAAGGTC 202 
ADIPOQ AGAGATGGCACCCCTGGT GACCTTCGATCCCAGTGATT 100 
ADIPOR1 TCTCCTGGCTCTTCCACACT AGCTCCCCATGATCAGCA 99 
ADIPOR2 AGGTCGGGAGCCTCTTGTAG TGAACCCCTCATCTTCCTGA 107 
INSR CACCATCACTCAGGGGAAAC CAGGAGGTCTCGGAAGTCAG 247 
SLC2A4 CCAGCATCTTTGAGTCAGCA CAGAAGCAGAGCCACAGTCA 188 
IRS1 ATCATCAACCCCATCAGACG GAGTTTGCCACTACCGCTCT 240 
IRS2 TCCAGAACGGCCTCAACTAC TCAGGTGATGCGTCAAGAAG 246 
TNF GGTGCCTCAGCCTCTTCT GAACCAGAGGCCTGTTGAAG 132 
IL6 AAATGACACCACCCCAAGCA CTCCAGAAGACCAGCAGTGG 253 
CCL2 GCTCCCACGCTGAAGCTTGAAT GATTGTCTTTAGACTCTTGGGTTGTGGAG 369 
Table 3.2 Forward and reverse primer sequences and product size for genes analysed in the fetal and 
postnatal adipose tissue using SYBR Green qRT-PCR. 
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3.2.3 Western Blotting 
Western blotting was performed to assess the protein level of PPARG in SAT of 11 months 
old prenatally androgenised ewes from the maternal injection cohort. Due to unequal sample 
number between control (n=5) and TP group (n=9), 5 samples from TP group were randomly 
selected for this analysis. The western blotting protocol is described in Section 2.5 with 20 µg 
of total protein per sample loaded onto gel columns. The size of the visualised protein band 
was confirmed with reference to the molecular weight markers. Protein densitometry was 
analysed with Image Studio Lite Software (Li-Cor, Lincoln, USA) with STAT1 protein levels 
used as the loading control. Specific details of antibodies used are outlined in Table 3.3.  
Primary Antibody Concentration Details 
PPARG 1:500 
Polyclonal Goat              
(SC-1984; N-20)           
Santa Cruz Biotechnology 
STAT1 1:1000 
Polyclonal Rabbit           
(SC-346; E-23)              
Santa Cruz Biotechnology 
Secondary Antibody Concentration Details 
IRDye 680RD 1:10000 
Donkey anti-Goat          
(926-68074; Li-Cor) 
IRDye 800CW 1:10000 
Donkey anti-Rabbit       
(926-32213; Li-Cor) 
Table 3.3 List of primary and secondary antibodies used for western blotting. The antibody suppliers 
and working concentrations are detailed. 
3.2.4 Intravenous Glucose Tolerance Test 
Intravenous glucose tolerance tests were performed regularly during animals’ development to 
assess impact of prenatal treatments on glucose-insulin homeostasis. IVGTTs were performed 
by Prof. Colin Duncan with assistance of the staff at the Marshall Building. Animals were 
fasted overnight, basal blood samples were collected and an IVGTT performed by 
administering a bolus glucose injection (10g glucose in 20ml saline). Post-glucose 
administration, blood was sampled at 15 min intervals for 45 min. Blood samples were 
decanted into heparinised test-tubes for hormonal/metabolite measurements or S-Monovettes 
containing sodium fluoride with anti-coagulant (Sarstedt Ltd, numbrecht, Germany) for 
glucose measurement. Tubes were then centrifuged at 1200g for 15 min at 4°C, and the plasma 
collected for storage at -20°C.  
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3.2.5 Glucose and insulin measurements 
Serum glucose concentrations were performed by Dr Forbes Howie with enzymatic-
colourimetric glucose assay kit (Alpha Laboratories Ltd., Eastleigh, UK) using a Cobas Fara 
centrifugal analyser (Roche Diagnostics Ltd, UK). Assay sensitivity was 0.2mmol/l. The intra 
and inter-assay coefficients of variation (CV) were <2% and <3% respectively.  
Plasma insulin was measured using the ALPCO Ovine Insulin Elisa kit (80-INSOV-E01; 
American Laboratory Products Company, Salem) as per the manufacturer’s instructions. 
Immunoassay absorbance was measured at 450nm with a reference wavelength of 630nm 
using a ThermoMax Microplate Reader (Molecular Devices, CA, USA) and the concentrations 
were calculated from a cubic spline standard curve. All samples were assayed in duplicate. 
The assay sensitivity was 0.14ng/ml intra and inter-assay CVs were <5% and <6%, 
respectively.  
3.2.6 Measurement of other plasma analytes  
Concentrations of plasma triglycerides and FFA were obtained by Dr Forbes Howie using 
commercial assay kits (Alpha Laboratories Ltd., Eastleigh, UK) as per manufacturer’s 
instruction, using a Cobas Fara centrifugal analyser (Roche Diagnostics Ltd, UK) with assay 
sensitivity of 0.05mmol/l and 0.02mmol/l, respectively and CVs <3%.  
3.2.7 Plasma leptin concentration  
Plasma leptin concentration was obtained using Bio-Plex Human Diabetes Assay 
(171A7001M; Bio-Rad, Watford, UK), as per the manufacturer’s instruction. This assay 
allows for measurement 10 analytes at the same time although, only leptin results will be 
discussed in this chapter. The principles of multi-plex immunoassays were discussed in section 
2.7. All samples were assayed in duplicate and the results were acquired and calculated using 
Bio-Plex 200 array reader system with Bio-Plex Manager software (Bio-Rad, Watford, UK). 
The assay working range for leptin was 0.011-129ng/ml, assay sensitivity 3.1pg/ml, and intra 
and inter-assay CVs were 3% and 4%, respectively. 
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3.2.8 Plasma adiponectin concentration 
Plasma adiponectin was measured using human Adiponectin ELISA kit (KHP041; Invitrogen, 
Life Technologies, Paisley, UK), as per the manufacturer’s instructions. Immunoassay 
absorbance was measured at 450nm using a ThermoMax Microplate Reader (Molecular 
Devices, CA, USA) and the concentrations were calculated from standard curve by plotting 
the known concentration of standard against the absorbance values. All samples were assayed 
in duplicate. The assay sensitivity was 0.1ng/ml intra and inter-assay CVs were <5% and <6%, 
respectively. 
3.2.9 Adipocyte morphometric analysis 
Morphometric analysis of adipocytes was performed by Flavien Coukan, an undergraduate 
student, under supervision. For adipocyte morphometric analysis, two 5µm sections were cut 
for each adipose tissue sample, a minimum of 50µm apart, and mounted on positively charged 
slides (Superfrost Plus Gold, Thermoscientific, Epsom, UK). Sections were than stained with 
haematoxylin and eosin following standard protocol, as described in section 2.4.3. Two 
randomly selected fields per section were captured at x4 magnification using cellSens 
Dimension (Olympus, Essex, UK). Images were analysed using Adiposoft, ImageJ Software 
(ImageJ, University of Navarra, Spain) (457). Results were than manually corrected as per 
Adiposoft instructions and confirmed on a graticuled microscope.  
3.2.10 Statistical analysis 
Statistical analysis was performed with GraphPad Prism version 6.0 (GraphPad Sowftware, 
Inc., San Diego, CA). For comparing means of two treatment groups with equal variances an 
unpaired, two-tailed Student’s t test was used. To compare multiple sets of data a one-way 
ANOVA was used. Log transformation was used to approximate the normal distribution for 
parametric analysis when necessary A P value of <0.05 was considered as statistically 
significant. Results are presented as mean + S.E.M, where * signifies a P<0.05, ** P<0.01 and 
*** P<0.001. Area under the curve (AUC) was calculated using the trapezoidal method. 
Correlation was assessed by calculation of the Pearson r co-efficient. A line of best fit was 
incorporated only in the figures where correlation was statistically significant.  
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3.3 Results 
3.3.1 Adipocyte differentiation in adolescent VAT and SAT 
To determine whether metabolic perturbations reported previously in adolescent PCOS-like 
sheep were associated with altered adipogenesis in VAT, mRNA expression of the master 
adipogenic regulators was evaluated. There was no difference in the expression of PPARG, 
CEBPA, CEBPB (Fig. 3.1 A-C) while CEBPD level was increased (P<0.05; Fig. 3.1 D) in the 
VAT of adolescent prenatally androgenised female sheep. To fully confirm adipocyte 
maturation status, mRNA expression of selected markers of fully mature adipocytes was also 
assessed. There was no difference in the mRNA levels of LEP and ADIPOQ, in VAT of 





































































































Figure 3.1 Adipogenesis markers expression in VAT in adolescent female controls (C) and prenatally 
androgenised (TP) ewes, as quantified by qRT-PCR. P value of <0.05 was considered as statistically 
significant. Results are presented as mean + S.E.M, where * signifies a P<0.05.  
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We then looked at the expression of markers of adipogenesis in SAT in the same cohort of 
animals. Expression of PPARG, CEBPA, CEBPB was significantly downregulated (P<0.05; 
Fig. 3.2 A-C) with no difference in the expression of CEBPD (Fig. 3.2 D). In addition, levels 
of LEP and ADIPOQ in SAT were decreased in adolescent prenatally androgenised females 





































































































Figure 3.2 Adipogenesis markers expression in SAT in adolescent female controls (C) and prenatally 
androgenised (TP) ewes, as quantified by qRT-PCR. P value of <0.05 was considered as statistically 
significant. Results are presented as mean + S.E.M, where * signifies a P<0.05, ** P<0.01. 
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We therefore assessed protein levels of PPARG in both SAT and VAT (Fig. 3.3 A-B, 
representative blot). There was no alteration in level of PPARG protein in VAT (Fig. 3.3 C; 
quantified blot) but it was confirmed to be decreased in the SAT (P<0.01; Fig. 3.3 D; quantified 
blot) of adolescent females exposed to increased concentration of TP in utero. 
 
 
Figure 3.3 PPARG protein level in VAT and SAT samples of adolescent control (C) and prenatally 
androgenised (TP) female sheep, as quantified by Western blot. P value of <0.05 was considered as 
statistically significant. Results are presented as mean + S.E.M, where ** signifies a P<0.01. 
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3.3.2 Link between altered adipogenesis and dyslipideamia 
Downregulated expression of PPARG and C/EBP family of transcription factors suggested 
decreased differentiation of preadipocytes into mature adipocytes in SAT of TP exposed 
adolescent sheep. This consequently could lower capacity of SAT to safely store fat. SAT 
depot is the main source of FFA, and plasma FFA is the main substrate for hepatic TG 
production. Therefore, to further evaluate link between metabolic perturbations, especially the 
early signs of fatty liver reported previously, and alterations in SAT, we evaluated levels of 
plasma fasting FFA and TG. There was no difference in the levels of plasma TG (Fig. 3.4 A), 
however fasting FFA levels were increased (P<0.05; Fig. 3.4 B) in adolescent prenatally TP 
exposed sheep. Increased FFA negatively correlated with mRNA expression of PPARG, the 
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Figure 3.4 Plasma fasting TG and FFA in adolescent control (C) and prenatally androgenised (TP) 
animals (A-B). Correlation of plasma FFA with PPARG mRNA expression in VAT and SAT (C-D). P 
value of <0.05 was considered as statistically significant. Results are presented as mean + S.E.M, where 
* signifies a P<0.05. 
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3.3.3 Leptin and adiponectin levels during adolescence 
To determine whether decreased mRNA expression of LEP and ADIPOQ in SAT has systemic 
consequences, levels of circulating leptin and adiponectin were measured. Prenatal 
androgenisation of adolescent female sheep resulted in decreased concentration of circulating 
leptin and adiponectin (P<0.05; Fig. 3.5 A-B). In addition, it was observed that circulating 
leptin levels positively correlated with LEP mRNA levels in VAT (P<0.01; r=0.65; Fig. 3.6 
A), not with mRNA in SAT (Fig. 3.6 B). In contrast circulating adiponectin levels positively 













































Figure 3.5 Plasma fasting leptin and adiponectin in adolescent control (C) and prenatally androgenised 
(TP) animals, as measured by ELISA. P value of <0.05 was considered as statistically significant. 
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Figure 3.6 Correlation of plasma leptin and adiponectin with LEP and ADIPOQ gene expression in 
VAT and SAT in adolescent control (C) and prenatally androgenised (TP) animals.  
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3.3.4 Adiponectin and insulin signalling in adipose tissue during 
adolescence 
Adiponectin regulates insulin sensitivity and lipid metabolism, mediating its action through 
adiponectin receptor 1 (ADIPOR1) and 2 (ADIPOR2). Adiponectin can act at endocrine, 
paracrine and autocrine levels. We therefore assessed mRNA levels of those receptors in VAT 
and SAT. There was no difference in mRNA expression of ADIPOR1 and ADIPOR2 in VAT 
(Fig. 3.7 A-B), however ADIPOR2 was significantly downregulated in SAT (P<0.05; Fig. 3.7 





































































Figure 3.7 Expression of adiponectin receptors ADIPOR1 and ADIPOR2 in VAT and SAT of adolescent 
control (C) and prenatally androgenised (TP) animals, as quantified by qRT-PCR. P value of <0.05 was 
considered as statistically significant. Results are presented as mean + S.E.M, where * signifies a 
P<0.05. 
 
To further evaluate downstream insulin signalling in adipocytes we assessed mRNA levels of 
INSR, IRS1, IRS2 and SLC2A4, encoding GLUT4, in VAT and SAT. Exposure to increased 
androgens levels in utero resulted in decreased mRNA levels of INSR, IRS2 and SLC2A4 
(P<0.05; Fig. 3.8 E, F, H, respectively), but no significant change in IRS1 (Fig. 3.8 G) in SAT, 
whereas there was no difference in the expression of those genes in VAT between control and 
TP exposed animals (Fig. 3.8 A-D).   








































































































































Figure 3.8 Insulin signalling in VAT and SAT of adolescent control (C) and prenatally androgenised 
(TP) animals, as quantified by qRT-PCR. P value of <0.05 was considered as statistically significant. 
Results are presented as mean + S.E.M, where * signifies a P<0.05. 
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3.3.5 Inflammation markers in adipose tissue 
It has been shown that increased levels of pro-inflammatory mediators TNFα and IL6 
downregulate adiponectin expression, therefore we evaluated mRNA expression of TNF and 
IL6 in VAT and SAT of adolescent sheep. Expression of TNF was significantly upregulated 
in SAT of prenatally androgenised sheep (P<0.05; Fig. 3.9 C) with no difference in the 
expression of IL6 (Fig. 3.9 D). There was no difference in the expression of TNF and IL6 in 





































































Figure 3.9 Expression of inflammation markers TNF and IL6 in VAT and SAT of adolescent control 
(C) and prenatally androgenised (TP) animals, as quantified by qRT-PCR. P value of <0.05 was 
considered as statistically significant. Results are presented as mean + S.E.M, where * signifies a 
P<0.05. 
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3.3.6 Adipocyte differentiation in SAT in fetal and early life. 
To determine, at what stage of development we can detect changes in adipogenesis, we have 
investigated expression of adipogenesis markers in SAT of prenatally androgenised female 
fetuses and juvenile prenatally androgenised sheep. There was no difference in the expression 
of PPARG, CEBPA, CEBPB and CEBPD in SAT of D112 female fetuses (Fig. 3.10 A-D) and 














































































































































Figure 3.10 Expression of adipogenesis markers in SAT in control (C) and prenatally androgenised (TP) 
animals at fetal day 112 (A-D) and at 11 weeks of age (E-H), as quantified by qRT-PCR. Results are 
presented as mean + S.E.M. 
Chapter 3 The effect of prenatal androgenisation on WAT 
87 
3.3.7 Temporal androgenisation of sheep did not result in altered 
adipogenesis 
To assess if temporal androgenisation of sheep might affect adipogenesis, we investigated 
expression of markers of adipogenesis in SAT of sheep treated with testosterone for two 
weeks. There was no difference in the expression of PPARG, CEBPA, CEBPB and CEBPD in 


































































Figure 3.11 Expression of adipogenesis markers in SAT in control (C) and temporally treated with 
testosterone (TP) normal animals, as quantified by qRT-PCR. Results are presented as mean + S.E.M. 
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3.3.8 The effect of different steroid classes on adipogenesis 
To establish if perturbations in adipocyte development in SAT is due to direct treatment with 
testosterone or indirect effect of estrogen or glucocorticoids, the effect of different steroid 
classes on adipocyte differentiation was assessed. To ascertain this question, we had a separate 
cohort of adolescent, 11 months old animals that were directly injected in utero with TP, DES 
and DEX. Direct fetal injection with DES and DEX showed no effect on the expression of 
PPARG, CEBPA, CEBPB and CEBPD in adolescent sheep (Fig. 3.12 A-D). In contrary, direct 
injection with TP resulted in decreased levels of PPARG, CEBPA and CEBPB (P<0.05; Fig. 
3.12 A-C), with no difference in the expression of CEBPD (Fig. 3.12 D).  


































































Figure 3.12 Effect of direct fetal steroid injections on the expression of adipogenesis markers in SAT 
in adolescent control (C), testosterone (TP), diethylstilbestrol (DES), and dexamethasone (DEX) treated 
animals, as quantified by qRT-PCR. P value of <0.05 was considered as statistically significant. Results 
are presented as mean + S.E.M, where * signifies a P<0.05. 
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3.3.9 Metabolic parameters of adult prenatally androgenised sheep 
In adulthood, at 24 and 30 months of age, PCOS-like sheep had increased body weight when 
compared with control animals (C: 79.73 ±1.57kg; TP: 85.75 ±0.75kg) (P<0.05; Fig. 3.13 A), 
and trend towards increased total abdominal adiposity however, this did not reach statistical 






















































































Figure 3.13 A) Birthweight and postnatal weight in control (white bars) and prenatally androgenised 
animals (black bars). B) Weight of omental fat in adult controls (C) and prenatally androgenised animals 
(TP), as excised and weighed during the animals’ dissection. Results are presented as mean + S.E.M, 
where * signifies a P<0.05. 
 
Adult, prenatally androgenised animals had increased basal (fasting) insulin concentrations 
and decreased basal G:I ratio (P<0.05; Fig 3.14 A and B, respectively), suggesting decreased 
insulin sensitivity. Over the duration of the 45 minutes IVGTT there was no difference in 
AUCglucose (Fig. 3.14 C), however AUCinsulin was significantly elevated in TP exposed 
adult ewes as compared to vehicle controls (P<0.05; Fig. 3.14 D).  
































































































Figure 3.14 Effect of prenatal androgenisation on A) Fasting glucose B) Fasting insulin C) Glucose 
dynamics during 45 min IVGTT and D) Insulin dynamics during 45 min IVGTT. P value of <0.05 was 
considered as statistically significant. Results are presented as mean + S.E.M, where * signifies P<0.05. 
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3.3.10 Markers of adipogenesis in adult SAT and VAT 
We next investigated expression of adipogenesis markers in adult VAT and SAT. There were 
no differences in the expression of PPARG, CEBPA, CEBPB and CEBPD in adult both VAT 
(Fig. 3.15 A-D) and SAT (Fig. 3.16 A-D). There were also no differences in the mRNA 
expression of selected markers of fully differentiated adipocytes (ADIPOQ and LEP) in VAT 





































































































Figure 3.15 Adipogenesis markers expression in VAT in adult female controls (C) and prenatally 
androgenised (TP) ewes, as quantified by qRT-PCR. Results are presented as mean + S.E.M.  
 


































































































Figure 3.16 Adipogenesis markers expression in SAT in adult female controls (C) and prenatally 
androgenised (TP) ewes, as quantified by qRT-PCR. Results are presented as mean + S.E.M. 
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3.3.11 Histological analysis of VAT and SAT  
We next performed histological analysis of adult VAT and SAT. Images of representative 
visceral and subcutaneous sections from control and PCOS-like animals are shown in Fig. 
3.17. The mean numbers of adipocytes analysed in visceral and subcutaneous adipose tissue 
were 1923 ±111 and 4028 ±197 cells/animal, respectively.  Adipocytes numbers were 
stratified according to 3 size categories: small (<1000µm2), medium (1000-5000µm2) and 
large (>5000µm2). Results from morphometric analysis of adipocytes revealed that although 
there was no statistically significant difference in the mean size of SAT adipocytes between C 
and TP animals (P=0.06; Fig. 3.18 D), there was increased number of large adipocytes in SAT 
of TP-exposed animals when compared to vehicle treated controls (P<0.05; Fig.3.18 E) and 
consequently decreased number of total adipocytes per mm2 of section analysed (P<0.05; 3.18 
B). There was no alteration in adipocyte size or total number in VAT of adult PCOS-sheep 
(Fig. 3.18 C, E and A, respectively). 
 
Figure 3.17 Representative adipose tissue sections from VAT and SAT of adult control (C) and 
prenatally androgenised animals (TP); scale bars = 100µm. 
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Figure 3.18 Total adipocyte count per mm2 in A) VAT and B) SAT. Mean size of adipocytes in C) VAT 
and D) SAT. Percentage of adipocyte per size category in A) VAT and B) SAT. Two sections per sample 
were analysed in adult control (C) and prenatally androgenised animals (TP). P value of <0.05 was 
considered as statistically significant. Results are presented as mean + S.E.M, where * signifies a 
P<0.05. 
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3.3.12 Consequences of adipocyte hypertrophy in adult SAT  
Adult, TP-exposed animals had increased levels of fasting FFA when compared to controls 
(p<0.05; Fig. 3.19 A) and there was negative correlation between total number of subcutaneous 
adipocytes and levels of circulating FFA (p<0.05; r=-0.61; Fig. 3.19 B). In addition, expression 
of inflammation markers TNF and IL6 as well as CCL2, encoding MCP-1 protein, was 
significantly upregulated in SAT (p<0.05-0.01; Fig. 3.20 D-F) but not VAT (Fig. 3.20 A-C) 
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Figure 3.19 A) Fasting plasma FFA in adult control (C) and prenatally androgenised animals (TP); B) 
correlation of FFA with total adipocyte count per mm2 in SAT of adult C and TP animals. P value of 
<0.05 was considered as statistically significant. Results are presented as mean + S.E.M, where * 
signifies a P<0.05. 
 









































































































Figure 3.20 Expression of inflammation markers in VAT and SAT in adult control (C) and prenatally 
androgenised animals (TP), as quantified by qRT-PCR. P value of <0.05 was considered as statistically 
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3.4 Discussion 
PCOS is characterised by a broad spectrum of symptoms, with insulin resistance, obesity and 
increased visceral adiposity playing significant role in its pathophysiology. Furthermore, 
metabolic problems of women with PCOS worsen with age. It is widely accepted that the 
degree of insulin resistance increases in parallel with excessive fat mass. However, 
lipodystrophic patients with insulin resistance or obese people with an otherwise overall 
healthy profile seem to contradict that. Therefore, it has been postulated that individual 
capacity for adipose tissue expansion to safely store caloric excess is more essential in 
determining metabolic health than total fat mass (458). This hypothesis is further supported 
by studies in animal models, where genetically modified mouse with limitless capacity for 
adipose tissue expansion remains insulin-sensitive and has no signs of fatty liver, despite 
having 50% body weight increase (459).   
Our lab reported previously that adolescent, 11 months old prenatally androgenised female 
sheep, were hyperinsulinemic and had early fatty liver changes with no difference in body 
weight or central obesity (411). We have now found that mRNA and protein expression of 
PPARG, the master regulator of adipogenesis, as well as CEBPA and CEBPB are 
downregulated in SAT, but not VAT, in adolescent prenatally TP-exposed animals. This 
finding suggests decreased differentiation of preadipocytes into mature adipocytes. 
Interestingly, only the expression of CEBPD in SAT was unaltered. Adipocyte differentiation 
is regulated by sequential expression of adipogenic factors. Early stage of preadipocyte 
differentiation is marked by increased expression of CEBPB and CEBPD, which in turn 
promote expression of CEBPA and PPARG in the late stage (460).  When expressed, CEBPA 
and PPARG act in the feedback loop to sustain their expression and direct adipocytes toward 
terminal differentiation (461). This is accompanied by expression of adipocyte-specific genes 
such as SLC2A4, LEP and ADIPOQ. No reduced expression of CEBPD might suggest that late 
stage of adipocyte differentiation, rather than early, is affected in SAT of adolescent PCOS-
like sheep.  Decreased adipogenesis indicates lower capacity of SAT to safely store fat. We 
also found increased levels of FFA in these animals, which supports evidence for decreased 
lipid storage volume in SAT. This could potentially explain presence of fatty liver and 
hyperinsulinemia in the adolescent TP-treated animals, due to increased release of FFA into 
circulation, subsequent lipotoxicity and decreased insulin sensitivity in peripheral tissue. 
Unfortunately, we were unable to perform morphological analysis of SAT from 11 month old 
animals. However, our findings are with agreement with these reported by Keller et. al and 
Veiga-Lopez et. al. where perturbed differentiation of subcutaneous adipocytes in prenatally 
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androgenised female monkeys and sheep were reported, respectively. (462,463). This finding 
is further supported by studies using the thiazolidinedione class of antidiabetic drugs which 
are also potent stimulators of adipose tissue differentiation. It has been shown that these drugs 
ameliorate NAFLD and reduce FFA by promoting adipose tissue expansion (464).   
We further investigated at what stage of development we could detect changes in adipocyte 
differentiation. We did not find any difference in the expression of adipogenesis markers in 
prenatally androgenised female fetuses during late gestation or in juvenile sheep, suggesting 
that altered adipogenesis correlates with onset of puberty. There was also no difference in the 
expression of adipogenesis markers in adult life.  This is in agreement with recent findings, 
showing that number of adipocytes is set during childhood and adolescence, and stays constant 
in adulthood, with 10% annual turnover, independent of BMI (465). Several studies have now 
shown that increase or decrease in body weight with corresponding fluctuations in body fat 
mass leads to changes in adipocyte volume but not the number (128,465-468). SAT represents 
about 80% of total body adipose tissue and given constant adipocyte number in adulthood, 
decreased SAT adipogenesis in adolescents would result in decreased storage capacity in 
adulthood and increased lipid storage in already developed adipocytes, resulting in 
hypertrophy. This is in agreement with our findings, showing that adult PCOS-like sheep have 
decreased total number of adipocytes in SAT with a corresponding increase in large, 
hypertrophic adipocytes. Enlarged adipocytes are less insulin sensitive and individuals with 
hypertrophic adipocytes in SAT are more insulin resistant than people with comparable 
adiposity but smaller adipocytes (469-471). In addition, hypertrophic expansion of SAT is 
associated with altered adipokine secretion, inflammation and  fibrosis (461). Interestingly, 
adult PCOS women were reported to have enlarged subcutaneous adipocytes, lower serum 
adiponectin levels and lower adipose tissue LPL activity compared to age and BMI matched 
controls (231,472). In addition, Manneras-Holm et al. noted that women with PCOS had 
increased waist-to-hip ratio compared to BMI matched controls, without differences in 
abdominal adipose tissue volume, as measured by MRI, potentially suggesting that these 
women might have lower volume of gluteofemoral adipose tissue (472). Therefore, it can be 
hypothesised, that due to decreased capacity of SAT in PCOS women and sheep, even normal 
caloric intake could be relatively excessive, eventually resulting in SAT hypertrophy, leading 
to subsequent increase in visceral adiposity and insulin resistance. Results from this study 
support this hypothesis. Despite being on a normal, healthy diet, our experimental, prenatally 
androgenised animals become obese in their early adulthood, have a trend for increased 
visceral adiposity, have increased fasting FFA and are hyperinsulinemic. Furthermore, we can 
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speculate that if these animals were fed a high fat diet, we would observe a faster and 
exaggerated metabolic perturbations.  
Adipogenesis in PCOS patients has not been investigated however, there is growing evidence 
of decreased adipogenesis in SAT from insulin resistant individuals and subjects with 
abdominal obesity (473-475). A recent study investigating genome-wide gene expression and 
DNA methylation in SAT from PCOS women, reported decreased mRNA expression and 
increased DNA methylation of the PPARG gene (476). Authors also reported that PPARG 
gene expression was positively correlated with insulin sensitivity and negatively correlated 
with adipocyte size and testosterone levels although association was diminished after 
adjustment for BMI (476). PPARG, the master regulator of adipogenesis, also controls gene 
expression related to a broad spectrum of physiological processes including insulin signalling, 
adipokine production, lipid transport and metabolism, macrophage function and immunity 
(477). It has been shown that there is 2-fold higher expression of PPARG in SAT than in VAT,  
PPARG adipogenic potential in vitro in VAT is reduced, and that PPARG agonists cause 
expansion of SAT, but not VAT (478-480). This evidence suggests that PPARG might play a 
more central role in regulating adipogenesis in SAT rather than VAT, possibly explaining why 
adipocyte differentiation is only affected in SAT in adolescent PCOS-like sheep.  
Decreased expression of LEP and ADIPOQ in SAT of adolescent prenatally androgenised 
animals suggest higher number of undifferentiated adipocytes, since these genes are expressed 
in mature adipose cells.  In addition, we found that levels of circulating leptin and adiponectin 
were correspondingly decreased in adolescent PCOS-like sheep. There was positive 
correlation of ADIPOQ mRNA in SAT, but not VAT, with circulating adiponectin, whereas 
circulating leptin correlated with LEP mRNA in VAT but not SAT. Degawa-Yamauchi et al. 
also reported similar associations, with ADIPOQ mRNA in human female SAT, but not VAT, 
being positively correlated with circulating adiponectin and negatively correlated with BMI, 
and LEP mRNA in VAT correlating with adiposity (481). Therefore, these findings indicate 
that circulating leptin levels are strongly associated with visceral adiposity, however, we 
observed decreased leptin levels without significant difference in visceral adiposity in 
adolescent TP-exposed animals, and therefore it is possible that decreased expression of LEP 
mRNA in SAT impact circulating leptin levels. Leptin is an important adipokine, suppressing 
food intake, promoting energy balance and regulating body weight. Therefore, low levels of 
leptin during puberty in TP-exposed sheep might contribute to increased body weight and 
adiposity in adult PCOS-like animals. Given that there is positive correlation between 
ADIPOQ mRNA in SAT and circulating adiponectin, decreased adiponectin levels might be a 
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consequence of decreased adipogenesis in SAT of adolescent PCOS-like sheep. This finding 
is further supported by evidence that both adiponectin and leptin levels are decreased in 
lipodystrophic patients (482). Adiponectin, primarily secreted from SAT, is an insulin 
sensitising adipokine, promoting lipid oxidation, inhibiting hepatic gluconeogenesis and 
reducing plasma concentrations of FFA (483-485). Adiponectin also stimulates glucose uptake 
in adipocytes by increasing mRNA and translocation of SLC2A4 (GLUT4), therefore low 
levels might contribute to insulin resistance (486).  Adiponectin was also reported as an 
autocrine factor regulating adipocyte differentiation and promoting cell differentiation 
(486,487). Adiponectin levels negatively correlate with BMI, however, decreased circulating 
adiponectin levels, independent of adiposity, are recurrently reported in adolescent  and adult 
PCOS patients (321,322,448,488-490), suggesting its potential use as a biomarker of PCOS 
(491-493). As recently reviewed by Li et al. there is inconsistent data with regards to  
relationship of adiponectin and androgen levels in PCOS (236). However, there is evidence 
that androgens decrease plasma adiponectin in vitro and in vivo (115,494) and that testosterone 
administration decreases adiponectin level in men and in female to male transsexuals (495-
497). Gender differences in adiponectin levels in adolescence were also described, with 
significantly lower adiponectin levels in  adolescent boys compared with girls, and adiponectin 
being inversely correlated with testosterone levels (498,499), therefore it is possible that 
androgens may play a role in dysregulation of adiponectin levels. Simultaneously, the 
relationship between adiponectin and testosterone concentrations in PCOS women could 
reflect the direct effect of adiponectin on ovarian steroidogenesis. Adiponectin decreases the 
production of androgens in theca cells in vitro and expression of adiponectin receptors is 
decreased in theca cells from polycystic ovaries, consequently low levels of adiponectin may 
contribute to hyperandrogenism in PCOS women (237,500,501). Our group have previously 
reported enhanced androgen synthesis capacity in theca cells from adolescent PCOS-sheep 
therefore, it is likely that decreased adiponectin levels in that sheep might contribute to 
hyperandrogenism during later life (412). Insulin is also implicated as a potential regulator of 
adiponectin expression, however the exact relationship between insulin and adiponectin is not 
fully elucidated. Motoshima et al. found that insulin stimulates adiponectin secretion from 
human omental cells but not subcutaneous cell in vitro (502). In contrast, study by Fasshauer 
et al. reported that insulin reduced adiponectin mRNA in 3T3-L1 adipocytes in dose- and time 
dependent manner (503).  In addition, it has been shown that hyperinsulinemia reduces 
circulating levels of adiponectin under euglycemic conditions (504) and that fasting plasma 
levels of insulin are an independent determinant of plasma adiponectin in multivariate 
regression analysis (505). Liu and colleagues demonstrated in an in vitro study using porcine 
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adipocytes that insulin inhibits the expression of adiponectin receptors ADIPOR2 and that 
rosiglitazone, the PPARG agonist, increases the expression of ADIPOR2 (506). This is in 
agreement with our findings. We found decreased expression of PPARG and ADIPOR2 in 
SAT of adolescent PCOS-like sheep, whereas in the previous studies it was demonstrated that 
these adolescent PCOS-like sheep are hyperinsulinemic, and that altered pancreatic phenotype 
with increased β-cell numbers may be the primary reason for that increased insulin levels 
(431). Therefore, it is likely that hyperinsulinemia contributes to the decreased level of 
adiponectin and that decreased concentrations of adiponectin might exaggerate 
hyperinsulinemia and lead to insulin resistance in future. Interestingly, we did not observe any 
difference in the mRNA and circulating level of adiponectin in adult PCOS-like animals. Since 
low levels of adiponectin are being reported in adolescent and adult PCOS patients, we 
hypothesise that normal adiponectin levels in adult PCOS-like animals might result from a 
temporary increase, as a consequence of transition from adolescent to adulthood with an early 
increase in visceral adiposity, which might contribute to circulating levels of adiponectin. We 
have also found upregulated expression of TNF but not IL6 in SAT of adolescent prenatally 
androgenised sheep. Increased levels of TNFα and IL-6 in adipose tissue are typically 
associated with obesity, hypertrophic adipocytes, inflammation and decreased insulin 
sensitivity, however, our adolescent PCOS-sheep have normal body weight. Increased TNFα 
levels have been shown to downregulate adiponectin, and conversely, adiponectin has been 
shown to decrease levels of inflammatory cytokines, including TNFα, thus it is possible that 
increased TNF expression in adolescent SAT might be the result of a cross-talk with 
adiponectin, rather than marker of inflammation (485). In adult PCOS-like sheep however, in 
SAT, but not VAT, there was increased expression of TNF, IL6 and CCL2 that paralleled 
adipocyte hypertrophy. It has been proposed that enlarged adipocytes overexpress MCP-1 
(CCL2) and this induces increased recruitment of proinflammatory M1 macrophages from the 
blood stream. This in turn increases the production of pro-inflammatory cytokines TNFα and 
IL-6, promoting altered gene expression and insulin resistance in adipocytes (121).  
While there is substantial evidence that hormones are involved in the adipose tissue 
distribution, hormonal influence on adipogenesis is not fully understood. There is a sex-
specific difference in body fat distribution, with women having higher percentage of body fat 
than men, and preferentially accumulating fat in gluteofemoral region while men tend to have 
a larger intra-abdominal fat mass. Estrogen promotes accumulation of subcutaneous fat and 
inversely correlate with visceral adiposity (507). In post-menopausal women there is a 
redistribution of fat depots with increasing amounts of visceral fat, suggesting that decreasing 
levels of estrogen may play a role (507). However, since estrogen regulates SHBG (508), 
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decreased levels of estrogen might result in reduced levels of SHBG and consequently 
increased levels of free testosterone. Indeed, there are some reports showing that androgen 
levels are elevated during the menopausal transition (509). Androgens, like estrogens, impact 
on body fat distribution in humans. In men, low testosterone levels are associated with visceral 
obesity and metabolic syndrome, and testosterone treatment in hypogonadal men results in 
decreased adiposity and improved metabolic characteristics. However, supra-physiological 
androgen treatment in case of female-to-male transsexuals has opposite effects, resulting in 
increased weight and  visceral adiposity (144,510). Interestingly, Elbers et al. reported that 1-
year treatment with estrogens and antiandrogens in male-to-female transsexuals, SAT volume 
and adipocyte size were increased together with decreased lipolytic activity (510). The 
opposite was seen in female-to-male transsexuals, after administration of testosterone for 1 
year, SAT and adipocyte size at the gluteal and abdominal depots were decreased, whereas 
lipolysis was increased significantly at the abdominal level but not at the gluteal level (511). 
Interestingly, we did not observe any difference in the expression of adipogenesis markers, 
total adiposity or body weight (data not published) in our adult female sheep temporally treated 
with testosterone for 2 weeks. This might suggest that only prolonged treatment with 
testosterone can impact on adipocyte differentiation or, as discussed earlier, it might be related 
to the accelerated adipogenesis during puberty. Glucocorticoids also play a role in body fat 
distribution. Elevated levels of circulating cortisol are linked with increasing central, 
especially visceral adiposity (512). In addition to the adrenal production, local production of 
cortisol in adipose tissue increases correspondingly with increasing body weight (512). 
Therefore, to evaluate which class of steroids could affect adipocyte development, we assessed 
adipogenesis in adolescent, 11 months old female sheep that were directly injected in utero 
with TP, DES and DEX. We found that TP treatment decreased the expression of markers of 
adipocyte development. This in in agreement with previously published studies since 
inhibitory effect of androgens on adipogenesis is well documented. Numerous studies have 
shown that T, DHT and DHEA prevented in vitro differentiation and proliferation of various 
murine preadipocyte cell lines (513-515) and human preadipocytes from both sexes, and from 
different fat depots (228,516-518). This anti-adipogenic effect was mediated through AR-
dependent pathways, since  adding AR antagonists blocked this action (513,515). We also 
found that direct fetal injection with DES showed no alteration in the expression of PPARG, 
CEBPA, CEBPB, and CEBPD in adolescent sheep. There are some conflicting data regarding 
effect of estrogens on adipogenesis. It has been shown that treatment of 3T3-L1 adipocytes, 
and ovariectomised mice, with 17β-estradiol resulted in downregulated expression of 
adipogenesis-related genes (519). Likewise, 17β-estradiol decreased the expression of the 
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adipocyte marker genes and inhibited adipogenesis in ovariectomised rat models and mouse 
embryonic fibroblasts (520). Interestingly, 17β-estradiol was also reported to increase 
proliferation of  human (521) and female rat preadipocytes (522).  
We did not observe any effect on adipogenesis with DEX treatment. It is well documented that 
glucocorticoids (GCs) stimulate adipogenesis, however, mechanisms through which GCs 
regulate adipocyte development are not fully understood. GCs were described to stimulate 
preadipocyte commitment rather terminal differentiation (523,524) and to prime preadipocytes 
to adipogenic stimuli through sensitising to insulin signalling. Additionally, it was reported 
that DEX does not induce adipogenesis alone but rather increase recruitment of adipose 
progenitors (525). There are also some implications that adipogenic action of GCs might be 
also depot-specific. It has been shown that GCs treatment of rats increases VAT but not SAT, 
through upregulating of adipocyte differentiation rather than hypertrophy (526). 
Unfortunately, we only studied expression of markers of terminal differentiation and did not 
investigate expression of markers of adipocyte commitment. We also did not investigate 
markers of adipogenesis in VAT from animals directly treated with steroids therefore we are 
unable to fully assess effect of glucocorticoids in our model. Nevertheless, adipogenesis was 
decreased during puberty in PCOS-like sheep therefore it is more likely that hormonal levels 
during this period will play a significant role in regulating adipocyte differentiation. We know 
from our previous studies that adolescent PCOS-like sheep have normal levels of systemic 
cortisol (data not published), estrogen and non-significant increase in systemic testosterone 
with significantly enhanced capacity for androgen synthesis in theca cells (412) and adrenal 
glands (data not published). What is more, it has been shown that local testosterone synthesis 
is increased, while local synthesis of estrone, estradiol and DHT is decreased in SAT of PCOS 
women (229). Therefore, this data suggests that increased levels of local and systemic 
testosterone or imbalance in androgen/estrogen ratio might be responsible for the 
downregulated adipogenesis in SAT of adolescent PCOS-like sheep.    
Lean women with PCOS have the same degree of insulin resistance as obese PCOS women 
(527). In our study adolescent PCOS-like sheep had significantly lower expression of INSR, 
SLC2A4 and IRS2 in SAT, potentially suggesting perturbed insulin signalling. Functional 
glucose uptake and metabolism are central for normal adipose tissue function (461). Animal 
studies showed that deletion of SLC2A4 from adipose tissue leads to systemic insulin 
resistance (528). In addition, SLC2A4 is decreased in SAT of PCOS women (320) and patients 
with T2DM and their first degree relatives (529,530). Interestingly, SLC2A4 is also a marker 
of mature adipocytes, therefore the decreased level of SLC2A4 supports our finding of 
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decreased adipocyte differentiation in adolescent PCOS-like sheep. Insulin regulates growth 
and differentiation of adipose tissue by controlling the expression of PPARG (531). INSR is 
up-regulated during adipogenesis however, lack of INSR does not result in selective 
impairment of the adipocyte differentiation but impacts on adipocyte volume (532,533). 
Interestingly, acute knockdown of the INSR or IRS1 and IRS2 in 3T3-L1 adipocytes suppresses 
adiponectin production (532). As shown in the knockout models of IRS1 and IRS2 in deficient 
embryonic fibroblast cells and 3T3-L1 murine adipocytes, both insulin receptor substrates are 
required during adipocyte differentiation (532,534). The ability of IRS1 deficient cells to 
differentiate into adipocytes was approximately 60% lower, and the ability of IRS2 dedficient 
was 15% lower than wild type cells, whereas double knockout cells (IRS-1-/-and IRS2-/-) 
were unable to differentiate into adipocytes (534). Therefore, reduced insulin signalling in 
SAT of adolescent PCOS-like sheep can contribute to decreased adipocyte development and 
reduced adiponectin levels. Though, puberty is associated with physiological reduction in 
insulin sensitivity, a compensatory increase in insulin secretion, and decreased levels of 
circulating adiponectin, however, insulin resistance is resolved at the end of pubertal transition 
(535,536). Our young adult 30 months old PCOS-like sheep have normal expression of INSR 
and SLC2A4 in SAT and normal levels of circulating adiponectin, yet are still 
hyperinsulineamic. Likewise, adult PCOS women have reduced insulin sensitivity after 
pubertal transition, which worsen with age. Therefore, it is possible that combination of 
decreased insulin sensitivity and increased androgen levels in adolescent PCOS women and 
sheep, rather than insulin resistance alone, leads to decreased adipogenesis in SAT during 
puberty resulting in adipocyte hypertrophy in early adulthood. Sequentially this could lead to 
altered adipokine secretion, IR, increased body weight and visceral adiposity resulting in a 
deteriorating metabolic profile in future. 
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In summary, we have shown that altered adipogenesis in the SAT of PCOS-like sheep and 
decreased levels of beneficial adipokines correlate with the pubertal/adolescent stage and 
hyperinsulinemia, independent of central adiposity. Decreased adipocyte differentiation in 
adolescent PCOS-like sheep might result from mutual action of decreased insulin sensitivity 
and hyperandrogenemia or altered androgen/estrogen ratio. Decreased adipocyte 
differentiation during adolescence result in hypertrophy and inflammation of adult SAT. This 
consequently lowers capacity of SAT to safely store fat and potentially explain metabolic 
perturbations observed in PCOS-like female sheep. These provide better understanding of the 
pathophysiology of PCOS from puberty to adulthood and give opportunities for early clinical 
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4.1 Introduction 
Adult, prenatally androgenised sheep had increased body weight when compared with control 
animals, and trend towards increased total abdominal adiposity, as discussed in chapter 3. In 
addition, those adult PCOS-like animals had increased insulin levels, both fasting and during 
45 min IVGTT. Obesity, increased central adiposity and reduced insulin sensitivity are 
common characteristics of PCOS. It is estimated that as many as 61% to 80% women with 
PCOS are overweight or obese, depending on ethnicity and geographical location (537,538). 
Although, both lean and overweight women can suffer from PCOS, there is evidence showing 
that women with PCOS have normal lean mass but increased central and global adiposity, 
independent of BMI (539-542). Obesity plays a negative role in pathophysiology of PCOS, 
amplifying hyperandrogenism and menstrual disturbances, impacting fertility and worsening 
insulin resistance and hyperinsulinemia in women with PCOS (440,538). Even modest weight 
reduction improves menstrual cyclicity, increases ovulation rates and fertility, reduces 
hyperandrogenism and improves insulin sensitivity in PCOS patients (194,328,543,544). In 
the view of detrimental role of obesity in PCOS, weight management is a preferable first line 
treatment in obese patients with PCOS (545), however is seems that women with PCOS find 
maintaining a healthy weight particularly difficult (546-548). While the mechanisms leading 
to obesity in PCOS remain uncertain there are a few studies looking at energy expenditure in 
PCOS. There are contradictory data regarding basal metabolic rate (BMR) in PCOS patients. 
One study reported decreased BMR in PCOS  (211), but others did not support this finding 
(549,550).  Franks and colleagues showed that PCOS subjects, both lean and obese, have a 
reduced postprandial metabolic rate, as measured by continuous indirect calorimetry, when 
compared to BMI matched controls (212). These authors also noted that the reduced 
postprandial thermogenesis (PPT) correlated with decreased insulin sensitivity in PCOS 
patients (212). However, another study looking at PPT in PCOS patients found no difference 
between controls and PCOS (551), therefore, the question of whether PCOS patients are 
predestined to become obese, due to difference in caloric utilisation, or if obesity is only a 
secondary factor aggravating the condition, is still unanswered. 
Obesity, a state of excessive accumulation of TG in adipose tissue, results from increased 
energy intake and/or reduced energy expenditure, and it is a major risk factor for development 
of T2DM, atherosclerosis, hypertension, heart disease, stroke, NAFLD, and dyslipidemia 
(552). It has been shown than even subtle perturbations in energy balance can lead to obesity. 
A persistent error of only 1% between input and output of energy will lead to a gain or loss of 
1 kg per year (553). Basal metabolic rate, adaptive thermogenesis and physical activity are the 
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three main components of total energy expenditure (554). Adaptive thermogenesis protects the 
organism from cold exposure (non-shivering thermogenesis) and regulates energy balance by 
heat production from combustion of food or stored forms of energy, therefore, both 
environmental temperature and diet impact adaptive thermogenesis (554). It has been shown 
that acute and chronic cold exposure in rodents can markedly increase adaptive thermogenesis 
however, since humans have a broader thermoneutral zone, an ability to adjust the amount of 
clothing and have a much smaller surface to volume ratio than rodents, environmental 
temperature plays relatively small part in overall energy expenditure (554). On the contrary, 
diet significantly contributes to human adaptive thermogenesis. It has been shown, that acute 
feeding, depending on macronutrient content of the meal, can acutely increase metabolic rate 
by 25-40%, and that overall energy expenditure after food intake (thermic effect of food, TEF; 
diet induced thermogenesis, DIT; postprandial thermogenesis, PPT) accounts for up to 15% 
of total energy expenditure (555-557). Thus, when the organism is resting and at 
thermoneutrality, postprandial thermogenesis can be measured directly as heat production 
(direct calorimetry), or as the amount of oxygen consumption (indirect calorimetry) (554). 
BAT, or brown fat, was first formally described as the ‘hibernating gland’ in 1551 by Conrad 
Gessner and over 300 years later, in 1961, identified as the main site of thermoregulatory non-
shivering thermogenesis (558). BAT play an important role in adaptive thermogenesis through 
its capacity to heat production and  energy dissipation from glucose and lipids via uncoupling 
proteins, mainly UCP1 (559). UCP1 is located in the inner mitochondrial membrane and its 
activation leads to redirection of protons from ATP synthesis, resulting in proton leakage, 
reduced ATP synthesis but increased energy expenditure. Brown adipocytes are characterised 
by rich vasculature, and abundant sympathetic nervous system (SNS) innervation, the presence 
of multilocular lipids droplets and densely packed large mitochondria (560). BAT 
thermogenesis is mainly regulated by sympathetic nervous system, where noradrenaline 
released from sympathetic ganglion cell terminals binds to β-adrenergic receptors on brown 
adipocytes, inducing their proliferation, increasing transcription and activity of UCP1, and 
mitochondrial biogenesis (561). BAT heat production however, can be also affected by other 
factors, such as FFA uptake and metabolism, substrate availability or oxidative 
phosphorylation (560).  It has been pointed out that UCP1 mRNA levels do not always reflect 
UCP1 activity therefore BAT function should be also evaluated by means of other parameters 
such as respiratory capacity or heat generation (559,562). Until recently it was thought that 
BAT was exclusively found in neonates, not in adults, but imaging studies using 
fluorodeoxyglucose-positron emission tomography (F-FDG-PET) together with computed 
tomography (CT) in adult humans, revealed presence of metabolically active BAT in the 
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clavicular, neck and sternal regions of the body (563). What is more, there is also growing 
evidence that there are two types of UCP1 positive thermogenic adipocytes, classical brown 
and beige or brite (brown in white) adipocytes, that are dispersed in WAT (559). Although 
sharing its main metabolic role, classical brown and beige adipocytes have distinct 
developmental origins as well as gene expression patterns. BAT share the same precursor cells 
expressing Myf5 with skeletal muscles but BAT divergence from myoblasts is determined by 
expression of different transcriptional regulators, such as PRDM16 and C/EBPβ (564-566). In 
contrast, beige adipocytes do not originate from cells expressing Myf5 and although they 
express the majority of BAT-enriched genes, such as UCP1, PPARGC1A and PRDM16, they 
also have distinct beige cell markers, such as TMEM26, CITED1 and TBX1 (567). Beige 
adipocytes also have a distinct molecular signature when compared to white adipocytes, 
therefore, the existence of defined beige precursors have been suggested. However, it has been 
shown that upon stimulation with β3-ADR or PPARG agonists, white adipocytes can become 
UCP1 positive, hence cellular plasticity between white and beige preadipocytes or mature 
adipocytes cannot be excluded (568-571).  Interestingly, it was recently reported that human 
BAT isolated from multiple body locations abundantly express beige cell markers suggesting 
that human BAT may be primary composed of beige adipocytes (572). BAT activation is 
mainly stimulated by cold exposure however, diet can also induce BAT thermogenesis. 
Overfeeding triggers PPT and activates BAT, leading to excessive calorie intake being 
dissipated as heat, therefore protecting individuals from obesity (573,574). This physiological 
process is known as luxuskonsumption (573). Variability in PPT responses has been proposed 
as a major factor contributing to large individual variances in weight gain in response to 
overfeeding (575). Indeed, it has been shown that decreased BAT prevalence and activity 
correlates with obesity, increased adiposity and reduced insulin sensitivity, suggesting 
regulatory links between BAT and whole body energy metabolism (576).   
  
Chapter 4 The effect of prenatal androgenisation on energy expenditure 
111 
Adult prenatally androgenised female sheep have ovarian, hormonal and metabolic 
characteristics of PCOS. These PCOS-like sheep are obese and insulin resistant. Furthermore, 
obesity in those animals, like in women with PCOS, is not a consequence of intrauterine 
growth restriction and catch-up growth, but is likely programmed by their intrauterine 
environment. In addition, those sheep have comparable body weight, similar surface to volume 
ratio, and brown and beige adipose tissue distribution as adult women (577). Given the 
inconsistent data regarding the role of PPT and predisposition to obesity in PCOS and a 
potential role of BAT in regulating body weight, we aimed to: 
1. determine whether differences in PPT, measured as direct calorimetry, predict the 
propensity for obesity in our adult PCOS-like sheep 
2. identify the possible involvement of BAT and other potential molecular mechanisms 
in regulating PPT 
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4.2 Methods 
4.2.1 Experimental animals 
The ovine model, the animals used, their husbandry and treatments have been described 
previously in Section 2.2. The female animals assessed in this chapter are detailed in Table 
4.1. 












Ewes 11 months old C=5, TP=9 
Adult 
Maternal Injections 





Table 4.1 Treatment regime, age, and corresponding sample numbers of experimental animals discussed 
in this chapter. 
 
4.2.2  Measuring postprandial thermogenesis  
For this experiment, adult ewes prenatally exposed to increased levels of androgens (TP=4) 
and a subset of lean (CN=4) and naturally obese (CO=4) control animals were selected. 
Datalogger thermometers were implanted by Prof. Colin Duncan into the interscapular adipose 
tissue (IAT) under local anaesthesia, with the lead and download point being exteriorised, and 
the wound sutured. Animals were allowed to recover from surgery before the onset of the 
experiment. Measurement of PPT was carried during the times when ovaries are quiescent (the 
non-breeding season) to eliminate potential biases because of known hormonal regulation of 
temperature (e.g. progesterone increase temperature after ovulation). During the experiment, 
animals were kept in individual pens allowing them to sit and stand but restricting further 
movement, to exclude other confounding factors. Ewes were placed on a feeding schedule, 
with access to feed between 07:00 to 9.30 to entrain a postprandial thermogenic response, food 
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intake was recorded, and postprandial temperature measurement were logged from 10:00 till 
16:00, at 1 min intervals, on 2 separate days.  
4.2.3  Gene expression analysis using qRT-PCR. 
Extraction of RNA from fetal and postnatal adipose tissue was performed using the 
combination of TRI reagent and Qiagen RNeasy Mini Kit (Qiagen Ltd., West Sussex, UK), as 
described in section 2.8.1. Extraction of RNA from muscles was performed using Qiagen 
RNeasy Fibrous Tissue Mini Kit (Qiagen Ltd., West Sussex, UK), as described in section 
2.8.1. Protocols for cDNA synthesis and qRT-PCR are described in section 2.8.3. and 2.8.4, 
respectively. Forward and reverse primers were designed and validated as stated in section 
2.8.6 and primer sequences analysed in this chapter are listed in Table 4.2. 
Gene Forward Sequence Reverse Sequence 
Product 
Size (bp) 
UCP1 AGAGCCATCTCCACGGTCCCA CCAAAGCCCCGTCAAG 92 
UCP2 AAGGCCCACCTAATGACAGA CCCAGGGCAGAGTTCATGT 128 
UCP3 AGATGAGCTTCGCCTCCAT TGAAAGCGGATCTTCACCAC 172 
ADRB1 CTTCTTCCTGGCCAACGTG GGGTTGAAGGCCGAGTTG 105 
ADRB2 CATGCCCAAAACGTCAGTC TCTTGAGGGCTTTGTGTTCC 100 
ADRB3 GCACCCAATACTGCCAACG GTTGGTCATGGTCTGGAGTCT 159 
PPARGC1A ATGAGTCAGGCCACTGCAGAC CTCTGCGGTATTCTTCCCTCT 150 
PRDM16 GGACAACCACGCACTTTTAGA GGTGCCATCTAGGTTCTGGA 136 
TMEM26 TCCTTATGTTTGTGGGGACAG TAGCATGCTCCAGGTCCATA 128 
SIRT1 GGAAGGAAAACTACTTCGCAAC CCTCGTACAGCTTCACAGTCA 150 
TLE3 CTGCAGCAGCACGACTTTAC GTAGGCGAACTTGAGGGACA 174 
RYR1 GGACCTCATCGGCTACTTTG GACATTTAGGCGGTCAATGC 151 
ATP2A1 GACAGGGTAGATGGGGACCT GTCCAAGGAGGAGTCATTGC 171 
ATP2A2 GGTGCTCCTGAAGGTGTCAT CAGTGGGTTGTCATGAGTGG 168 
Table 4.2 Forward and reverse primer sequences and product size for genes analysed in the fetal and 
postnatal adipose tissue using SYBR Green qRT-PCR. 
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4.2.4 Immunohistochemistry 
Adipose tissue samples from four different anatomical locations per animal were processed 
and immunohistochemistry was carried out as described in section 2.3, using antibodies to 
UCP1 and UCP3. Negative controls consisted of omission of the primary antibody and 
substitution with serum immunoglobulins of equivalent concentrations. Details of primary and 
secondary antibodies and optimised working concentrations are listed in Table 4.3. 
Primary Antibody Dilution Secondary Antibody Dilution 
UCP1 Polyclonal Goat 
(M-17; sc-6529) 
Santa Cruz Biotechnology 
1:100 




UCP3 Polyclonal Goat 
(C-20; sc-7756) 
Santa Cruz Biotechnology 
1:100 




Table 4.3 Details of antibodies used for immunohistochemistry in the adult adipose tissue samples. The 
primary and secondary antibodies suppliers and optimised concentrations are listed. 
 
4.2.5 Noradrenaline ELISA 
Noradrenaline level within adipose tissue samples was measured using Noradrenaline 
Research ELISA (ImmuSmol, BA E-5200, Pessac, France), as per the manufacturer’s 
instruction. A representative sample of adipose tissue was cut on dry ice and transferred into 
2ml eppendorf tube containing a metal bead (Qiagen Ltd.) and 300µl of a homogenisation 
buffer (HCl 0.01N; EDTA 1mM; sodium metabisulfite (Na2S2O5) 4mM), using TissueLyser 
(Qiagen Ltd.) and homogenised at 25Hz for total of 4 min. The homogenate was transferred 
into a new eppendorf tube and centrifuged at 1600g at 4°C for 10 min, and the supernatants 
stored at -20°C. Protein concentration in sample was quantified using the Bradford assay as 
described in section 2.4.2. A 10µl aliquot of standards, controls and sample supernatants were 
pipetted into respective wells of the ELISA plate and filled up with distilled water to a final 
volume of 100µl. Immunoassay absorbance was measured at 450nm, with a reference 
wavelength of 650nm to control for background, using a ThermoMax Microplate Reader 
(Molecular Devices, CA, USA) and the concentrations were calculated from standard curve 
by plotting the known concentration of standard against the absorbance values. All samples 
were assayed in duplicate. Calculated results were corrected by the total protein content in the 
sample. The assay sensitivity was 0.1ng/ml intra and inter-assay CVs were <8.4% and <6.9%, 
respectively. 
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4.2.6 Statistical analysis 
Statistical analysis was performed with GraphPad Prism version 6.0 (GraphPad Sowftware, 
Inc., San Diego, CA). For comparing means of two treatment groups with equal variances an 
unpaired, two-tailed Student’s t test was used. To compare multiple sets of data a one-way 
ANOVA was used. Log transformation was used to approximate the normal distribution for 
parametric analysis when necessary. A P value of <0.05 was considered as statistically 
significant. Results are presented as mean + S.E.M, where * signifies a P<0.05, ** P<0.01 and 
*** P<0.001. Area under the curve (AUC) was calculated using the trapezoidal method. 
Correlation was assessed by calculation of the Pearson r co-efficient. A line of best fit was 
incorporated only in the figures where correlation was statistically significant.     
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4.3 Results 
4.3.1 PPT is decreased in adult PCOS-like sheep 
To investigate the potential role of PPT in the propensity to obesity in PCOS-like sheep, we 
measured food intake and thermogenic output after standard meal in controls and TP-exposed 
animals. The thermogenesis experiment was undertaken in adult PCOS-like sheep (TP; n=4) 
and a subset of adult female control sheep selected based on weight characteristics, normal 
(CN; n=4) and obese (CO; n=4). CN animals had significantly lower body weight when 
compared to both CO and TP groups (P<0.0001; Fig. 4.1 A) however, there was no difference 
in body weight between CO and TP animals (CN: 74.75 ± 0.75kg; CO: 85.5 ± 1.25kg; TP: 
85.75 ± 0.75kg). There was also no statistical difference in visceral adiposity among all groups 
(Fig. 4.1 B) (CN: 1.08 ± 0.2kg; CO: 1.55 ± 0.22kg; TP: 1.62 ± 0.23kg). In addition, fasting 
insulin and G:I ratio were analysed in those selected animals. PCOS-like animals had 
significantly increased fasting insulin levels when compared with lean controls (Fig. 4.1 C; 
P<0.05) however, there was no difference between CO and TP animals. Further, there was no 
statistical difference in G:I ratio among groups (Fig. 4.1 D). 


























































































Figure 4.1 Characteristics of animals selected for thermogenesis study. A) Body Weight, B) Omental 
Fat, C) Fasting Insulin and D) Fasting Glucose to Insulin Ratio in adult lean control (CN), obese control 
(CO) and prenatally androgenised (TP) animals. P value of <0.05 was considered as statistically 
significant. Results are presented as mean + S.E.M, where * signifies a P<0.05, *** P<0.001 
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Adult PCOS-like sheep had a decreased amplitude of PPT (P<0.05; Fig. 4.2 A), despite 
consuming the same amount of food and without difference in basal body temperature (Fig. 
4.2 C). Decreased change in postprandial temperature was not primarily a function of 
increased body weight as a difference in PPT was also observed between a subset of matched 
obese controls (CO) and TP exposed animals (P<0.05; Fig. 4.2B). There was no difference in 
the duration of the peak postprandial thermogenic response (Fig. 4.2D) however, prenatally 
androgenised females demonstrated increased latency from commencement of feeding to 
maximal postprandial temperature when compared with normal (CN) and obese (CO) controls 
(P<0.05; Fig. 4.2 E and F). 







C h a n g e  in
p o s tp ra n d ia l te m p e ra tu re































C h a n g e  in




















































D u ra t io n  o f  th e  p e a k  p o s tp ra n d ia l














T im e  to  r e a c h  m a x im a l















T im e  to  r e a c h  m a x im a l













Figure 4.2 A-B) Postprandial thermogenesis; C) Basal body temperature; D) Duration of the peak 
postprandial thermogenic response; E-F) Time to reach maximal postprandial temperature in adult 
normal controls (CN), obese controls (CO) and prenatally androgenised (TP) animals. P value of <0.05 
was considered as statistically significant. Results are presented as mean + S.E.M, where * signifies a 
P<0.05. 
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4.3.2 Gene expression of uncoupling proteins in adipose tissue depots 
Brown and beige adipose tissue are an important site of cold and diet-induced thermogenesis. 
The primary molecule involved in adaptive thermogenesis is UCP1 and its two homologues, 
UCP2 and UCP3. In the view of decreased PPT in adult PCOS-like sheep, we next assessed 
gene expression of uncoupling proteins (UCPs) in four different fat depots: interscapular 
adipose tissue (IAT), neck adipose tissue (NAT), SAT and VAT. In IAT, near the site where 
we implanted temperature dataloggers, there was no significant difference in the expression of 
UCP1 (Fig. 4.3 A) but expression of UCP2 and UCP3 was significantly downregulated in 
prenatally TP-exposed animals (P<0.05; Fig.4.3 B and C, respectively). Expression of UCP1 
was significantly decreased in NAT, SAT and VAT of prenatally androgenised adult ewes 
(P<0.05-0.01; Fig. 4.3 D, G and 2, respectively) however, there was no difference of the 







































































































































































































Figure 4.3 Expression of UCP1, UCP2 and UCP3 in different adipose tissue depots of adult control (C) 
and prenatally androgenised (TP) animals, as quantified by qRT-PCR. P value of <0.05 was considered 
as statistically significant. Results are presented as mean + S.E.M, where * signifies a P<0.05. 
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Subsequently we evaluated the association of differently expressed UCP mRNA in all selected 
fat depots with the amplitude of PPT. In IAT there was significant correlation of PPT with 
expression of UCP1 (P<0.05; r=0.53; Fig. 4.4 A), UCP2 (P<0.05; r=0.68; Fig. 4.4 B) and 
UCP3 (P<0.01; r=0.72; Fig. 4.4 C). PPT was also correlated with expression of UCP1 in SAT 
(P<0.05; r=0.66; Fig. 4.4 E) and VAT (P<0.05; r=0.52; Fig. 4.4 F), but not NAT (Fig. 4.4 D).  
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Figure 4.4 Correlation of expression of UCPs mRNA in different fat depots with change in postprandial 
temperature in adult controls and prenatally androgenised animals. 
4.3.3 Immunohistochemical examination of the UCP1 and UCP3 
expression in adipose tissue depots.  
We next performed histological analysis of adipose tissue from control and TP-exposed 
animals dissected from four different anatomical locations. In all sections analysed 
histologically, adipose tissue was composed mainly of adipocytes with unilocular lipid 
droplets, and no cells with classical multilocular brown adipocyte morphology were identified. 
However, in controls but not PCOS-like sheep, we observed some UCP3-positive adipocytes 
in IAT (Fig. 4.5 A), which tended to be smaller than adjacent adipocytes. We also detected 
some UCP1-positive adipocytes in NAT and SAT of control animals (Fig. 4.5 C and E, 
respectively), but not prenatally TP-exposed animals (Fig. 4.5 D and F). In VAT, UCP1 was 
undetectable in section from both controls and TP-exposed animals (Fig. 4.5 G and H, 
respectively). 




Figure 4.5 Immunohistochemical examination of the UCP1 and UCP3 expression in adipose tissue 
depots. A-B) Representative images of IAT from control (A) and PCOS-like sheep (B) stained with 
anti-UCP3. C-D) Representative images of NAT from control (C) and PCOS-like sheep (D) stained 
with anti-UCP1. E-F) Representative images of SAT from control (E) and PCOS-like sheep (F) stained 
with anti-UCP1. G-H) Representative images of VAT from control (G) and PCOS-like sheep (H) 
stained with anti-UCP1. Images are shown at 10X magnification; scale bar 100 µm. 
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4.3.4 Insulin resistance in adult PCOS-like sheep correlates with 
decreased PPT 
Female sheep prenatally programmed to develop PCOS-like condition are insulin resistant 
with increased fasting insulin concentrations and elevated AUCinsulin but normal 
AUCglucose during a 45-min IVGTT as discussed in chapter 3. Since decreased insulin 
sensitivity is associated with reduced glucose induced thermogenesis (GIT), we performed a 
correlation analysis to determine the relationship between PPT and fasting levels of insulin.   
There was negative correlation between the reduction in PPT and increasing levels of fasting 
insulin (P<0.05; r= -0.56; Fig. 4.6 A) while increased time to reach maximal temperature post-
feeding correlated positively with increased levels of fasting insulin (P<0.05; r=0.56; Fig. 4.6 
B). We also analysed association between fasting insulin levels and gene expression of UCP1 
in fat depots. UCP1 mRNA levels in NAT, SAT and VAT correlated negatively with fasting 
insulin (P<0.05-0.01; r=-0.73, r=-0.56, r=-0.79, respectively; Fig. 4.6 D-F), whereas this 
association was not evident in IAT (Fig. 4.6 C). 
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Figure 4.6 The association between A-B) fasting insulin levels and changes in postprandial 
thermogenesis dynamics; C-F) Relationship between mRNA expression of UCP1 in different fat depots 
and fasting insulin levels in adult control and prenatally androgenised animals.  
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4.3.5 Noradrenaline levels and β-adrenergic receptors expression 
Considering the importance of β-adrenergic system in regulation of adaptive thermogenesis 
we assessed gene expression of three subtypes of β-ADR (β1-, β2-, and β3-ADRs) in all four 
adipose tissue depots analysed. There was no difference in the expression of ADRB1, ADRB2 
or ADRB3 between control and TP-exposed animals in any of fat depots (Fig. 4.7 A-K). Of 
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Figure 4.7 Expression of ADRB1, ADRB2 and ADRB3 in four different adipose tissue depots in adult 
control (C) and prenatally androgenised (TP) animals, as quantified by qRT-PCR. Results are presented 
as mean + S.E.M. 
 
We next assessed levels of noradrenaline in adipose tissue from four different anatomical 
locations. Noradrenaline was measured directly in adipose tissue and its levels were corrected 
for total amount of proteins. Noradrenaline levels were significantly lower in NAT, SAT and 
VAT (P< 0.05; Fig. 4.8 B-D) but not IAT of PCOS-like sheep when compared to controls (Fig. 
4.8 A). Average amount of noradrenaline measured in all fat depots was significantly lower in 
TP-exposed animals (P<0.05; Fig. 4.8 E) and this decreased concentration could not be solely 
attributed to increased body weight as a difference in averaged noradrenaline levels was also 
noticed between a subset of matched obese controls (CO) and TP exposed animals, although 
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this did not reach statistical significance (P=0.12; Fig. 4.8 F). However, there was a negative 
correlation between body weight and average levels of noradrenaline (P<0.05; r= -0.59; Fig. 
4.8 G). There was also a positive correlation between average levels of noradrenaline in 
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Figure 4.8 Noradrenaline concentrations in A-D) different adipose tissue depots; E) average 
noradrenaline levels in four different anatomical adipose tissue location in control (C) and prenatally 
androgenised (TP) animals; F) Average noradrenaline level in four different anatomical location in 
normal control (CN), obese control (CO) and prenatally androgenised (TP) animals; Correlation of 
average noradrenaline level in four different anatomical adipose tissue location in control and prenatally 
androgenised animals with G) body weight and H) postprandial temperature increase. P value of <0.05 
was considered as statistically significant. Results are presented as mean + S.E.M, where * signifies a 
P<0.05. 
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Since FFA are well known activators of UCP1 and BAT thermogenesis, we therefore looked 
also at association of fasting FFA in circulation with PPT, UCP1 mRNA levels and average 
noradrenaline levels from four different adipose tissue depots. There was no correlation 
between levels of UCP1 mRNA and FFA (data not shown), but we found that there was a 
negative correlation between fasting FFA and both PPT (P<0.05; r=-0.56; Fig. 4.9 A) and 
average noradrenaline levels (P<0.05; r=-0.60; Fig. 4.9 B). 
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Figure 4.9 Correlation of fasting FFA with A) postprandial temperature change; B) with average 
noradrenaline level in four different anatomical adipose tissue location in adult control and prenatally 
androgenised animals. 
 
4.3.6 Expression of beige adipocyte markers is depot specific 
Given the white adipose tissue like morphology but propensity toward higher expression of 
UCP1 in control animals, we next looked at the expression of selected beige adipocyte markers 
in adipose tissue dissected from all four different anatomical locations. There was no 
difference in the expression of selected beige markers in NAT (Fig. 4.10 F-J) and VAT (Fig. 
4.10 P-U). In IAT expression of PPARGC1A was significantly upregulated in TP-exposed 
animals (P<0.01; Fig. 4.10 A), but there was no difference in the expression of the remaining 
beige adipocyte markers (Fig. 4.10 B-E). In contrast, in SAT expression of PPARGC1A and 
SIRT1 was significantly downregulated in PCOS-like sheep (P<0.05; Fig. 4.10 K and N, 
respectively), and there was a trend for decreased expression of TMEM26 (P=0.058; Fig. 4.10 
M), however, this did not reach statistical significance. There was no difference in the levels 
of PRDM16 and TLE3 (Fig. 4.10 L and O, respectively). 
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Figure 4.10 Expression of selected beige adipocyte markers in four different adipose tissue locations, 
A-E IAT; F-J NAT; K-O SAT and P-T VAT, in adult control (C) and prenatally androgenised (TP) 
animals, as quantified by qRT-PCR. P value of <0.05 was considered as statistically significant. Results 
are presented as mean + S.E.M, where * signifies P<0.05, **P<0.01. 
4.3.7 Thermogenic potential of skeletal muscles 
Thermogenesis primarily takes place in brown and beige adipose tissue however, it has been 
shown that skeletal muscles also exhibit thermogenic properties. Therefore, we investigated 
thermogenic potential of skeletal muscles in adult female sheep to assess if muscle 
thermogenesis could contribute to differences in PPT that we observed between C and TP 
animals. Although we did not measure postprandial thermogenesis in muscle directly, we 
looked at the expression levels of genes associated with dissipation of energy through the 
production of heat in muscle (UCPs) and genes involved in calcium cycling (RYR1, ATP2A1 
and ATP2A2). There was a trend toward increased expression of UCP3 in PCOS-like sheep 
(P= 0.06; Fig. 4.11C) however, this did not reach statistical significance and there was no 
difference in the expression of UCP1, UCP2, RyR1, ATP2A1 and ATP2A2 between control 
and TP-exposed animals (Fig. 4.11 A-B and Fig. 4.11 D-F, respectively).  



































































































Figure 4.11 Expression of UCPs mRNA and genes involved in calcium cycling in muscles of adult 
control (C) and prenatally androgenised (TP) animals, as quantified by qRT-PCR. Results are presented 
as mean + S.E.M. 
 
4.3.8 Expression of thermogenic genes across different developmental 
stages 
To establish the potential timing of reduced expression of UCPs in adipose tissue of TP-
exposed animals, we investigated the expression of UCP1, UCP2 and UCP3 in SAT from 
D112 fetuses and prepubertal animals. We also looked at the expression of UCPs in SAT from 
normal ewes treated with androgens for two weeks. Unfortunately, we did not have samples 
of intersacapular or neck adipose tissue from those animals. Altered expression of UCP1, 
UCP2 or UCP3 was not observed in fetal life (Fig. 4.12 A-C), prepubertally (Fig. 4.12 D-F) 
or in animals contemporaneously treated with androgens (Fig. 4.12 G-I).   
 


































































































































































































Figure 4.12 Expression of UCP genes in A-C) SAT of fetal day 112 control (C) and prenatally 
androgenised (TP) animals; D-F) 11 weeks old control (C) and prenatally androgenised (TP) animals; 
G-I) adolescent controls (C) and animals contemporary treated with testosterone for 2 weeks (TP), as 
quantified by qRT-PCR. Results are presented as mean + S.E.M. 
 
Finally, we investigated expression of UCPs and selected beige fat markers in adolescent 
adipose tissue. There was no alteration in the expression of UCPs in VAT (Fig.4.13 A-C) and 
no difference in the expression of UCP1 and UCP2 in SAT (Fig, 4.13 D-E) however, 
expression of UCP3 was decreased in prenatally TP-exposed animals (P<0.05; Fig. 4.13 F). 
In addition, expression of PRDM16 was downregulated (P<0.05; Fig. 4.13 H), but no 
difference in expression of other beige fat markers was detected (Fig. 4.13 G and 4.13 I-K). 
 












































































































































































Figure 4.13 Expression of UCP genes in A-C) VAT; D-F) SAT and G-K) expression of selected beige 
adipocyte markers in SAT of adolescent control (C) and prenatally androgenised (TP) animal, as 
quantified by qRT-PCR. P value of <0.05 was considered as statistically significant. Results are 
presented as mean + S.E.M, where * signifies a P<0.05.  
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4.4 Discussion 
The aim of this study was to assess the potential role of PPT in obesity of female sheep 
prenatally programmed to develop PCOS-like condition. We found that adult PCOS-like sheep 
have a decreased amplitude of PPT when compared with controls, measured through direct 
calorimetry, without a difference in basal body temperature, despite receiving the same caloric 
intake, and independent of obesity. What is more, we also report that these PCOS-like sheep 
have increased time to reach their maximal postprandial temperature, again independent of 
obesity. These findings suggest that prenatally androgenised sheep have reduced capacity for 
energy expenditure, which may explain propensity for obesity in these animals. Interestingly, 
it has been shown that obese individuals, with a childhood history of obesity, have lower PPT, 
before and after weight loss, suggesting that thermogenic defect may be a cause rather than a 
consequence of obesity (578). In addition, recent work by Henry et al. documented that 
genetically fat sheep have reduced PPT when compared with lean animals, and this is likely a 
consequence of decreased UCP1 expression in retroperitoneal adipose tissue (579). However, 
there is a lot of discrepancies regarding the potential role of decreased PPT in obesity, mainly 
due to varying methodologies applied in different studies (580). To our knowledge this is the 
first study reporting decreased PPT in an animal model of PCOS, however, analogous findings 
were reported in women with PCOS (212). A limited number of studies have examined the 
role of basal metabolic rate in PCOS associated obesity, although reports are inconsistent. Five 
case-control studies reported no difference in BMR between PCOS and age- and BMI-matched 
controls, and regardless of insulin resistance status (212,546,549-551). On the contrary, 
Georgopoulos et al. reported that BMR was lower in PCOS women than in age- and BMI-
matched controls, and the lowest BMR was found in women with both PCOS and insulin 
resistance, suggesting that insulin sensitivity can affect overall energy expenditure (211). 
However, it should be noted that participants in the latter study were younger and had overall 
lower BMI than subjects in the remaining five studies and this could contribute to the result 
discrepancies among those reports. Obesity results from increased calorie intake, reduced 
energy expenditure or a combination of both. We have investigated only one aspect of energy 
expenditure, PPT, in controlled environment, with set caloric intake and restricted movement 
in order to exclude possible confounding factors. However, we cannot exclude that increased 
calorie consumption or decreased physical activity in uncontrolled environment also 
contribute to increased body weight in those animals. There are several reports looking at other 
aspects of energy intake and expenditure in patients with PCOS. There is inconsistent data 
regarding energy intake in PCOS women. Decreased (581), and increased (582,583) dietary 
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intake have been reported in women with PCOS, however, the majority of the studies found 
no differences in daily food and nutrient consumption in PCOS women when compared with 
controls (547,584-587). Wright et al. reported that PCOS patients with a normal BMI 
consumed significantly lower number of calories (≥250 kcal/day) than BMI-matched controls, 
hypothesising that this might be necessary to prevent weight gain in those women (547). They 
also noted that in higher BMI categories there was no difference in calorie intake between 
PCOS and BMI-matched controls (547). Studies evaluating physical activity levels in women 
with and without PCOS have greater result consistency, reporting no difference in overall 
levels of physical activity (547,582,583,587,588). Therefore, based on the current status of 
knowledge, it can be implied that the tendency to obesity in PCOS women is unlikely to result 
from increased calorie intake or decreased physical activity, suggesting that a decreased PPT 
might play a role. So, what is the possible mechanism programming decreased PPT and obesity 
in PCOS? 
Insulin resistance and compensatory hyperinsulinemia are key factors contributing to 
pathophysiology of PCOS (589,590). It is estimated that as many as 50-70% PCOS women 
are insulin resistant, independent of BMI (190,191,591,592). On average, insulin sensitivity is 
decreased by 35–40% in patients with PCOS when compared to matched controls (590). Some 
authors suggested that intrinsic pancreatic β-cell dysfunction and hyperinsulinemia may be a 
key pathogenic determinant in PCOS (193,593-595). In our ovine model of PCOS, lean 
adolescent (411) and obese adult prenatally androgenised sheep are hyperinsulinemic and have 
decreased insulin sensitivity. Prenatal androgenisation results in increased number of 
pancreatic β-cells, which correlates with hyperinsulinemia, in both ovine and nonhuman 
primate models of PCOS (431,596,597). These findings suggest that hyperinsulinemia might 
precede insulin resistance, at least in animal models of PCOS. Indeed, some authors suggested 
that hyperinsulinemia itself might be causing or sustaining insulin resistance (598). We have 
found a negative correlation between increasing levels of fasting insulin with reduction in PPT 
and positive association with increasing time to reach maximal temperature post-feeding. 
Parallel findings were reported by Robinson et al. in their study on PPT in PCOS women, 
showing that decreased PPT is associated with reduced insulin sensitivity in patients with 
PCOS (212). The link between decreased insulin sensitivity and reduced PPT has been also 
shown by others although the mechanisms are still not fully understood (599-602). A proposed 
explanation was that peripheral insulin resistance results in decreased glucose uptake and 
hence decreased glucose substrate availability (603). However, a study on intranasal insulin 
administration in healthy men, reported that insulin increased PPT by 17% when compared to 
placebo, decreased level of circulating insulin and temporarily decreased FFA in serum, thus 
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showing that efficient brain insulin signalling is necessary for whole-body energy flux (604). 
Since peripheral insulin resistance and obesity has been shown to be associated with reduced 
insulin sensitivity in central nervous system (605-607), it can be speculated that prenatally 
androgenised sheep and women with PCOS might also have decreased central insulin 
sensitivity, which in turn might be accountable for reduced PPT, although currently there is 
no data to support this hypothesis. Additionally, it has been demonstrated that direct injections 
of insulin into the preoptic area of the mice hypothalamus, activated BAT thermogenesis and 
stimulated increase in core body temperature in dose-dependent manner (608), whereas a study 
on streptozotocin-induced diabetes in mice showed that the thermogenic capacity of BAT 
declined progressively with insulin deficiency (609). Recent study in humans demonstrated 
that BAT is a highly insulin-sensitive tissue, with comparable rate of glucose uptake to that in 
skeletal muscle (610). Furthermore, a study in rodents demonstrated that increasing BAT 
mass, by transplantation into the visceral cavity, improved glucose tolerance and insulin 
sensitivity, decreased body weight and fat mass, in dose-dependent manner (611). In addition, 
it was also documented that BAT transplantation increased glucose uptake into BAT, WAT 
and heart muscle, but not skeletal muscle (611). These studies provide a strong evidence for a 
direct link between insulin, thermogenesis and BAT, therefore, we have also investigated 
potential role of BAT and/or beige adipocytes in regulating PPT in our ovine model of PCOS. 
Histological analysis of adipose tissue dissected from four different anatomical locations from 
control and PCOS-like animals revealed that none of the tissues analysed had a classical 
multilocular brown adipocyte morphology. Despite that, in control animals but not PCOS-like, 
some adipose cells, especially from IAT, NAT and SAT depots, expressed low levels of UCP1 
and UCP3 proteins, as verified through immunohistochemical examination. Additionally, 
adipocytes from control animals in IAT and NAT and SAT depots appeared to be smaller than 
those from TP-exposed animals, although we only quantified this in SAT depot, confirming 
that PCOS-like animals have hypertrophic adipocytes when compared with controls, as 
discussed in chapter 3. The above findings suggest that some adipose cells in IAT, NAT and 
SAT depots might have properties of beige rather than brown adipocytes and that there might 
be increased number of thermogenic adipocytes in control than in PCOS-like animals.  
To further confirm this initial hypothesis, we looked at the expression of selected markers of 
beige adipocytes in four adipose tissue depots, IAT, NAT, SAT and VAT of controls and 
prenatally androgenised animals. All selected markers were detectable in adipose tissue depots 
analysed. We found no difference in the expression of beige markers in NAT and VAT, but to 
our surprise, there was significant upregulation of PPARGC1A in IAT of the TP-exposed 
animals with no difference in the expression of the remaining markers, namely PRDM16, 
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TMEM26, SIRT1 and TLE3. In contrary, in SAT expression of PPARGC1A and SIRT1 was 
significantly downregulated in PCOS-like sheep but no difference in the levels of PRDM16 
and TLE3.  PPARGC1A (PPARG coactivator-1α; PGC-1α) is an important regulator of 
mitochondrial biogenesis and oxidative metabolism (612,613). Gain of function experiments 
have shown that ectopic expression of PPARGC1A in white adipocytes induced characteristics 
of brown fat cells, including increased expression of mitochondrial and thermogenic genes 
(614), whereas PPARGC1A deficient mice have increased body fat and are unable to maintain 
core body temperature after cold exposure (615). SIRT1 (Sirtuin 1) regulates PPARGC1A  
expression and equally plays an important role in brown adipocyte biology and thermogenesis 
(616-618). SIRT1 is a protein deacetylase, targeting transcription factors and enzymes with 
key roles in mitochondrial biogenesis, lipid catabolism, cholesterol homeostasis and 
gluconeogenesis (619).  It has been shown that moderate overexpression of SIRT1 in mice 
results in amplified BAT activity and thermogenic potential, increased lipolysis and improved 
insulin sensitivity due to enhanced transcriptional responses to β3-adrenergic stimulation 
(620). What is more, SIRT1 has been shown to increase browning of WAT (621), and to 
protect against high-fat diet-induced metabolic damage (622) whereas  SIRT1 deficient mice  
show increased adiposity, lower thermogenic activity and metabolic dysfunction (623). We 
also observed trend for decreased expression of TMEM26 in SAT of PCOS-like sheep. 
Transmembrane protein 26 (TMEM26) was first identified as specific beige adipocyte marker 
(567,624), however, others have suggested that TMEM26 might be actually a marker of beige 
adipocyte precursors in WAT rather than differentiated beige adipocytes (625). Our data 
indicate depot specific expression of beige adipocyte markers. We do not know how these 
different adipose tissue depots contribute to overall metabolic status however, it is tempting to 
speculate that considering the much greater volume of SAT compared with remaining adipose 
depots, decreased expression of beige fat markers in SAT might contribute to decreased PPT 
in those animals. As shown by others, beige adipocytes resemble white adipocytes in having 
unilocular appearance and low basal level of UCP1 expression, however upon stimulation with 
cyclic AMP, β-adrenergic or PPARG  agonists, beige cells show significantly increased UCP1 
expression and high rates of respiration and energy expenditure, comparable to that of brown 
adipocytes (567). Interestingly, recent studies have provided evidence that in humans, fat 
depots previously identified as BAT are actually composed mainly of beige adipocytes (567).  
Therefore, in order to further evaluate thermogenic potential of adipocytes in our animals, we 
have studied mRNA expression of three isoforms of UCP proteins (UCP1, 2 and 3) in four 
adipose tissue depots, IAT, NAT, SAT and VAT. We have found that in IAT, near the site 
where we implanted temperature dataloggers, mRNA expression of UCP2 and UCP3 was 
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significantly decreased in PCOS-like animals as compared with controls, and there was a trend 
toward decreased expression of UCP1, although this did not reach statistical significance. 
There was also reduced UCP1 expression in the remaining three adipose tissue depots, NAT, 
SAT and VAT. Interestingly, similar findings were reported in genetically fat sheep, where 
significant downregulation of PPT and UCP1 in retropertitoneal adipose tissue, but not UCP2 
or UCP3, was reported (579). Although we did not quantify UCP protein levels, there was a 
positive correlation between amplitude of PPT increase and expression of UCP1, UCP2 and 
UCP3 mRNA in IAT, as well as UCP1 in SAT and VAT, indicating that mRNA levels of 
UCP might be also a reliable measure of thermogenic potential. There was also a negative 
correlation between UCP1 expression in adipose tissue and fasting insulin level, suggesting 
that hyperinsulinemia in PCOS-like sheep might contribute to decreased expression of UCP1 
and hence reduced thermogenic potential of BAT and/or beige adipocytes, which in turn might 
account for the diminished postprandial thermogenic response in those animals. This 
hypothesis is further supported by existing evidence on the role of BAT and UCPs in diet 
induced thermogenesis from both rodent and human studies. The first observations that BAT 
is involved in PPT came from studies in rodents, showing that rats fed with a highly palatable 
diet, voluntarily overfeed however, have an ability to dissipate extra energy from food as heat 
(575,626) and demonstrate a significant increase of UCP1, both mRNA and protein, in BAT 
(627,628). In parallel,  pair-fed studies of genetically obese mice and their lean siblings showed 
that the development of obesity is associated with diminished thermogenesis (629,630), and 
this was further linked to a reduced concentration of UCP1 in BAT (631). Further research 
demonstrated that these genetically obese rodents have lower sympathetic activity in BAT, at 
thermoneutral conditions, as shown through noradrenaline turnover assessment (632). 
However, the final evidence for the central role of BAT and UCPs in PPT came from UCP1 
knockout studies, demonstrating that mice lacking UCP1 become obese when kept at 
thermoneutrality even when consuming normal diets (633,634). However, a persisting 
question was, whether animal data on BAT and its role in PPT and development of obesity, is 
applicable to humans. Several studies demonstrated decreased BAT activity in obese subjects 
however, there was a lot of controversy weather diminished BAT activity is a cause rather than 
a consequence of obesity and to what degree PPT actually contributes to overall energy 
expenditure (635). However, more recent human studies  showed that UCP1 polymorphisms 
are related to decreased PPT (636) and that  BAT recruitment due to cold acclimation at 19°C 
enhances PPT and insulin sensitivity without muscle shivering (637). In the latter study Lee 
at al. demonstrated that increased BAT volume and activity, with possible enhanced browning 
of WAT, resulted in increased levels of circulating adiponectin and decreased levels of 
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circulating leptin, and these changes were mirrored in altered gene expression in adipose 
tissue, even at thermoneutrality, suggesting that increased BAT/ beige fat proliferation and/or 
transformation, impacts whole-body metabolism (638). Furthermore, it was reported that 
humans with active BAT, as evaluated by (F-FDG-PET/CT), have increased PPT by 56 kcal 
per day and an enhanced rate of fat utilisation as compared to BAT-negative subjects, under 
free-living and thermoneutral conditions, suggesting that metabolically active BAT can 
contribute to PPT in humans  (639). However, while the role of UCP1 in adaptive 
thermogenesis is well established, the precise function of UCP2 and UCP3 in cells remains 
unknown. Since UCP2 and UCP3 have 60% sequence identity with UCP1 and 70% similarity 
with each other, it has been suggested that these proteins are likely to have also similar 
biochemical function, however, early studies did not confirm this hypothesis (640). It has been 
shown that UCP2 and UCP3 are able to catalyse proton conductance of mitochondria but only 
when specific activators, such as FFA or free radicals, are present (641). The genomic location 
of human UCP2 and UCP3 is in a chromosomal locus mapped as relevant to obesity and 
hyperinsulinemia (642,643). Indeed, studies on transgenic animals have demonstrated that 
rodents overexpressing UCP2/UCP3 have decreased adiposity and are protected from diet-
induced obesity (644-646). Human studies looking at polymorphisms of UCP2 and UCP3 
further support link between differential expression of those genes and obesity (647-649). 
However, it has been shown that UCP2 and UCP3 knockout mice have normal body weight, 
metabolic rate, and responses to cold, indicating that these proteins are not essential for normal 
metabolic function, but presence of other compensatory mechanisms cannot be excluded 
(650,651). What is more, a study on the expression of thermogenesis-related genes in WAT of 
lean and obese subjects reported that expression of UCP2 is significantly downregulated, but 
with no difference in methylation levels, in SAT and VAT of obese individuals, whereas no 
difference was found in the expression of UCP1 and UCP3 (652). The authors concluded that 
this might indicate that there were no differences in the content of beige adipocytes between 
lean and obese individuals (652). This finding might appear contradictory to our results, as we 
report decreased UCP1 expression in WAT, potentially resulting in decreased content of beige 
adipocytes in obese PCOS-like sheep. However, as discussed earlier, differences in 
thermogenic potential between controls and PCOS-like animals in our study do not result from 
obesity per se but most likely is a consequence of prenatally programmed reduced energy 
expenditure.  
In contrast to the expression of UCP1, which is restricted to thermogenic adipocytes, the 
expression of UCP2 is ubiquitous (including pancreas, muscles, WAT and BAT), whereas the 
expression of UCP3 is limited to muscles and BAT (642). The wide distribution of these 
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proteins has implicated their potential role in FFA transport, the attenuation of reactive oxygen 
species (ROS) production and protection against oxidative damage, degenerative disease and 
aging (653). Additionally, UCP2 has been suggested to decrease insulin secretion in pancreas 
whereas UCP3 has been suggested to mediate thermogenesis in muscle (653). Interestingly, it 
has been demonstrated that mRNA expression of UCP2 and UCP3 in rat muscles is increased 
during starvation and decreased after refeeding, suggesting regulatory role of FFA on 
expression of UCP2 and UCP3 (654). In addition, Bezaire et al. has shown that the proteins 
involved in FFA uptake and oxidation are increased in muscle of transgenic mice 
overexpressing UCP3, supporting a role for UCP3 in fatty acid metabolism (655). 
Furthermore, human studies reported that elevated FFA levels, during triglyceride infusion, 
increased the expression of UCP3, but not UCP2, in muscles, and that physiological 
hyperinsulinemia  prevents this upregulation of UCP3, which again supports potential 
regulatory role of insulin on the expression of UCPs (656). A study in UCP1 knockout mice  
reported that UCP3 expression increases in skeletal muscle upon cold exposure suggesting 
interdependence of UCP1 in BAT and UCP3 in skeletal muscle (657). In contrast, a recent 
study has reported that expression of UCP3 directly correlated with levels of UCP1 in murine 
BAT, demonstrating that UCP3, but not UCP2, is significantly lower in BAT, but not skeletal 
muscles, of UCP1 knockout mice (658). Interestingly, the authors also noted that in wild-type 
mice cold exposure increased UCP3 expression in BAT, but not skeletal muscles, however, 
cold acclimation of UCP1 knockout mice resulted in the lowest UCP3 levels (658). All above 
findings indicate that UCP2 and UCP3 are not able to overcome the loss of the thermogenic 
function of UCP1 in BAT and are more likely to be involved in FFA transport and metabolism. 
As pointed out by Thompson and Kim in their review on links between FFA and expression 
of UCP2 and UCP3, in physiological and pathological states leading to significant FFA 
elevation, there is a trend in the literature showing that in muscles UCP3 is increased, with no 
change in UCP2 levels, and the reverse correlation is present in WAT, whereas in BAT UCP3 
tends to be decreased (659). This is partially in agreement with our results. PCOS-like sheep 
have elevated fasting FFA, decreased UCP3 mRNA in IAT and trend for increased UCP3 
mRNA in muscles, however, with no difference in the expression of UCP2 in WAT. Assuming 
UCP2 and UCP3 have roles as FFA transporters, decreased expression of UCP2 and UCP3 in 
IAT of PCOS-like sheep could indicate that there is lower uptake of FFA into this adipose 
tissue depot. Interestingly, experiments in both rodents and humans showed that BAT mainly 
utilises FFA as energy, and that individuals with higher BAT activity have increased fat 
oxidation under thermoneutral conditions (639,660). Since low fat oxidation predicts future 
weight gain (661,662), perhaps it can be suggested that subjects with decreased BAT activity 
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and hence lower fat utilisation are more likely to gain weight and have decreased insulin 
sensitivity (639). Adolescent and adult PCOS-like sheep have increased fasting FFA in the 
circulation. Although we did not measure levels of PPT in adolescent prenatally androgenised 
sheep, we have now found that there is negative correlation between levels of fasting FFA in 
adult animals and amplitude of PPT, suggesting that decreased PPT and BAT activity in 
PCOS-like animals might contribute to decreased fat oxidation in BAT resulting in increased 
FFA in the circulation. Furthermore, there was a negative relationship between average 
noradrenaline levels in adipose tissue with fasting FFA, again supporting the role of SNS and 
BAT in the regulation of FFA levels. BAT thermogenesis is controlled by the SNS, where 
localised release and action of noradrenaline increases the mass, temperature and lipolytic 
response of BAT through activation of UCP1 (574). This effect is conducted via the β-
adrenergic receptors located in thermogenic adipose tissue and deletion of all three isoforms 
of (ADRB1, ADRB2 and ADRB3) results in an obese phenotype and decreased UCP1 
expression (663). It has been demonstrated that noradrenaline concentration is increased after 
feeding and correlates closely with heat production in response to overfeeding and mild cold 
exposure (664-667). Although we did not measure the circulating noradrenaline concentration 
during the postprandial period in our animals, we have investigated noradrenaline levels and 
mRNA expression of β-adrenergic receptors in four adipose tissue depots after 15 minutes of 
a IVGTT test. There were no differences in the expression of adrenergic receptors, however, 
noradrenaline concentrations were significantly lower in NAT, SAT and VAT, but not IAT of 
PCOS-like animals when compared to controls. Interestingly, the IAT adipose tissue depot 
was also the only depot where UCP1 expression was not significantly decreased as in the 
remaining adipose depots of TP-exposed animals, therefore it is likely that the relatively 
increased levels of noradrenaline in that depot may have a contributory role.  In addition, the 
total average level of noradrenaline from those four adipose tissue depots was significantly 
lower in prenatally androgenised animals, and this was independent of obesity. Furthermore, 
there was a positive correlation between average level of noradrenaline and PPT amplitude, 
but not individual mRNA UCPs levels in adipose tissue depots. These findings suggest that 
the SNS might contribute towards decreased PPT in PCOS-like animals due to decreased 
sympathetic activity, but not sensitivity, however, this should be further investigated. 
Interestingly, since noradrenaline action in BAT results also in hydrolysis of TG in lipid 
droplets (559), the decreased level of noradrenaline in adipose tissue depots of PCOS-like 
animals could also contribute to the increased adipocyte size observed in those animals. To 
our knowledge, there is no study available looking directly at noradrenaline levels in adipose 
tissue of PCOS women however, there are reports showing a generally increased sympathetic 
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tone (668) but decreased adrenergic responsiveness and consequently reduced lipolysis in 
adipose tissue in PCOS women (231,669). In addition, Backstrom et al. reported that, in 
response to hypoglycaemia, peripheral serum noradrenaline levels, which originate from both 
the sympathetic nervous system and the adrenal medulla, were lower in the obese women with 
PCOS than in the BMI matched controls as well as in lean women with and without PCOS 
(670). The authors also noted that decreased noradrenaline concentrations correlated inversely 
with increased fasting insulin levels in obese women with PCOS (670). Insulin is an important 
regulator of sympathetic activity and it has been shown that intracerebroventricular injection 
of insulin increases sympathetic activation in animal studies (671) however, the stimulatory 
actions of insulin on the sympathetic outflow may be reduced in obesity and the metabolic 
syndrome (672). Therefore, it is possible that the decreased noradrenaline levels observed in 
adipose tissue of PCOS-like animals is a secondary to the potential peripheral and central 
insulin resistance in those animals.  
It has been suggested that skeletal muscle also play a role in adaptive thermogenesis (673,674). 
Skeletal muscles express all three UCP proteins, with UCP3 being the most abundant. Initial 
in vitro studies in isolated mitochondria hinted that UCP3 has uncoupling potential however, 
in vivo studies indicated that UCP3 levels typically mirror peripheral FFA (640,659,675). 
Some authors, however, indicated that brown adipocytes interspersed among muscle fibres 
might be the actual source of thermogenic potential of skeletal muscles (676). We did not find 
any difference in the expression of UCP1, UCP2, and UCP3 in skeletal muscles of control 
and PCOS-like sheep although there was non-statistically significant trend towards increased 
expression of UCP3 in TP-exposed animals, which, as mentioned earlier, might reflect 
increased levels of fasting FFA in those animals. In addition to mitochondrial uncoupling, 
cellular pathways such as the futile calcium cycling and myosin-ATP turnover have also been 
indicated to underpin thermogenesis in skeletal muscle (673). Calcium cycling occurs across 
the sarcoplasmic reticulum membrane in skeletal muscle and involves the ryanodine type 1 
receptor (RYR1) and the sarcoendoplasmic reticulum calcium-dependent ATPases (ATP2A1 
and ATP2A2) (673). Studies in sheep demonstrated that feeding increases muscle temperature 
and expression of RYR1 and ATP2A1 (677,678). There were no differences in the expression 
of elements of the futile calcium cycling pathway in skeletal muscle between control and 
prenatally androgenised sheep after 15 min of an IVGTT test. However, since we did not 
measure postprandial temperature directly in muscle, we cannot answer if and to what extent 
skeletal muscle contributes to decreased postprandial thermogenesis observed in PCOS-like 
animals. 
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We also aimed to establish the potential timing of reduced expression of thermogenic genes in 
adipose tissue of prenatally androgenised animals. There were no differences in the expression 
of UCPs in SAT of fetal and juvenile sheep however, due to limited tissue availability we only 
assessed expression of those genes in one adipose tissue depot in those animals. Interestingly, 
adolescent PCOS-like animals had significantly decreased expression of UCP3 and PRDM16 
in SAT but there was no difference in the expression of any of the thermogenic associated 
genes in VAT. Again, we did not have samples of IAT or NAT from this age cohort. PRDM16 
is an enriched factor of both beige and brown adipocytes and plays a pivotal role in regulating 
brown/beige fat cell fate and function (679). It has been demonstrated that PRDM16 is 
essential to induce full molecular programming of brown adipose cells, including the 
expression of thermogenic genes, mitochondrial components and increased cellular respiration 
in cell culture models, and to promote browning of VAT under β-adrenergic stimulation (680). 
PRDM16 also represses white adipose tissue-specific genes (681). In addition, depletion of 
PRDM16 in brown fat cells causes a near total loss of the brown characteristics, and in 
subcutaneous adipocytes decreases the recruitment of beige adipocytes in WAT in response to 
a PPARG agonist (564,569,680). Rodents with ablated beige fat function, due to a mutation in 
the PRDM16 gene, develop obesity, insulin resistance, hepatic steatosis as well as enlarged 
subcutaneous adipocytes with virtually no UCP1 expression, and increased level of 
inflammatory markers in that depot, when exposed to high-fat diet (HFD) (682). PRDM16 
evokes its function through coactivating PGC-1α, PPARG and C/EBPs (559). It has been 
demonstrated that PRDM16 forms a complex with C/EBPβ to induce the expression of brown-
fat specify genes, loss of C/EBPβ results in impaired thermogenesis, while increased levels of 
C/EBPβ lead to browning of WAT, and PRDM16-C/EBPβ-PPARG interaction is indicated as 
central pathway in brown and beige adipose cell development (559,566,683-685). Assuming 
that beige adipocytes differentiate from defined precursor cells rather than pre-existing 
adipocytes (624), this finding suggest that reduced expression of PRDM16 in adolescent SAT 
might program decreased brown/beige development in that depot, which presumably explains 
decreased expression of UCP1 and beige cell markers in adult SAT of PCOS-like animals. 
Interestingly, in chapter 3 we had reported previously decreased expression of PPARG, 
CEBPA and CEBPB associated with decreased adipogenesis in SAT of those adolescent 
prenatally androgenised sheep. We hypothesise that prenatal androgen exposure could 
underline those changes. Is there evidence for a role of sex hormones in programming brown 
and beige adipose tissue function?  
Sex hormones play an important role in the regulation of energy balance and determination 
the distribution and function of WAT. However, the potential mechanisms underpinning the 
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link between sex hormones and energy homeostasis in beige/brown adipocytes is not well 
understood. Sex differences in BAT thermogenic capacity have been reported suggesting a 
potential link between sex hormones and BAT. Women have higher BAT prevalence, mass 
and activity than men (146,147,576,686). In addition, lower incidence of BAT has been linked 
to increased visceral adiposity in men rather than in women (686). Parallel results were also 
reported in rodents. Female rats were found to have 2-fold higher UCP1 content and higher 
energy expenditure than males (149), and when exposed to high fat diet, male rats were 
described to gain more body weight than females (687). In addition, the authors reported that 
mitochondria in female BAT were larger and had greater amount of cristae than males, 
suggesting that this might account for increased thermogenic potential in females (149). 
Furthermore, higher AR mRNA expression in male rodent BAT was reported (688). While in 
vitro studies on the effect of sex hormones on differentiated brown adipocytes found that 
testosterone treatment resulted in dose-dependent inhibition of UCP1 mRNA expression in 
noradrenaline stimulated adipocytes and this was reversed when adipocytes were co-treated 
with flutamide, an androgen antagonist (689). The authors also reported that progesterone 
treatment caused increased expression of UCP1 whereas no effect was found in 17β-estradiol 
treated cells (689). Testosterone has also been reported to decrease the expression of PGC-1α 
in cell-cultured brown adipocytes (690). There is also evidence that estrogens impact energy 
expenditure and stimulate BAT activity, mainly through interaction with melanocortin and 
leptinergic systems (691-693). It was shown that UCP1 expression in BAT of ovariectomised, 
estrogen-deficient rats, was significantly lower (694) whereas estrogen receptor-alpha 
knockout mice had increased body weight and decreased energy expenditure by 11% when 
compared with control animals (695). A role for sex hormones in regulating BAT activity 
might be further supported by the evidence that physiological states characterised by changes 
in sex steroid levels, such as pregnancy and lactation, result in altered BAT function. It has 
been demonstrated that pregnancy and lactation in rodents is associated with BAT atrophy, 
decreased levels of UCP1 and reduced noradrenaline turnover in BAT, most likely to preserve 
energy (696,697). In addition, it has been suggested that age related decreases in BAT activity 
might be due to declining levels of sex steroids (698,699). The α2A/β3 adrenoreceptor ratio 
has been indicated as an important regulatory factor in lipolysis and thermogenesis, with a 
lower ratio resulting in greater thermogenic activity (700). Interestingly, in vitro studies also 
demonstrated that testosterone treatment of brown adipocytes leads to increased expression of 
α2A-adrenergic receptors, whereas progesterone and 17β-estradiol have an opposite effect, 
resulting in a lower α2A/β3 ratio (700). Lower ratios were also reported in female rats when 
compared to males, further supporting the fact that sex hormones might drive higher 
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thermogenic capacity in females (149). Unfortunately, we did not investigate gene and protein 
expression of ADRA2A, therefore we are unable to define the ratio in our animals. However, 
since one of the main features of PCOS is increased antenatal and postnatal androgen levels it 
is very likely that increased testosterone levels might be responsible for the decreased 
BAT/beige fat thermogenic potential in PCOS-like sheep and women with PCOS. 
Interestingly, a recent study in a DHEA-induced rat model of PCOS demonstrated that PCOS-
like rats have significantly reduced BAT activity with decreased UCP1 and PGC-1α 
expression, and lower thermogenic capacity (701). Transplantation of BAT from age- and sex-
matched donors not only improved metabolic profile but also reversed anovulation, 
hyperandrogenism, polycystic ovaries and improved fertility in this animal model of PCOS 
(701). Furtermore, the authors also reported that BAT transplantation activated endogenous 
BAT and increased levels of circulating adiponectin, an insulin sensitising adipokine, which 
is often reported to be lower in PCOS patients (701).  
In summary, obesity and increased adiposity are highly prevalent in PCOS patients and 
decreased energy expenditure has been documented in women with PCOS, however, to date 
there was a limited evidence that women with PCOS might be predisposed to obesity. Using 
clinically realistic ovine model of PCOS we have demonstrated that adult PCOS-like sheep 
have a decreased amplitude of PPT when compared with controls, without differences in basal 
body temperature, despite receiving the same caloric intake, and independent of obesity. These 
findings suggest that prenatally androgenised female sheep as adults have reduced capacity 
for energy expenditure, which is mirrored in women with PCOS. This reduced capacity for 
postprandial thermogenesis is correlated to hyperinsulinemia and deceased noradrenaline 
rather than obesity, and might result from reduced thermogenic potential of BAT and/or beige 
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5.1 Introduction 
As stated in previous chapters, prenatally androgenised adolescent sheep had evidence of fatty 
liver, as examined through histological analysis, but without changes in serum determinants 
of liver function, and independent of body weight or central adiposity (411). NAFLD is a term 
describing a spectrum of liver pathologies, from simple hepatic steatosis, characterized by 
more than 5% fat infiltration on imaging or histology, and a benign prognosis, to non-alcoholic 
steatohepatitis (NASH) (702). It is estimated that about 15% of patients with simple steatosis 
will eventually develop NASH, a combination of  hepatocellular injury, inflammation, and an 
increased risk of liver fibrosis, which might result in cirrhosis and hepatocellular carcinoma 
(252,703). 
NAFLD is the most common cause of chronic liver disease in western countries and a major 
public and clinical health burden (702,703). NAFLD is highly prevalent, it is estimated that in 
general population 30-40% of men and 15-20% of women are affected, with occurrence 
significantly increasing to 60%-70% in overweight people and subjects with T2DM, and over 
90% in morbidly obese patients (252,704,705). In addition, NAFLD is the most prevalent 
chronic liver disease in paediatric population, with up to 17.3% of adolescents, aged 15 to 19 
years, affected (706). A recent meta-analysis reported that mean prevalence of NAFLD in 
children from general population was 7.6% however,  in children with obesity occurrence 
increased to 34.2% (707). There was also evidence that the prevalence was higher in males 
compared with females, and increased proportionally with BMI (707).  
The majority of patients with NAFLD are asymptomatic until the late stage of disease (708). 
The disease can be diagnosed through ultrasonography, although liver biopsy is still 
considered a gold standard for diagnosing NASH and to assess degree of fibrosis (708). In 
addition, liver function tests (LFTs) measuring alanine transaminase (ALT) and aspartate 
transaminase (AST) in blood samples can be used, however, it has been demonstrated that 
biochemical tests are not reliable markers for assessing NAFLD severity, since patients with 
normal transaminases may still have NASH (252,709). NAFLD is considered a hepatic 
manifestation of metabolic syndrome and a risk factor for developing IR and T2DM, 
dyslipidaemia and hypertension, obesity and PCOS (710,711). NAFLD is therefore a 
multisystem disease, affecting a several extra-hepatic organs and regulatory pathways (703). 
However, it was also postulated that NAFLD precedes the development of the metabolic 
syndrome, which indicates that resolution of NAFLD could prevent the development of the 
metabolic syndrome and its cardiovascular consequences (712). Currently, there are no 
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pharmacological therapies approved for treating NAFLD, therefore therapeutic approaches 
centre on treating associated comorbidities, such as obesity, insulin resistance, dyslipidaemia 
and inflammation (713). Lifestyle modifications and weight management, through diet 
improvements and increased physical activity, remain the cornerstone approach to improving, 
or at least delaying progression of the disease (713). In addition, pharmacological treatment 
with TZDs, PPARG agonists, has been shown to have some potential benefits, promoting fatty 
acid oxidation, decreasing hepatic lipogenesis, and reducing inflammation, resulting in 
decreased hepatic TG accumulation in patients with NAFLD (714,715). 
The mechanisms underlying aetiology and pathophysiology of NAFLD are not fully 
understood. It was demonstrated that NAFLD shows some familial clustering, suggesting a 
possible genetic predisposition (716). In addition, obesity and T2DM are known risk factors 
for development of NAFLD. However, since numerous subjects with NAFLD are lean and not 
diabetic it has been postulated that insulin resistance might be the main risk factor (717). 
Indeed, a decline in whole-body, hepatic, and adipose tissue insulin sensitivity was 
documented in NAFLD (717).  
Insulin is crucial for the regulation of carbohydrate and lipid homeostasis. In response to 
increased postprandial glucose levels insulin is secreted by pancreatic β cells. A large 
proportion of glucose is instantly transported to the liver, which converts it into glycogen. 
However, when glycogen saturation occurs, any additional glucose transported into liver is 
shunted into pathways synthesising fatty acids, which will be further esterified into TG. In 
addition, in a fed state, insulin inhibits FFA release from adipose tissue, reduces hepatic 
glucose production, through decreased gluconeogenesis and glycogenolysis, and increases the 
rate of glucose uptake, primarily into skeletal muscle and adipose tissue. Consequently, 
decreased insulin sensitivity results in elevated postprandial levels of insulin and insufficiently 
supressed lipolysis in adipose tissue, increased FFA in circulation, independent of nutritional 
status, and increased flux of FFA to the liver. In turn, fatty acids in the liver can promote 
hepatic lipotoxicity by stimulating TNFα expression and reactive oxygen species (ROS)  
formation, which can further exaggerate inflammation and apoptosis, subsequently resulting 
in progression to NASH and fibrogenesis (718,719). In addition, hyperinsulinemia may lead 
to increased de novo lipogenesis, while hepatic insulin resistance may also lead to inadequately 
suppressed gluconeogenesis. Overall this may result in increased hepatic lipid accumulation, 
dyslipidaemia and progressive insulin resistance. The onset of NAFLD is associated with 
progressive accumulation of lipids in the liver. The liver has a crucial role in lipid metabolism, 
through importing FFA, manufacturing, storing and exporting lipids and thus dysregulation of 
Chapter 5 The effect of prenatal androgenisation on hepatic phenotype 
146 
any of those processes can lead to development of NAFLD (702). The mechanisms leading to 
accumulation of lipids in the liver include increased delivery of FFA to the liver, decreased 
fatty acid oxidation, and amplified de novo lipogenesis (717). However, it has been 
demonstrated that NAFLD results mainly from increased transport of FFA to the liver and 
enhanced de novo lipogenesis, whereas removal, by mitochondrial fatty acid oxidation and 
lipid export are only moderately affected (702,720). Of the total hepatic triglyceride content 
in patients with NAFLD, 60% resulted from adipose-derived NEFA, 10% from the diet, and 
30% came from de novo lipogenesis (720). 
Hepatic FFA uptake is facilitated by FFA transporters and depends on FFA concentration in 
the plasma, hepatocellular capacity, and number and activity of those transporters. The main 
plasma transporters for FFA are the fatty acid transporter proteins (FATP), of which FATP2 
and FATP5 are the major ones, caveolins (1-3), the fatty acid binding proteins (FABP), of 
which FABP2 and FABP5 have been demonstrated to play an important role in normal hepatic 
physiology and pathophysiology, and fatty acid translocase (FAT)/CD36 (702). 
De novo lipogenesis, the mechanism in which liver synthesises endogenous FAs from glucose 
is a complex process, regulated by insulin and glucose levels, in which acetyl-CoA 
carboxylase (ACC1), FA synthase (FAS) and sterol CoA desaturase 1 (SCD1) play a crucial 
role. The rate of de novo lipogenesis is regulated primarily at transcriptional level by several 
nuclear transcription factors among which are sterol regulatory element-binding protein 1C 
(SREBP1c), regulated by insulin, and carbohydrate-responsive element binding protein 
(ChREBP), regulated by glucose, are among the main ones.  
Fatty acid oxidation takes place mainly in mitochondria although, it can also occur in 
peroxisomes and endoplasmic reticulum (ER). It is suppressed in a fed state and upregulated 
during fasting. The rate of oxidation is mainly regulated by insulin and peroxisome proliferator 
receptor alpha (PPARA). PPARA controls the expression of several genes related to 
mitochondrial FA oxidation and therefore activation of PPARA prevents lipid accumulation 
in the liver and leads to decreased hepatic fat storage. Conversely, inefficient activation of 
PPARA may lead to hepatic steatosis. 
Hepatic gluconeogenesis occurs during prolonged fasting by the induction of pyruvate 
carboxylase in an abundance of acetyl-CoA and is further regulated by transcriptional 
activation of phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase 
(G6PC). Insulin normally suppresses gluconeogenesis however, this inhibitory function of 
insulin might be impaired in insulin resistance. In addition, ChREBP and forkhead box O1 
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(FOXO1) further regulate rate of hepatic glucose formation, through activating PEPCK and 
G6PC. 
Women with PCOS are at increased risk of developing NAFLD, and these women are more 
likely to have the more severe forms of NAFLD (708,721,722). Moreover, it was noted that 
PCOS is diagnosed  frequently in female patients with biopsy-confirmed NAFLD (723). The 
estimated prevalence of NAFLD in women with PCOS varies between 35 to 70 %, compared 
to 20 to 30 % in the control population. (256,708,724-727). In addition, as demonstrated in 
some studies, this might be independent of age, BMI, waist circumference and associated 
comorbidities, however, it should be noted that majority of the studies on assessing the risk of 
NAFLD in PCOS, included only the overweight/obese population with PCOS. Furthermore, 
it was demonstrated that NAFLD was more prevalent in adolescent girls with PCOS than girls 
without PCOS, 37.5% vs 15.1% respectively, and that degree of steatosis in girls with both 
NAFLD and PCOS was greater than in those with NAFLD but without PCOS (728). Insulin 
resistance is a central factor contributing to pathophysiology of both PCOS and NAFLD, and 
both conditions are now considered as manifestations of metabolic syndrome (722). In 
addition, it has been documented that the prevalence of PCOS and NAFLD rise proportionally 
to the degree of insulin resistance. Moreover, it was demonstrated that decreased SHBG and 
increased androgens were associated with the incidence of NAFLD in women with PCOS 
(729,730). However, it was also shown that among women with PCOS, patients with NAFLD 
and PCOS demonstrate greater insulin resistance, but have similar circulating androgen levels, 
when compared with those with PCOS alone (731). Interestingly, NAFLD is an early predictor 
of metabolic disorders, particularly in the normal weigh population (711). Moreover, it was 
found that young, lean subjects with insulin resistance in skeletal muscle, have redirected 
energy derived from carbohydrates into hepatic de novo lipogenesis, also have increased 
hepatic triglyceride synthesis, as compared with healthy controls (732,733). Given, than young 
lean PCOS women often present with insulin resistance (734), and insulin resistance is central 
in the aetiology and pathophysiology of NAFLD, it is likely that lean PCOS women might be 
at higher risk of developing NAFLD than age- and BMI-matched controls. 
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Adolescent PCOS-like sheep were hyperinsulinemic, but normoglycemic, and had evidence 
of subclinical hepatic steatosis, but without changes in plasma ALT and AST, and independent 
of body weight and central adiposity (411). Further, it was demonstrated that these prenatally 
androgenised 11 months old sheep had normal levels of circulating testosterone but increased 
expression of hepatic AR, when compared with controls (411). In addition, in chapter 3, it was 
reported that that these adolescent PCOS-like sheep had evidence of decreased adipogenesis 
in SAT and impaired expression of genes associated with insulin signalling in that adipose 
depot. Further, these animals had also increased fasting FFA concentrations, likely due to 
decreased adipose tissue storage.  
The aims of this chapter were to: 
1. establish molecular mechanisms underlying fatty liver in adolescent PCOS-like sheep 
2. evaluate hepatic liver fat content in adult control and PCOS-like animals  
3. investigate gene expression associated with hepatic lipid and glucose metabolism in 
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5.2 Methods 
5.2.1 Experimental animals 
The ovine model, the animals used, their husbandry and treatments have been described 
previously in Section 2.2. The female animals assessed in this chapter are detailed in Table 
5.1. 








Ewes 30 months old C=11, TP=4 
Table 5.1 Treatment regime, age and corresponding sample numbers of experimental animals discussed 
in this chapter. 
 
5.2.2 Gene expression analysis using qRT-PCR. 
Extraction of RNA from liver tissue was performed using Qiagen RNeasy Mini Kit (Qiagen 
Ltd., West Sussex, UK), as described in section 2.8.1. Protocols for cDNA synthesis and qRT-
PCR are described in section 2.8.3. and 2.8.4, respectively. Forward and reverse primers were 
designed and validated as stated in section 2.8.6 and primer sequences analysed in this chapter 
are listed in Table 5.2. 
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Gene Forward Sequence Reverse Sequence Product 
Size (bp) 
SLC27A2 GTGGAAAGGGGAAAATGTGG TCAAATTCATGGTCTGCCTTC 156 
SLC27A5 CGGACATCAAGTTGCGAAG ATCCCTGATACCTGCAGCAC 109 
CAV1 CATCTCTACACTGTTCCCATCC ACGTCGTCGTTGAGATGCTT 155 
CAV2 CCACAGCAGCGTCGATTAC CACTGGCTCTGCAATCACAT 121 
FABP4 TGTAAATGGGGATGTGGTCA CAGCACCAGCTTATCATCCA 217 
FABP5 TTCAGCAGCTGGTAGGAAGA GCACCTACTTTTCGCAGAGC 100 
SREBF1 CAATGTGTGAGAAGGCCAGT AGGAGCAGGTCACACAGGAG 106 
ACACA CTCGCCAGCAGAATTTGTTA CGGATGGATCTCATGCATTT 105 
FASN CATGGCGTTCCACTCCTATT GGACTCGGGGATGGAAGT 124 
PPARA CACAAGTGCCTTTCCGTTGG ATGACGAAGGGCGGATTGTT 248 
MLX1PL CTCTGACACGCTCTTCACCA GTCAGGTCTGGCTGGATCAT 105 
FOXO1 CCAGCTCGAACGCTAGTACC GGGGTTACTGATCTCGGACA 155 
PEPCK AAAGAGATACGGTGCCCATC ATGCCAATCTTGGACAGAGG 178 
G6PC GAATGTCTGCCTGTCACGAA ATCCAATGGCGAAACTGAAC 179 
GHR CGTCTCTGCTGGTGAAAACA AGGATGTCGGCATGAATCTC 204 
STAT5A CTTGTTGCGCTTTAGCGACT GTGTGGTGAATGGCTTCAGA 101 
STAT5B GTCAGCATTTCCCCATTGAG TGGGTGGCCTTAATGTTCTC 109 
Table 5.2 Forward and reverse primer sequences and product size for genes analysed in the postnatal 
liver tissue using SYBR Green qRT-PCR. 
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5.2.3 Oil Red O Lipid Staining and Analysis 
Oil Red O (ORO) lipid staining on the liver samples was performed and analysed as per 
protocol published in Nature Protocols for imaging of neutral lipids (735). Liver samples were 
embedded in OCT (VWR International, Leicestershire, UK), as described in section 2.2.5. 
Four frozen 10µm sections per animal, 40µm apart, were cut on a cryostat (Leica Cryostat 
Microtome 1900, Leica Biosystems, Germany) at -20°C, mounted onto glass slides and air-
dried. The ORO stock solution was prepared by dissolving 2.5g ORO in 400ml 99% (vol/vol) 
isopropanol, and the ORO working solution by mixing 1.5 part of stock solution with 1 part 
of distilled water. The working solution was filtered through 45µm filter to remove precipitates 
and used immediately. Sections were immersed in the ORO solution for 5 min at room 
temperature and rinsed under running tap water for 30 min, taking care that sections were not 
damaged during this process. Slides were mounted in Aqua-Mount media (Fisher Scientific 
Ltd.). On the same day, to prevent precipitation of the ORO dye, sections were visualised with 
light microscope at x20 magnification with and two representative images (frames) per section 
were captured. Lipid accumulation was quantified via the amount of ORO staining with 
ImageJ, as per the published protocol. 
5.2.4 Measurement of plasma analytes 
Measurement of plasma analytes was performed by Dr Forbes Howie. To measure the 
concentration of ALT, AST, albumin, cholesterol, LDL and HDL, commercial assay kits were 
employed (Alpha Laboratories Ltd., Eastleigh, UK) as per the manufacturer’s protocols, using 
a Cobas Fara centrifugal analyser (Roche Diagnostics Ltd.) to obtain analyte concentration. 
Assay sensitivities for ALT, AST, albumin, cholesterol, LDL and HDL were 2U/l, 2U/l, 0.5g/l, 
0.1mmol/l, 0.02mmol/l and 0.02mmol/l, respectively, and the overall CVs were all <3%.  
5.2.5 Statistical analysis 
Statistical analysis was performed with GraphPad Prism version 6.0 (GraphPad Sowftware, 
Inc., San Diego, CA). For comparing means of two treatment groups with equal variances an 
unpaired, two-tailed Student’s t test was used. To compare multiple sets of data a one-way 
ANOVA was used. Log transformation was used to approximate the normal distribution for 
parametric analysis when necessary. A P value of <0.05 was considered as statistically 
significant. Results are presented as mean + S.E.M, where * signifies a P<0.05, ** P<0.01 and 
*** P<0.001. Area under the curve was calculated using the trapezoidal method. Correlation 
was assessed by calculation of the Pearson r co-efficient. A line of best fit was incorporated 
only in the figures where correlation was statistically significant.   
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5.3 Results 
5.3.1 Hepatic FA uptake in adolescent animals 
Considering the evidence of hepatic steatosis and increased fasting FFA in the circulation of 
11 months old PCOS-like animals, we assessed hepatic fatty acid uptake potential in 
adolescent animals. Adolescent prenatally androgenised animals had significantly upregulated 
expression of SLC27A2 and SLC27A5, encoding FATP2 and FATP5 respectively (P<0.05; 
Fig. 5.1 A and B). In addition, adolescent PCOS-like sheep had a significantly elevated 
expression hepatic CAV2 (P<0.05; Fig. 5.1D) and trend for increased FABP4 expression 
(P=0.06; Fig. 5.1 E) however, this did not reach statistical significance.. There was no 
difference in the expression of CAV1 and FABP5 between control and prenatally TP-exposed 

































































































Figure 5.1 Hepatic expression of genes associated with FA uptake in adolescent controls (C) and 
prenatally androgenised (TP) animals, as quantified by qRT-PCR. P value of <0.05 was considered as 
statistically significant. Results are presented as mean + S.E.M, where * signifies a P<0.05. 
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5.3.2 Hepatic de novo lipogenesis in livers of 11 months old animals.  
Next, we investigated a possible role of de novo lipogenesis in hepatic phenotype of adolescent 
PCOS-like sheep. Adolescent prenatally androgenised animals had significantly elevated 
mRNA expression of ACACA, encoding ACC1, and FASN, encoding FAS (P<0.05; Fig. 5.2 
B and C, respectively), and a trend towards increased expression of SREBF1, encoding 






















































Figure 5.2 Hepatic expression of genes involved in de novo lipogenesis in adolescent control (C) and 
prenatally androgenised (TP) animals, as quantified by qRT-PCR. P value of <0.05 was considered as 
statistically significant. Results are presented as mean + S.E.M, where * signifies a P<0.05. 
 
5.3.3 Hepatic fatty acid utilisation and storage in adolescent animals 
Subsequently, we evaluated gene expression associated with fatty acid utilisation and storage. 
There was no difference in the expression of PPARA, regulating FA oxidation, and PPARG, 
promoting lipid storage, between control and PCOS-like animals (Fig. 5.3 A and B, 
respectively). However, there was trend towards decreased expression of PPARGC1A, a 
transcriptional co-activator regulating fatty acid oxidation, mitochondrial biology and energy 


















































Figure 5.3 Hepatic expression of genes associated with FA utilisation and storage in adolescent control 
(C) and prenatally androgenised (TP) animals, as quantified by qRT-PCR. Results are presented as mean 
+ S.E.M. 
Chapter 5 The effect of prenatal androgenisation on hepatic phenotype 
154 
5.3.4 Gluconeogenesis in adolescent PCOS-like animals 
In the view of hyperinsulinemic normoglycaemia in adolescent PCOS-like animals we further 
investigated expression of main molecular components of the hepatic gluconeogenic pathway. 
Adolescent PCOS-like animals had a trend towards decreased expression of MLXIPL, 
encoding ChREBP (P=0.09; Fig. 5.4 A) however, this did not reach statistical significance. 
There was no difference in the expression of FOXO1, as well as PEPCK and G6PC, a 
downstream component of gluconeogenesis between control and prenatally TP-exposed 

































































Figure 5.4 Hepatic expression of genes associated with gluconeogenesis in adolescent control (C) and 
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5.3.5 Hepatic expression of insulin and growth hormone receptors 
Considering the normal expression of genes involved in gluconeogenic pathway we next 
evaluated expression of INSR and GHR, and components of its downstream signalling pathway 
(STAT5A and STAT5B). There was no difference in the expression of INSR, GHR and STAT5A 
between controls and PCOS-like animals (Fig. 4.5 A-C) however, there was a trend towards 
decreased expression of STAT5B in TP-exposed animals (P=0.08; Fig. 4.5 D) but this did not 

































































Figure 5.5 Hepatic expression of insulin and growth hormone receptors, STAT5A and STAT5B in 
adolescent control (C) and prenatally androgenised (TP) animals, as quantified by qRT-PCR. Results 
are presented as mean + S.E.M. 
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5.3.6 Correlation of insulin with selected hepatic gene expression 
In view of importance of insulin in regulation of de novo lipogenesis and gluconeogenesis we 
next examined any potential correlation of insulin levels in blood samples collected after 15 
min of IVGTT test with hepatic expression of INSR, SREBF1 and PEPCK and G6PC. In 
adolescence, there was no correlation between level of insulin with hepatic expression of 
INSR, PEPCK and G6PC (Fig. 5.6A, C and D, respectively) however, there was a significant 
correlation between insulin and hepatic SREBF1 expression (P<0.01; r=0.68; Fig. 5.6 B). 
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Figure 5.6 Correlation of insulin level at 15min of IVGTT with hepatic expression of INSR, SREBF1, 
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5.3.7 Liver lipid content in adult animals 
To determine hepatic lipid content in adult animals, four frozen sections of liver tissue from 
each animal were stained with an ORO histological lipid stain, and analysed using image J. 
This analysis revealed that there was no difference in the amount of hepatic fat between adult 
control and PCOS-like animals (Fig. 5.7 B). Subsequently, we evaluated the determinants of 
liver function. There was no difference in the levels of ALT, AST and Albumin between 
control and PCOS-like animals (Fig. 5.7 C-E). In addition, we assessed the levels of circulating 
total cholesterol, LDL and HDL. Again, there was no difference in level of total cholesterol, 





































































































Figure 5.7 Liver lipid content, plasma liver analytes and cholesterol level in adult animals. A) 
representative Oil red O histological stain for lipids in adult liver sections of control (C) and prenatally 
androgenised (TP) animals; scale bars = 100µm; B) quantification of liver lipid content using Image J; 
C-E) plasma liver analytes; F-H) plasma cholesterol level. Results are presented as mean + S.E.M. 
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5.3.8 Hepatic FA uptake in adult old animals.  
In adulthood, there was a trend towards decreased expression of SLC27A2 (P=0.08; Fig. 5.8 
A), SLC27A5 (P=0.11; Fig. 5.8 B) and FABP4 (P=0.15; Fig. 5.8 E) in PCOS-like animals, but 
this did not reach statistical significance. Conversely, there was a trend for increased 
expression of CAV1 and CAV2 in TP-exposed animals (P=0.14 and P=0.16; Fig. 5.8 C and D, 
respectively). There was no difference in the expression of FABP5 between control and PCOS-



































































































Figure 5.8 Hepatic expression of genes associated with FA uptake in adult controls (C) and prenatally 
androgenised (TP) animals, as quantified by qRT-PCR. Results are presented as mean + S.E.M. 
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5.3.9 Hepatic de novo lipogenesis in adult animals.  
Next, we assessed expression of genes involved in de novo lipogenesis. There was no 
difference in the expression of SREBF, ACACA and FASN between adult control and PCOS-

















































Figure 5.9 Hepatic expression of genes associated with de novo lipogenesis in adult control (C) and 
prenataly androgenised (TP) animals, as quantified by qRTR-PCR. Results are presented as mean + 
S.E.M 
 
5.3.10 Hepatic fatty acid utilisation and storage in adult animals.  
There was no difference in the expression of PPARA and PPARG between control and PCOS-
like animals (Fig. 5.10 A and B; respectively). There was a trend towards increased expression 
of PPARGC1A in prenatally androgenised animals however, this did not reach statistical 

















































Figure 5.10 Hepatic expression of genes associated with fatty acid utilisation and storage in adult control 
(C) and prenatally androgenised (TP) animals, as quantified by qRT-PCR. Results are presented as mean 
+ S.E.M. 
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5.3.11 Gluconeogenesis regulation in adult animals.  
Analysis of the expression of genes involved in hepatic gluconeogenesis revealed that there 
was no difference in the expression of MLXIPL, FOXO1, PEPCK and G6PC between adult 



































































Figure 5.11 Hepatic expression of genes associated with gluconeogenesis in adult control (C) and 
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5.3.12 Hepatic expression of insulin and growth hormone receptors 
In adult PCOS-like animals there was a trend towards decreased expression of INSR (P=0.08; 
Fig. 5.12 A) however, this did not reach statistical significance. There was no difference in the 

































































Figure 5.12 Hepatic expression of insulin and growth hormone receptors, STAT5A and STAT5B in 
adolescent control (C) and prenatally androgenised (TP) animals, as quantified by qRT-PCR. Results 
are presented as mean + S.E.M 
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5.3.13 Correlation of insulin with selected hepatic gene expression 
In adulthood, there was a positive correlation between levels of circulating insulin in blood 
samples collected after 15 min of IVGTT and hepatic INSR expression (P<0.05; r=-0.051; Fig. 
5.13 A) however, there was no correlation between insulin and SREBF1, PEPCK and G6PC 
(Fig. 5.12 B-D). 
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Figure 5.13 Correlation of insulin level at 15min of IVGTT with hepatic expression of INSR, SREBF1, 
PEPCK and G6PC in adult control (C) and prenatally androgenised animals (TP). 
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5.4 Discussion 
Previous research has demonstrated that adolescent PCOS-like sheep had evidence of 
subclinical hepatic steatosis (411). Furthermore, in chapter 3, it was reported that these 
adolescent prenatally androgenised animals had increased circulating fasting FFA, most likely 
due to decreased adipogenesis and perturbed insulin signalling in SAT, but independent of 
body weight and central adiposity. Since, it was established that circulating FFA comprise 
majority of hepatic lipids in NAFLD, we aimed to investigate the potential role of increased 
fasting FFA in hepatic phenotype of adolescent PCOS-like animals. Here, we provide evidence 
that these adolescent PCOS-like sheep had upregulated expression of genes involved in hepatic 
FA uptake and de novo lipogenesis, but normal expression of genes associated with FA 
oxidation, which might elucidate the mechanisms involved in increased lipid accumulation in 
those animals.  
The mRNA expression of SLC27A2 (FATP2) and SLC27A5 (FATP5) was significantly 
upregulated in livers of adolescent PCOS-like animals. Although, there are 6 FATP isoforms 
that have been identified in mammalian cells, FATP2 and FATP5 are utilised as the major 
FATPs in liver (736,737). It was demonstrated that mice with liver specific FATP2 deficiency, 
when fed a high fat diet, had reduced liver TG levels and decreased fasting glucose and insulin 
levels, when compared with control mice (738). Correspondingly, mice with hepatic FATP5 
knockdown had reduced FA uptake and were protected from NAFLD (739). In addition, 
authors found that induced FATP5 deficiency in mice liver can reverse already established 
NAFLD, resulting in significantly improved whole-body glucose homeostasis (739). 
Moreover, human studies shown that hepatic FATP5 mRNA is upregulated in patients with 
steatosis (740), and FATP5 promoter polymorphism is associated with features of the 
metabolic syndrome and steatosis (741) 
Our results also demonstrated that expression of hepatic CAV2, but not CAV1, was 
significantly upregulated in livers of adolescent PCOS-like animals. Caveolins are fatty acid 
and cholesterol binding proteins and main structural components of caveolae, which are 
plasma membrane pits implicated in endocytosis, cholesterol homeostasis and signal 
transduction  (742,743). It was demonstrated that CAV1 and CAV2 have the same tissue 
distribution, as CAV1 usually forms oligomers with CAV2, and are mainly localised to the 
plasma membrane compartment, but also mitochondria, lipid droplets, and liver peroxisomes 
(744). However, whereas much is known about potential role of CAV1 in pathophysiology of 
NAFLD (745,746), reports on the role of CAV2 are scarce (747). Hepatic overexpression of 
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CAV1 or CAV2 increased bile flow (748). In addition, the same study demonstrated that 
overexpression of CAV1, but not CAV2, induced increase in plasma HDL cholesterol levels 
and hepatic free cholesterol content (748). Several mouse models have shown that global 
CAV1 deficiency prevents fat accumulation within hepatocytes, and therefore prevents 
steatosis, however CAV1 overexpression does not appear to cause liver steatosis. Therefore, 
based on the current knowledge we are unable to draw any definite conclusions regarding 
potential role of increased CAV2 in the livers of adolescent PCOS-like animals. 
In addition, our results showed that 11 months old prenatally androgenised sheep had trend for 
upregulated expression of FABP4. Cytoplasmic FABPs actively regulate FA trafficking to 
specific organelles in the cell for lipid oxidation storage as lipid droplets in the cytoplasm 
(749). It was demonstrated that hepatic FABP4 expression is upregulated in patients with 
NAFLD and that levels of FABP4 positively correlate with liver fat content (750,751). 
Overall, these results provided strong evidence that upregulated expression of hepatic FA 
transporters likely contribute to hepatic steatosis in adolescent prenatally androgenised 
animals. Interestingly, we found a positive correlation between levels of fasting FFA with 
expression of FATP2 and FABP4, suggesting that circulating FFA might directly regulate 
expression of those transporters in liver. Indeed, based on experimental data it was proposed 
that FFA can upregulate expression of hepatic transporters when existing ones become 
saturated (752). Consequently, increased FFA in adolescent PCOS-like animals could directly 
upregulate specific hepatic FA transporters in those animals. However, to explore other 
potential mechanisms contributing to increased hepatic lipid content, the expression of genes 
indicated in de novo lipogenesis, a process in which the liver synthesises endogenous FAs 
from glucose, was also investigated. 
Our result demonstrated that ACACA (ACC1) and FASN (FAS) were significantly 
overexpressed, together with a trend for increased expression of SREBF1 (SREBP1C) in 
adolescent PCOS-like animals. In the process of FA synthesis, ACC1 converts acetyl-CoA, an 
essential substrate of fatty acids, to malonyl-CoA. FAS then utilises both acetyl-CoA and 
malonyl-CoA to form palmitic acid (702). SCD1 catalyses the synthesis of monounsaturated 
FAs. Both ACC1 and FAS are highly regulated by the transcriptional factor SREBP1c, which 
could be reflected in the positive correlation in the expression of SREBP1c with ACC1 and 
FAS, as demonstrated in adolescent animals. In turn, expression of SREBF1 is directly 
regulated by insulin (753-755), which again was mirrored in positive correlation between 
levels of insulin after 15 min of IVGTT and hepatic mRNA expression of SREBF1 in 
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adolescent animals. Hepatic expression of ACC1, FAS and SREB1C have been shown to be 
upregulated in patients with NAFLD (740,756,757). FAS catalyses the last step in FA 
biosynthesis therefore, it is considered a main determinant of the maximal hepatic capacity to 
generate de novo fatty acids (757). Furthermore, results from animal studies provide additional 
information about importance of ACC in the pathogenesis of NAFLD. It was demonstrated 
that mice with hepatic ablation of ACC1 accumulated 40% less TG than control mice (758), 
whereas in rats with NAFLD, suppression of ACC1 and ACC2 resulted in decreased hepatic 
lipids content and improved hepatic insulin sensitivity (759). In summary, it is likely that 
hepatic steatosis in adolescent PCOS-like animals might result from combination of elevated 
circulating FFA and subsequent increased transport of FFA into liver as well as 
hyperinsulinemia and amplified de novo lipogenesis in those animals.  
We also assessed the hepatic expression of PPARA and PPARG and found no difference in the 
expression those genes between control and prenatally androgenised animals. PPARA plays a 
central role in fatty acid metabolism by controlling expression of numerous genes involved in 
mitochondrial and peroxisome fatty acid oxidation, therefore, activation of PPARA can 
prevent or at least decrease hepatic lipid content (702). It was demonstrated that mice with 
hepatocyte specific PPARA deletion had impaired fatty acid homeostasis and developed 
NAFLD (760), whereas treatment of mice with spontaneous hepatic steatosis with a PPARA 
agonist, fenofibrate, decreased hepatic lipid content by activating expression of genes involved 
in fatty acid turnover (761). Therefore, comparable expression of PPARA between control and 
PCOS-like animals indicate that increased uptake of FAs and de novo lipogenesis is not 
countered by increased oxidation. Interestingly, PPARA activity and FA oxidation are also 
directly influenced by adiponectin (108). Treatment with recombinant adiponectin of mice 
with induced steatosis has been shown to reduced steatosis and inflammation, due to enhanced 
hepatic FA oxidation and decreased activity of ACC1 and FAS (762). Moreover, it was 
reported that patients with NAFLD have decreased levels of circulating adiponectin, 
independent of BMI and adiposity (763,764), suggesting that adiponectin can be a  potential 
therapeutic agent for NAFLD (765). Thus, decreased level of circulating adiponectin in 
adolescent PCOS-like animals could also contribute to increased hepatic steatosis in those 
animals.  
PPARG, in opposite to PPARA function, promotes lipid storage. It was found that expression 
of PPARG was elevated in a murine model of steatosis (766), and some researchers (750,767), 
but not others (768), reported increased expression of PPARG in NAFLD patients. In addition, 
it was shown that mice with liver specific PPARG knockdown had reduced hepatic TG content 
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(769,770). It was proposed that steatosis promoting the activity of hepatic PPARG is due to 
the upregulation of genes involved in lipogenesis, TG synthesis and lipid droplet formation 
(771). However, in contrast to these studies presenting potential adverse effects of PPARG on 
NAFLD, adenovirus-mediated overexpression of PPARG in the liver was shown to decrease 
hepatic steatosis, inflammation and fibrosis (772). Moreover, treatment with PPARG agonists 
have been shown to reduce liver steatosis in a mouse model of induced NAFLD (773) and 
humans with steatosis (774). PPARG could modulate NAFLD through several mechanisms. 
First, numerous studies documented that PPARG agonists improve insulin sensitivity in 
peripheral tissues, leading to enhanced uptake of FFA in skeletal muscle and adipose tissue, 
thus decreased FFA flux to the liver. In addition, since PPARG stimulates adipogenesis, it 
increases capacity of adipose tissue to buffer FFA in the circulation, thus again shunting them 
from liver. Finally, treatment with PPARG agonists increase circulating adiponectin, which in 
turn, increase insulin sensitivity, decrease hepatic steatosis and inflammation (775). 
We also found a trend towards decreased hepatic expression of PPARGC1A (PGC1α) in 
adolescent PCOS-like animals. In liver PGC1α regulates mitochondrial biogenesis, oxidative 
metabolism, and a complex program of metabolic changes that occur during the transition 
from fasted to fed state, including gluconeogenesis and fatty acid oxidation (776). Moreover, 
it was reported that activity of PGC1α was decreased in rodent model of steatosis, which was 
further paralleled by reduced mitochondrial biogenesis (777). Similarly, it was found that 
insulin resistant patients with NAFLD had decreased mitochondrial DNA content and higher 
PPARGC1A promoter methylation levels which was further associated with decreased 
PPARGC1A mRNA levels showing that DNA methylation of the promoter silenced gene 
expression (778). Furthermore, the authors demonstrated that the abundance of liver 
PPARGC1A mRNA inversely correlated with fasting plasma insulin levels and homeostasis 
model assessment of insulin resistance (HOMA-IR), indicating that peripheral insulin 
resistance and the transcriptional activity of PPARGC1A in the liver might be interrelated 
(778). Likewise, we also found a negative correlation between fasting insulin and hepatic 
PPARGC1A expression, suggesting that high insulin levels in PCOS-like animals suppress 
expression of PPARGC1A in livers of those animals. Interestingly, PGC1α has also been 
indicated in regulating hepatic insulin sensitivity and gluconeogenesis (779). Recently, it was 
found that women with PCOS have increased PPARGC1A promoter methylation and 
decreased mitochondrial content in leukocytes (780).  Furthermore, a positive correlation was 
found between the PPARGC1A promoter methylation ratio and the FAI in women with PCOS, 
suggesting that PPARGC1A promoter hypermethylation can be induced by androgens (780). 
Therefore, it is likely that reduced hepatic PPARGC1A in adolescent prenatally androgenised 
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animals could result from early epigenetic programming. However, PGC1α expression was 
upregulated in a mouse models of diabetes where it promoted constitutive activation of 
gluconeogenesis (779). In addition, it was demonstrated that PGC1α expression, like 
gluconeogenesis, is suppressed by insulin and the action of the INSR (779) and that PGC1α 
directly stimulate FOXO1, which in turn regulates gluconeogenesis (781). Mice with hepatic 
deletion of PPARGC1A had an increased TG content and diminished expression of genes 
involved in β-oxidation in their livers, but also reduced fasting glucose levels and decreased 
expression of PEPCK and G6PC (782). However, PCOS-like animals had normal fasting 
glucose levels and comparable hepatic expression of PEPCK and G6PC despite 
downregulated expression of PPARGC1A. Moreover, our result showed that these animals had 
normal expression of other hepatic genes controlling gluconeogenesis, MLXIPL (ChREBP) 
and FOXO1, as well as INSR. However, considering increased circulating insulin in adolescent 
PCOS-like animals, both fasting and during glucose load, the predicted expression of genes 
associated with gluconeogenesis should be lower than in control animals. In addition, there 
was no correlation between levels of insulin and hepatic expression of PEPCK and G6PC. 
Therefore, these results might indicate potentially perturbed hepatic insulin signalling in 
prenatally androgenised animals. Interestingly, comparable mRNA levels of MLXIPL support 
similar levels of circulating glucose after 15 minutes of glucose load in control and PCOS-like 
sheep, as ChREBP is directly stimulated by glucose (783). However, since ChREBP regulates 
gluconeogenesis and lipogenesis (784), it seems that increased de novo lipogenesis in PCOS-
like animals is independent of glucose levels. 
Finally, we assessed growth hormone signalling. There was no difference in the expression of 
GHR and STAT5A between control and PCOS-like animals however there was a trend towards 
reduced expression of hepatic STAT5B in prenatally androgenised animals. Growth hormone 
(GH) plays an important role in regulating hepatic biology (785). GH action is facilitated via 
the GH receptor (GHR) and downstream hepatic GH signalling is mediated by STAT5A and 
STAT5B, which in turn control hepatic lipid metabolism. It was demonstrated that diminished 
GH-STAT5 signalling predisposes mice and humans to early development of hepatic steatosis 
(786-790). Further, it was found that reduced hepatic STAT5 signalling was paralleled by 
increased expression of SREBP1c and fatty acid transporters in the liver (790). GH also has 
significant roles in regulating hepatic glucose homeostasis. Increased GH is linked with 
impaired glucose tolerance, insulin resistance and compensatory hyperinsulinemia, whereas 
GH deficiency is associated with increased insulin sensitivity, decreased fasting glucose 
levels, decreased insulin secretion, and lowered hepatic glucose production (791). However, 
hepatic STAT5 deficient mice have impaired insulin signalling and are affected by 
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hyperinsulinemia and insulin resistance (791). Interestingly, GH, through different patterns of 
pulsatility, with more frequent pituitary GH secretion in females than in males, and therefore 
more continuous pattern of plasma GH in females, has an important role in regulating sex-
dependent hepatic gene expression (792,793). Hence, STAT5B, a downstream effector of GH 
signalling, is considered a key regulator of sexually dimorphic gene expression in the liver 
(794). Females, due to the persistence of plasma GH stimulation display partial desensitisation 
and consequently have decreased expression of STAT5B as compared to males (793,794). 
Since, decreased STAT5B is associated with NAFLD, and males present more frequently with 
hepatic steatosis than females, it was proposed that “feminisation” of the male liver leads to 
accumulation of hepatic triglycerides (793). It was demonstrated that castrated mice had 
reversed gene expression pattern, comparable to intact male STAT5B-null mice, which could 
mostly be restored by treatment with DHT (793). Furthermore, female mice treated with DHT 
presented with that the male-like expression pattern of the STAT5B, however, ovariectomy did 
not have significant impact on gene expression pattern, nor does treatment of ovariectomised 
females with estradiol, suggesting that STAT5B might be more of an androgen-driven than an 
estrogen-driven sexually dimorphic gene (793). Considering, a possibly reduced expression of 
STAT5B in adolescent PCOS-like sheep, it could be speculated that these females, due to 
prenatal androgen exposure, are born with somewhat male-like liver gene expression pattern, 
which is being altered - feminised during puberty, leading to decreased STAT5B expression 
and hepatic steatosis. Although, we did not investigate GH pulsatility in prenatally 
androgenised sheep, studies on androgenised mice revealed that early androgen exposure in 
females reprograms partially GHRH-GH system and defeminises hepatic-steroid-metabolising 
enzymes (795).  
Interestingly, adult PCOS-like sheep had comparable levels of hepatic fat content with control 
animals, similar levels of hepatic analytes and cholesterol levels in blood. Further, there was 
no statistically significant difference in the expression of hepatic genes involved in fatty acid 
uptake, de novo lipogenesis, fatty acid utilisation and gluconeogenesis, despite increased body 
weight, elevated FFA and hyperinsulinemia. Adult PCOS-like sheep did however display a 
trend towards increased expression of PPARGC1A and decreased expression of hepatic INSR 
which further negatively correlated with insulin levels. Increased expression of PPARGC1A 
in adult PCOS-like animals could indicate induced hepatic fatty acid oxidation and 
mitochondrial biogenesis (796), which in turn, could contribute to normalised, as compared 
with control animals, levels of liver fat content in those animals. Further, it could be speculated 
that considering the hyperinsulinemia in PCOS-like animals, decreased hepatic INSR mRNA 
expression, likely due to chronically elevated insulin levels, might be beneficial and serve as 
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a limiting factor preventing hyperinsulinemic drive for increased de novo lipogenesis. In 
addition, changes in hepatic fat content in PCOS-like animals could be attributed to 
hypertrophic expansion of SAT and normalised leptin levels, as described in Chapter 4, which 
could increase adipose tissue capacity for FFA storage, hence redirecting FFA from liver to 
adipose tissue. This observation is reinforced by normal expression of hepatic fatty acid 
transporters, despite increased circulating FFA concentrations in prenatally androgenised 
animals. Moreover, this hypothesis is further supported by findings from studies on partial 
lipodystrophy, in humans and experimental animal models, demonstrating strong association 
between lipodystrophy with NAFLD, presumably due to decreased adipose tissue capacity 
(797-800). In addition, treatment of lipodystrophic patients with leptin or TZDs, can reverse 
or at least decrease hepatic steatosis, due to reduction in lipoatrophy and lipotoxicity, improved 
insulin sensitivity (95,800,801). Interestingly, a very similar metabolic and hepatic phenotype 
to adolescent PCOS-like sheep was reported in lipodystrophic mice (797), and prenatally 
androgenised pubertal female rats (802). Although, we are unable to verify if the normalised 
level of hepatic fat in PCOS-like animals is due to increased hepatic fat accumulation in control 
animals or due to hepatic changes in PCOS-like animals, it seems that combination of 
relatively increased fatty acid utilisation, decreased fatty acid uptake and de novo lipogenesis, 
as compared with adolescent PCOS-like animals, might underlie that change. 
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In summary, adolescent PCOS-like animals display a more perturbed hepatic phenotype than 
adult PCOS-like sheep. Adolescent prenatally androgenised animals have increased hepatic 
steatosis and display a mixed pattern of hepatic insulin sensitivity and resistance. Considering 
the presence of hyperinsulinemia in those animals, insulin resistance is demonstrated by 
disproportionally normal gluconeogenesis whereas sensitivity by upregulated de novo 
lipogenesis. Furthermore, adolescent PCOS-like animals had increased hepatic uptake of fatty 
acids, likely due to decreased buffering capacity of adipose tissue. Adult prenatally 
androgenised sheep have normalised hepatic fat content, which is paralleled by normal levels 
of FFA uptake, likely due to SAT hypertrophy. In addition, paradoxically, decreased 
expression of INSR in adult PCOS-like animal might protect these animals from increased de 
novo lipogenesis, as observed in adolescent animals. However, it can be speculated that once 
the capacity of adipose tissue is saturated fatty acids might be shunt back to the liver, resulting 
in NAFLD once again.
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6.1 Introduction 
Fibroblast growth factor 21 (FGF21) and irisin are recently identified novel metabolic 
regulators with ability to regulate glucose metabolism, insulin sensitivity, lipid homeostasis 
and energy balance. As described in previous chapters, adolescent and adult prenatally 
androgenised sheep display various metabolic perturbations, including obesity, decreased PPT 
and reduced thermogenic potential of BAT/beige adipocytes, hyperinsulinemia, increased 
circulating FFA and fatty liver, decreased adipogenesis and SAT hypertrophy. Therefore, this 
chapter aimed to assess potential role of FGF21 and irisin in metabolic phenotype of 
adolescent and adult PCOS-like ewes.  
Mammalian FGF21 belongs to the FGF superfamily comprising of 22 structurally related 
factors with diverse biological functions, including cell growth and differentiation, embryonic 
development, and metabolism (803). However, abnormal FGF signalling has been also 
indicated in pathological conditions, such as cancer and metabolic disease (804,805). FGFs 
propagate their signal through binding to four different plasma membrane tyrosine kinase 
receptors (FGFR1-4) (805). FGFs are further divided into 7 subgroups, with FGF21 belonging 
to hormonal subfamily, together with FGF19 and FGF23 (803). These hormonal FGFs are 
unique, as they require an additional co-receptor for signalling, klotho for FGF23 and β-klotho 
(KLB) for FGF19 and FGF21 (803,806). FGF21 is conserved in mammals, with only one 
amino acid difference between human and gorillas and 80% homology between human and 
rodents (807). The physiology of FGF21 is complex. It is synthesised in multiple organs, 
although mainly secreted from liver, it can be also expressed in pancreas, muscle and adipose 
tissue (807,808). FGF21 also act on multiple target tissue, such as hypothalamus, heart, 
pancreas and liver, in endocrine, paracrine and autocrine fashions. Adipose tissue however, is 
the primary target of FGF21 action, in which it preferentially binds to FGFR1 linked to KLB 
co-receptors (809). It has been shown that both WAT and BAT express high levels of KLB 
co-receptors and are sensitive to exogenous FGF21 stimulation (810). 
The first reports on FGF21 action documented that it stimulates glucose uptake, in insulin 
independent manner, in mouse and human adipocytes in vitro (811). Furthermore, it has been 
shown that transgenic animals overexpressing hepatic FGF21 have improved insulin 
sensitivity, reduced TG levels and are resistant to diet-induced obesity whereas mice lacking 
FGF21 have increased body weight, hypertrophic adipocytes with decreased lipolysis rates, 
and accumulated hepatic TG (812). What is more, FGF21 infusions were shown to reduce 
serum glucose and lipids, and improve insulin sensitivity in genetic murine models of obesity, 
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Zucker diabetic fatty rats and diabetic rhesus monkeys (813,814). Interestingly, it was also 
reported that during carbohydrate intake FGF21 is an inducible factor, which functions in a 
feed-forward loop in adipose tissue to regulate the activity of PPARG, a master transcriptional 
regulator of adipogenesis (812). FGF21 deficient mice have defects in PPARG signalling and 
decreased body fat (812). These data suggest that FGF21 might act as regulator of the adipose 
tissue storage capacity. FGF21 treatment was also shown to increase serum adiponectin levels, 
a potent insulin sensitising adipokine, while adiponectin knockout mice were refractory to 
therapeutic benefits of FGF21 (815,816). In addition, it was reported that FGF21 treatment of 
obese mice resulted in weight loss through increased energy expenditure and fat utilisation 
(817). In line with these findings further reports demonstrated that FGF21 regulates also 
adaptive thermogenesis through upregulating UCP1 and PGC1α as well as browning WAT, 
while FGF21-knockout mice have impaired response to cold (818). Interestingly, mild cold 
exposure has been shown to also induce circulating FGF21 levels in humans, which further 
correlates with increased energy exposure and lipolysis (819). Paradoxically, however, it has 
been shown, in both mice and humans, that obesity also results in increased serum FGF21 
levels suggesting that obesity is an FGF21-resistant state (820,821). Indeed, there are reports 
showing a reduced expression of KLB in adipose tissue of obese mice and humans (822,823). 
Interestingly, increased FGF21 concentrations were also documented in various pathological 
conditions such as anorexia nervosa (824), metabolic syndrome (825), mitochondrial diseases 
(826), autophagy deficiency (827), and nephropathy (828,829). Not much is known about the 
regulation of FGF21 expression. It has been demonstrated that hepatic FGF21 level is induced 
directly in response to fasting as well as a protein insufficiency, by the corresponding actions 
of PPARA and activating transcription factor 4 (ATF4) (830,831). In mice, fasting for 24 
hours, increased hepatic and plasma FGF21 levels however, in humans increased circulating 
FGF21 levels were only observed after a prolonged, seven day, fast (832,833). Interestingly, 
FGF21 deficient mice, in response to a ketogenic diet, gain weight and develop hepatosteatosis 
(834). However, hepatic FGF21 is upregulated not only by nutrient deficiency but also by 
nutrient excess. In humans, five days of high-fat feeding resulted in significantly increase in 
plasma FGF21 concentrations (835). It has been shown that in states of calorie excess, FGF21 
is upregulated through carbohydrate response element binding protein (836,837). Therefore, 
it has been suggested recently that FGF21 is a stress hormone, protecting tissue from the 
oxidative environment seen during various pathological conditions (838,839) .  
Irisin is a novel hormone-like polypeptide, proposed to mediate the beneficial effects of 
exercise on metabolism, recently identified in both mice and human. Irisin is encoded by the 
FNDC5 gene, cleaved and secreted part of the transmembrane protein FNDC5 (fibronectin 
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type III domain containing 5) (840). It was firstly discovered by the research group of 
Spiegelman from Harvard University in 2012 and described as muscle-derived factor 
(myokine) induced by exercise downstream of PGC1α, with the potential to stimulate 
browning of the white adipose tissue and thermogenesis, both in vitro and in vivo (840). The 
paper from this group also reported that mildly increased blood levels of irisin, through viral-
delivery, in a high fat diet induced mouse model of obesity resulted in increased energy 
expenditure, caused small, but statistically significant weight loss and improved glucose 
homeostasis (840). Interestingly, as the secreted portion of FNDC5 is highly conserved among 
species it was speculated that irisin evolved as a muscle secreted hormone that was stimulated 
as result of muscle contraction during shivering, which in turn activated adipose thermogenesis 
as a defence against hypothermia  (840). Indeed, Lee et al. found that induction of irisin 
secretion was proportional to shivering intensity, in magnitude similar to exercise-stimulated 
secretion (841). Further reports supported the original discovery showing that irisin levels are 
upregulated in response to exercise, enhancing browning of WAT and energy expenditure, and 
mediating some of the beneficial effects of exercise, in both rodents and humans (841-846). 
What is more, it was found that diabetic patients have decreased levels of circulating irisin, 
and that the expression of FNDC5 in both skeletal muscle and white adipose tissue is reduced 
and negatively correlated with obesity, insulin resistance and liver fat content (847-852). This 
evidence made irisin a potential new target for the treatment of metabolic disease. However, 
some researchers have raised doubts regarding the physiological function of irisin in humans, 
reporting no association between levels of irisin and exercise training, and no effect on the 
browning of WAT (853-856). In addition, controversy has arisen regarding the molecular 
weight of the soluble portion of irisin, mechanisms of its secretion, and lack of identified 
receptor (857).  Further, a positive correlation of circulating irisin with BMI, insulin resistance 
(843,848,858) and metabolic syndrome (859), was also reported. Huh et al. noted that weight-
loss was linked to diminished levels of circulating irisin and that there was a positive 
correlation between muscle mass and circulating irisin concentrations (843). These data 
suggest that the positive association of irisin with BMI might be partially explained by a 
decrease in muscle mass. Although the first reports documented the expression of irisin in 
skeletal muscle only, further investigations reported its expression, but to a lesser extent, in 
adipose tissue, liver, brain, bone, pancreas, kidney and ovary (850,860). Several studies 
reported a positive association of circulating irisin with fat mass in human (850,861,862). 
Interestingly, some researchers postulated that irisin might also be an adipokine, regulated by 
exercise and nutritional status (863). Therefore, a positive correlation between BMI and irisin 
could be also attributed to both muscle and adipose tissue mass and their differential 
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contributions to circulating irisin levels in different physiological and pathological states 
(857). Alternatively, increased irisin levels in obesity might be a compensatory mechanism 
trying to counteract metabolic disturbances associated with obesity by increasing browning of 
WAT and energy expenditure.  
In view of metabolic perturbations present in adolescent and adult prenatally androgenised 
sheep, which were described in previous chapters of this thesis, this chapter aimed to: 
1. Investigate the potential role of FGF21 in adolescent and adult phenotype of PCOS-
like sheep 
2. Determine the possible involvement of irisin into the metabolic pathophysiology of 
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6.2 Methods 
6.2.1 Experimental animals 
The ovine model, the animals used, their husbandry and treatments have been described 
previously (section 2.2). The female animals assessed in this chapter are detailed in Table 6.1. 




Fetal day 70 C=3, TP=6 
Maternal Injection 
D62-collection 
Fetal day 90 C= 6, TP=6 
Maternal Injection 
D62-102 












Ewes 30 months old C=11, TP=4 
Table 6.1 Treatment regime, age, and corresponding sample numbers of experimental animals discussed 
in this chapter. 
 
6.2.2 Measuring gene expression using qRT-PCR 
Extraction of RNA from fetal and postnatal adipose tissue was performed using the 
combination of TRI reagent and Qiagen RNeasy Mini Kit (Qiagen Ltd., West Sussex, UK), as 
described in section 2.8.1. Extraction of RNA from liver was performed using Qiagen RNeasy 
Mini Kit (Qiagen Ltd., West Sussex, UK), and from skeletal muscles using Qiagen RNeasy 
Fibrous Tissue Mini Kit (Qiagen Ltd., West Sussex, UK), as described in section 2.8.1. 
Protocols for cDNA synthesis and qRT-PCR are described in section 2.8.3 and 2.8.4, 
respectively. Forward and reverse primers were designed and validated as stated in section 
2.8.6 and primer sequences analysed in this chapter are listed in Table 6.2. 
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Gene Forward Sequence Reverse Sequence 
Product 
Size (bp) 
FGF21 ATGATGCCCAGGAGACAGAG TCAAAGTGCAGCGATCCATA 196 
KLB CAGAGGATACCACAGCCATCT CCAGGCTGTGTAACCAAACA 101 
FGFR1 TCAGAGACCCACCTTCAAGC GAAGCTGGGGGAGTATTGGT 115 
FGFR2 GCTGAAAAACGGGAAGGAAT GTCAGACGGGACCACACTTT 103 
FGFR3 ACCCTGGGCAAGCCTCTT ATCTCCATCTCGGACACCAG 167 
FGFR4 GGCTGAAGCACATCGTCAT CCTCCACCTCTGAGCTATTGA 102 
ATF4 TCTCCTGCGACAAGGCTAAG CTCCACCATCCAATCTGTCC 116 
ATF6 ACTTGGATTTGATGCCTTGG CTTGAGGAGGCTGGTGAAAG 109 
XBP1 AGACTGCCAGAGACCGAAAG GGCCATGAGTTTTCTCTCGT 123 
SLC2A1 TGCTGAGCGTCATCTTCATC GGCTCTCCTCCTTCATCTCC 180 
EIF2AK3 TTCAATGCTTGGTTGGAAGC CCATGGGACTAGGAGAGCTG 109 
ERN1 CAACAACCTGCCCAAACAC CGGAGAAACCGTGGTAGGT 121 
FNDC5 GTAAGCTGGGACGTCTTGGA GTGGTGTTCACCTCCTGGAT 104 
Table 6.2 Forward and reverse primer sequences and product size for genes analysed in the postnatal 
liver tissue using SYBR Green qRT-PCR. 
 
6.2.3 FGF21 ELISA 
Plasma FGF21 was measured using the Abcam Human FGF21 ELISA kit (ab125966; Abcam 
Cambridge, UK) as per the manufacturer’s instructions. Immunoassay absorbance was 
measured at 450nm using a ThermoMax Microplate Reader (Molecular Devices, CA, USA) 
and the concentrations were calculated from four-parameter logistic curve. All samples were 
assayed in duplicate. The assay sensitivity was 0.03 ng/ml intra and inter-assay CVs were 
4.7% and 7.2%, respectively.  
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6.2.4 Irisin ELISA 
Plasma Irisin was measured using the Recombinant Irisin (Human, Mouse, Rat, Canine) 
ELISA kit (EK-067-29; Phoenix Pharmaceuticals, Karlsruhe, Germany) as per the 
manufacturer’s instructions. Immunoassay absorbance was measured at 450nm using a 
ThermoMax Microplate Reader (Molecular Devices, CA, USA) and the concentrations were 
calculated from four-parameter logistic curve. All samples were assayed in duplicate. The 
assay sensitivity was 0.1 ng/ml intra and inter-assay CVs were <10% and <15%, respectively.  
6.2.5 Statistical analysis 
Statistical analysis was performed with GraphPad Prism version 6.0 (GraphPad Sowftware, 
Inc., San Diego, CA). For comparing means of two treatment groups with equal variances an 
unpaired, two-tailed Student’s t test was used. To compare multiple sets of data a one-way 
ANOVA was used. Log transformation was used to approximate the normal distribution for 
parametric analysis when necessary. A P value of <0.05 was considered as statistically 
significant. Results are presented as mean + S.E.M, where * signifies a P<0.05, ** P<0.01 and 
*** P<0.001. AUC was calculated using the trapezoidal method. Correlation was assessed by 
calculation of the Pearson r co-efficient. A line of best fit was incorporated only in the figures 
where correlation was statistically significant.   
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6.3 Results 
6.3.1 FGF21 expression in adolescents and adult PCOS-like sheep 
To determine whether metabolic disturbances present in prenatally androgenised sheep might 
be associated with altered levels of FGF21, circulating and hepatic expression of FGF21 were 
assessed in serum samples from adolescent and adult animals. In addition, we had serum 
samples from the adult cohort animals, which were taken from those animals at 22 months of 
age. Adolescent and young adult (11 and 22 months of age, respectively), but not adult (30 
months of age) PCOS-like sheep had decreased levels of circulating FGF21 (P<0.05; Fig. 6.1 
A). Correspondingly, there was decreased hepatic expression of FGF21 in adolescent (11M), 
but not adult (30M) prenatally androgenised animals (P<0.05; Fig. 6.1 B). Therefore, to 
establish the onset of the altered expression of hepatic FGF21, gene expression was further 
evaluated in fetal (D70, F90 and D112 of gestation) and juvenile (11 weeks of age) livers.  
Hepatic expression of FGF21 was very low during all stages of fetal life (D70, D90 and D112) 
and increased sharply (~20 fold) after birth (11W), however there was no difference in the 
expression of FGF21 between control and PCOS-like sheep during early-life (Fig. 6.1 C). 
Although both hepatic and circulating levels of FGF21 were decreased in adolescence, there 
was no direct correlation between hepatic expression and levels of circulating FGF21, in both 
11 months old and adult animals (Fig. 6.1 E-F), suggesting an additional source of circulating 
FGF21. Therefore, the expression of FGF21 in SAT, VAT and muscle tissue were 
investigated. The expression levels in both adipose tissue depots were undetectable, whereas 
the expression of FGF21 in muscle tissue, although still very low, was elevated in adult PCOS-
like sheep, with no difference during adolescence (P<0.05; Fig. 6.1 D). However, there was 
no correlation between muscle FGF21 and circulating levels of FGF21 in both adolescent and 
adult animals (Fig. 6.1 G-H).  
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Figure 6.1 FGF21 levels in control (C) and prenatally androgenised (TP) animals. A) serum FGF21 
levels in adolescent and adult animals; B) Hepatic FGF21 expression in adolescent and adult sheep; C) 
Hepatic expression of FGF21 in fetal and juvenile animals; D) Muscle FGF21 expression in adolescent 
and adult animals; E-F) Correlation of hepatic FGF21 expression with circulating FGF21 in adolescent 
and adult animals; G-H) Correlation of muscle FGF21 expression with circulating FGF21 in adolescent 
and adult animals. P value of <0.05 was considered as statistically significant. Results are presented as 
mean + S.E.M, where * signifies a P<0.05. 
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6.3.2 Potential regulatory mechanisms underlying altered levels of 
FGF21  
We next investigated the potential regulatory mechanisms underlying decreased levels of 
FGF21 in adolescent PCOS-like sheep. The nuclear fatty acid receptor, PPARA, is suggested 
to be a main regulator of hepatic FGF21 expression during fasting, however, there was no 
difference at the expression of PPARA between control and prenatally TP-exposed animals in 
adolescent (chapter 5, Fig. 5.3 A) and adult animals (chapter 5, Fig. 5.10 A). Furthermore, 
there was no correlation between expression of hepatic FGF21 and PPARA at 11M (Fig. 6.2 
A) and at 30M of age (Fig. 6.2 B), suggesting other regulatory mechanisms. PGC-1α was also 
showed as a potential regulator of FGF21 action therefore the hepatic expression of 
PPARGC1A was also investigated. There was a trend towards decreased hepatic PPARGC1A 
expression (chapter 5, Fig. 5.3 C) and positive correlation between hepatic PPARGC1A and 
FGF21 expression (P<0.001; r=0.72; Fig. 6.2 C) in adolescent PCOS-like sheep. At 30 months 
of age there was a trend towards increased expression of PPARGC1A in prenatally 
androgenised sheep (chapter 5; Fig. 5.10 C) however, there was no correlation between hepatic 
expression of PPARGC1A and FGF21 (Fig. 6.2 D). 
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Figure 6.2 Correlation of hepatic FGF21 expression A-B) with hepatic PPARA expression and C-D) 
hepatic PPARGC1A expression in adolescent and adult control and prenatally androgenised animals. 
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6.3.3 Autocrine regulation of FGF21 expression 
FGF21 has been also shown to act directly on the liver and expression of hepatic fibroblast 
growth factor receptor isoforms and β-klotho coreceptor has been postulated to be the 
regulatory factor for FGF21 signalling within this tissue. Therefore, hepatic expression of FGF 
receptors and β-klotho coreceptor in adolescent and adult sheep liver was determined. There 
was no difference in the expression of hepatic KLB, FGFR2, FGFR3 and FGFR4 in adolescent 
animals (Fig. 6.3 A, E, G and I, respectively). There was a trend towards decreased hepatic 
expression of FGFR1 in those animals (P=0.059; Fig. 6.3 C) however, this did not reach 
statistical significance. In adulthood, there was no difference in the hepatic expression of KLB, 
FGFR1, FGFR2, FGFR3 and FGFR4 (Fig. 6.3 B, D, F, H and J, respectively). 
 













































































































































































Figure 6.3 Hepatic expression of KLB and FGF receptors in adolescent and adult control (C) and 
prenatally androgenised (TP) animals, as quantified by qRT-PCR. Results are presented as mean + 
S.E.M. 
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6.3.4 FGF21 and endoplasmic reticulum stress 
FGF21 has been suggested to also act a stress-responsive hormone, and the FGF21 gene 
promoter has been shown to have specific response elements that are stimulated by ATF4.   
Therefore, the expression of selected endoplasmic reticulum stress markers, ATF4, the 
activating transcription factor 6 (ATF6) and the X-box-binding protein 1 (XBP1), were 
investigated in livers of adolescent and adult animals. There was no difference in the 
expression of ATF4, ATF6 and XBP1 in adolescent (Fig. 6.4 A, C and E, respectively) and 





































































































Figure 6.4 Hepatic expression of endoplasmic reticulum stress markers in adolescent and adult control 
(C) ad prenatally androgenised (TP) animals, as quantified by qRT-PCR. Results are presented as mean 
+ S.E.M. 
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6.3.5 Association between FGF21 and metabolic parameters 
FGF21 is known as a metabolic regulator, therefore we have investigated the relationship 
between FGF21 and selected metabolic parameters at 11 and 30 months of age. In adolescence, 
there was a positive correlation between serum leptin levels with circulating FGF21 (P<0.05; 
r=0.56; Fig. 6.5 A) and hepatic expression of FGF21 (P<0.05; r=0.64; Fig. 6.5 B). 
Furthermore, circulating levels of FGF21 correlated positively with the volume of omental fat 
(P<0.01; r=0.68; Fig. 6.5 C), and negatively with levels of circulating FFA (P<0.05; r= -0.59; 
Fig. 6.5 D). However, there was no correlation between FGF21 and levels of fasting insulin 
or adiponectin (Fig. 5.6 E and F, respectively). 
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Figure 6.5 Correlation of FGF21 with metabolic parameters in adolescent animals in control and 
prenatally androgenised animals. 
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In adult animals, there was a week positive relationship between serum leptin levels and 
circulating FGF21 although this did not reach statistical significance (P=0.059; r=0.56; Fig. 
6.6 A) however, there was no association with hepatic expression of FGF21 with leptin at 30 
months of age (Fig. 6.6 B). Circulating FGF21 levels correlated negatively with volume of 
omental fat (P<0.05; r=-0.61; Fig. 6.6 C) but there was no relationship between FGF21 and 
serum levels of FFA, fasting insulin and adiponectin at 30M (Fig. 6.6 D, E and F, respectively). 
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Figure 6.6 Correlation of FGF21 with metabolic parameters in adult animals in control and prenatally 
androgenised animals. 
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6.3.6 FGF21 signalling in adipose tissue 
We next investigated FGF21 signalling in adipose tissue in adolescent and adult animals. 
Expression of KLB was significantly downregulated in SAT of 11 months old PCOS-like 
sheep (P<0.05; Fig. 6.7 A), whereas expression levels of FGFR1 in SAT as well as KLB and 
FGFR1 in VAT at 11months did not differ between control and prenatally TP-exposed animals 
(Fig. 6.7 C, E and H, respectively). In adult 30 months old animals, there were no difference 
in the expression of KLB and FGFR1 in SAT (Fig. 6.7 B and D) however, in VAT both KLB 

















































































































































Figure 6.7 FGF21 signalling in subcutaneous (SAT) and visceral adipose tissue (VAT) in adolescent 
and adult control (C) and prenatally androgenised (TP) animals, as quantified by qRT-PCR. P value of 
<0.05 was considered as statistically significant. Results are presented as mean + S.E.M, where * 
signifies P<0.05. 
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6.3.7 Downstream FGF signalling in adipose tissue 
In adipose tissue FGF21 regulates the activity of PPARG, the master regulator of adipogenesis, 
and adiponectin is a downstream effector of FGF21 signalling. We have previously shown that 
both PPARG and ADIPOQ are significantly downregulated in SAT of adolescent PCOS-like 
sheep (chapter 3, Fig. 3.2 A and F, respectively). Subsequently the correlation between 
expression of KLB, PPARG and ADIPOQ in SAT and VAT was investigated. There was a 
strong positive correlation between expression of KLB and PPARG in SAT at 11M (P<0.0001; 
r=0.94; Fig. 6.8 A) and at 30M (P<0.0001; r=0.85; Fig. 6.8 C). In addition, there was a positive 
association between expression of KLB and PPARG in VAT at 11M (P<0.0001; r=0.90; Fig. 
6.8 E) and at 30M (P<0.001; r=0.73; Fig. 6.8 G). Likewise, the expression of ADIPOQ was 
also strongly correlated with KLB expression at 11M in SAT (P<0.001; r=0.79; Fig. 6.8 B) 
and in VAT (P<0.01; r=0.7; Fig. 6.8 F). Similarly, at 30M there was a strong correlation of 
between KLB and ADIPOQ in SAT (P<0.001; r=0.77; Fig. 6.8 D) and in VAT (P<0.0001; 
r=0.92; Fig. 6.8 H). 
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Figure 6.8 Correlation of KLB expression with PPARG and ADIPOQ in subcutaneous and visceral 
adipose tissue in adolescent and adult control and prenatally androgenised animals. 
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To further investigate FGF21 action in adipose tissue, levels of SLC2A1, encoding GLUT1 
was assessed through qRT-PCR. FGF21 has been shown to induce glucose uptake in 
adipocytes through activation and up-regulation of the glucose transporter GLUT1. However, 
our result showed that there were no differences in the expression of SLC2A1 in SAT and VAT 
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Figure 6.9 Expression of SLC2A1 in subcutaneous and visceral adipose tissue of adolescent and adult 
control (C) and prenatally androgenised (TP) animals, as quantified by qRT-PCR. Results are presented 
as mean + S.E.M. 
6.3.8 FGF21 signalling in muscle tissue 
We next investigated FGF21 signalling in skeletal muscles. At 11 months of age there was a 
trend towards a decreased expression of KLB (P=0.79; Fig. 6.10 A) and FGFR1 (P=0.63; Fig. 
6.10 B) in skeletal muscles of PCOS-like sheep, however this did not reach statistical 
significance. Nevertheless, there was decreased expression of PPARG in adolescent TP-
exposed sheep (P<0.05; Fig. 6.10 C), and levels of PPARG positively correlated with levels 
of KLB expression (P<0.05; r=0.57; Fig. 6.10 D). In adult animals, there was upregulated 
expression of FGFR1 in TP-exposed animals (P<0.05; Fig. 6.10 F) however, there was no 
difference in the expression of KLB (Fig. 6.10 E). There was a trend towards decreased 
expression of PPARG, however this did not reach statistical significance (P=0.075; Fig. 6.10 
G) and there was no association between levels of KLB and PPARG (Fig. 6.10 H). 







































































































































Figure 6.10 Expression of KLB, FGFR1 and PPARG in skeletal muscle of adolescent (A-C) and adult 
(E-G) control (C) and prenatally androgenised (TP) animals, as quantified by qRT-PCR. Correlation of 
PPARG with KLB expression in skeletal muscle in aolescent (D) and adult (H) animals. P value of <0.05 
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6.3.9 Insulin and adiponectin signalling in muscle tissue 
Subsequently we have assessed insulin and adiponectin signalling in skeletal muscles. There 
was no difference in the expression of INSR, IRS1 and IRS2 in skeletal muscles of 11 months 
old sheep (Fig. 6.11 A, C and E, respectively) and 30 months old (Fig. 6.11 B, D and F, 
respectively). Likewise, the expression levels of adiponectin receptors ADIPOR1 and 
ADIPOR2 in skeletal muscles of adolescent and adult animals were similar between control 










































































































































































Figure 6.11 Expression of INSR, IRS1, IRS2, ADIPOR1 and ADIPOR2 in skeletal muscle of adolescent 
and adult control (C) and prenatally androgenised (TP) animals, as quantified by qRT-PCR. Results are 
presented as mean + S.E.M. 
Chapter 6 Role of FGF21 and irisin in the metabolic phenotype 
193 
6.3.10 Expression of ER stress markers in muscle tissue  
Considering the importance of ER stress in the regulation of FGF21 and overall muscle 
function, the expression of selected markers of ER stress was determined. There were no 
differences in the expression of ATF4, ATF6, EIF2AK3 and ERN1 in muscles of 11 months 









































































































































Figure 6.12 Expression of selected ER stress markers in skeletal muscle of adolescent and adult control 
(C) and prenatally androgenised (TP) animals, as quantified by qRT-PCR. Results are presented as mean 
+ S.E.M. 
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6.3.11 Prenatal androgenisation does not affect levels of irisin 
Considering that irisin is a regulator of insulin sensitivity and energy metabolism we aimed to 
assess the levels of circulating irisin and expression of muscle FNDC5 in adolescent and adult 
animals.  There was no difference in the expression of FNDC5 in muscles between control and 
TP-exposed animals at 11 months and 30 months (Fig. 6.13 A). Correspondingly, there was 
no difference in circulating levels of irisin between control and TP-exposed animals at 11 
months and 30 months of age however, there was a significant increase in levels of circulating 
irisin in adult PCOS-like animals as compared with adolescent PCOS-like sheep, but this 
difference was not observed in control animals (Fig. 6.13 B). In addition, there was no 
correlation between muscles expression of FNDC5 and serum irisin level in both adolescent 
and adult animals (Fig. 6.13 C and D, respectively). 
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Figure 6.13 A-B) Expression of FNDC5 in skeletal muscles and level of circulating irisin in adolescent 
and adult control (C) and prenatally androgenised (TP) animals. C-D) Correlation of FNDC5 expression 
in skeletal muscle with circulating levels of irisin in adolescent and adult control and TP-exposed 
animals. P value of <0.05 was considered as statistically significant. Results are presented as mean + 
S.E.M, where * signifies a P<0.05. 
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6.3.12 Correlation of irisin with metabolic parameters  
Finally, the association of irisin with selected metabolic parameters was assessed in both 
adolescent and adult animals. There were no associations between levels of circulating irisin 
and fasting insulin in both adolescent and adult animals (Fig. 6.14 A and E, respectively). 
Nevertheless, there was a positive correlation between circulating irisin and omental fat 
(P<0.01; r=0.72; Fig. 6.14 B) and leptin (P<0.05; r=0.59; Fig. 6.14 C) in adolescent, but not 
in adult sheep (Fig. 6.14 F and G, respectively). In addition, there was a negative correlation 
between circulating irisin and FFA in adolescent ewes however, this did not reach statistical 
significance (P=0.052; r= -0.55; Fig. 6.14 D). The potential association between plasma irisin 
and FFA was not present in adult animals (Fig. 6.14 H).  
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Figure 6.14 Association of circulating irisin with selected metabolic parameters in adolescent and adult 
control and prenatally androgenised animals 
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6.4 Discussion 
Adolescent prenatally androgenised sheep were hyperinsulinemic, and had early fatty-liver 
changes without difference in body weight and non-significant reduction in adiposity (411). 
These 11 months old sheep also had altered pancreas structure and function, with increased β-
cell number (431,596). In addition, these adolescent PCOS-like animals had decreased 
adipocyte differentiation in SAT, decreased plasma levels of leptin and adiponectin, and 
elevated FFA, as described in chapter 3. In adulthood (30M), PCOS-like sheep become obese, 
had adipose tissue hypertrophy in SAT, hyperinsulinemia and lipodystrophy, however, at this 
age, there was no difference in hepatic TG content between control and PCOS-like animals, 
as discussed in chapter 5. Furthermore, these adult prenatally androgenised sheep had a 
decreased amplitude of PPT, independent of obesity, which was paralleled by diminished 
noradrenaline levels and reduced expression of thermogenic genes in adipose tissue, as 
demonstrated in chapter 4.  This chapter provides evidence that hepatic and circulating levels 
of FGF21 are decreased in prenatally androgenised sheep in puberty (11M) and during the 
transition from adolescents to adulthood (22M) however, there is no difference in the FGF21 
level between adult (30M) PCOS-like sheep and controls. FGF21 is a hormone primarily 
secreted from the liver, which regulates glucose metabolism, insulin sensitivity, lipid 
homeostasis and energy balance. Therefore, it is likely that changes in its expression might 
contribute to the perturbed metabolic phenotype, as observed in adolescent and adult 
prenatally androgenised sheep.  
Indeed, experimental animals with a complete absence of FGF21, FGF21 knockout (FGF21-
KO) mice, had a comparable metabolic profile to adolescent PCOS-like sheep. FGF21-KO 
mice were normoglycemic, hyperinsulinemic and insulin resistant, and displayed pancreatic 
islet hyperplasia and increased β-cell proliferation (864). In addition, FGF21-KO mice were 
prone to delayed weight gain, displaying mild obesity with increased volume of adipose tissue, 
after 24 weeks on standard diet (834). Interestingly, it was demonstrated that weight gain in 
FGF21-KO mice was attributed to increased caloric intake and decreased energy expenditure 
(834). FGF21-KO mice have also been shown to have increased fat content in their livers when 
compared with wild type (WT) mice, when fed a methionine- and choline- deficient diet, a 
known inducer of murine non-alcoholic liver steatohepatitis, or a ketogenic diet (833,834,865). 
However, treatment with exogenous FG21 has been shown to reverse hepatic steatosis in diet-
induced obesity (DIO) mice (866). In addition, FGF21 deficient mice had decreased 
expression of hepatic PGC1α, a gene involved in fatty acid β-oxidation, which was 
independent of PPARA levels (834). Likewise, our results show that adolescent PCOS-like 
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sheep have an increased hepatic TG content, but normal hepatic PPARA expression and trend 
towards decreased expression of PPARGC1A, as demonstrated in chapter 5, which further 
positively correlated with hepatic FGF21 levels. Interestingly, wild type mice with alcohol or 
diet induced fatty liver were shown to have elevated hepatic and serum FGF21 levels 
(865,867). However, it was demonstrated that FGF21-KO mice had more pronounced hepatic 
fat accumulation and inflammation, and a more pronounced decrease in PGC1α activity, when 
compared with wild type mice with alcoholic liver disease, independent of food and alcohol 
intake (867). Likewise, some studies described that adult humans with alcoholic fatty liver 
disease, NAFLD or NASH had higher levels of circulating FGF21 (868-870). Moreover, a 
study by Yan et al. reported that although serum FGF21 increased progressively with the 
increase of hepatic fat content in adults with mild to moderate hepatic steatosis, when hepatic 
fat content increased significantly, FGF21 levels started to decline (870). Similar findings were 
described in study by Dushay et al., were hepatic FGF21 mRNA expression was significantly 
elevated in NAFLD but not in NASH (820). Confounding findings were reported in the 
paediatric population, where no differences in FGF21 were reported in children with NAFLD 
(871-873). A study in obese adolescents with NAFLD, with average age 14-15 years and BMI 
34-35, found increased levels of FGF21 (871), whereas no association was found in children 
with average age 12-13, and BMI of 28 (874). Interestingly, in study of children with biopsy-
proven NAFLD, with a median age 10-11, and BMI of 25, FGF21 and hepatic KLB expression 
were inversely correlated with NAFLD progression and fibrosis (872). These findings indicate 
that FGF21 might be differentially expressed in paediatric and adult populations with NAFLD. 
In addition, it is likely that link between FGF21 and NAFLD in children might be modified 
by age and BMI. It has been suggested that FGF21 might participate in the defence against 
hepatic steatosis and hepatoxicity, and that increased levels of FGF21 in alcoholic liver 
disease, NAFLD and NASH might be an adaptive response against lipid dysregulation and ER 
stress, through increased FGF21 dependent lipid oxidation (834,867). Correspondingly, it was 
demonstrated that treatment with recombinant FGF21 in mice attenuated hepatic fat 
accumulation and inflammation, and upregulated the expression of hepatic PPARGC1A 
(875,876). These findings could suggest that decreased FGF21 levels in adolescent PCOS-like 
sheep might be a primary rather than secondary factor contributing to hepatic TG 
accumulation.  
Adolescent, prenatally androgenised sheep had normal body weights but a non-significant 
reduction in omental fat when compared with control animals (411). In addition, in chapter 3, 
we demonstrated that these 11 months old PCOS-like sheep had a diminished mRNA 
expression of genes regulating adipogenesis in SAT, with decreased leptin mRNA, which was 
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further paralleled by reduced circulating leptin levels. We have now established that there is a 
positive correlation between circulating leptin levels with hepatic and plasma FGF21 levels in 
adolescent sheep. Furthermore, there was a positive association between omental fat and 
circulating FGF21 in 11 months old sheep. Leptin is an adipokine, which correlates with body 
fat, and  maintains homeostatic control of body weight, adipose tissue mass and energy balance 
through a negative feedback on hypothalamus, protecting individuals from the risks associated 
with having too little or too much adipose tissue (877). In addition, leptin plays an important 
role in glucose and lipid regulation, reproduction, inflammation and tissue remodelling (878). 
Mutations in leptin or its receptor, cause massive obesity in mice and humans, and leptin can 
effectively treat obesity in leptin-deficient patients (877). In addition, patients with 
lipodystrophy syndromes and anorexia nervosa display leptin deficiency (878). Numerous 
studies demonstrated that body weight and body fat mass correlate with plasma FGF21 in 
anorexic, lean, overweight and obese adult subjects (879-881). Similar findings were reported 
in the paediatric population, showing that in both lean and obese children, circulating FGF21 
is correlated to BMI and leptin levels (874). In addition, it was reported that weight loss in 
obese children and adults resulted in a corresponding decrease in FGF21 concentrations 
(873,882). Furthermore, it was found that leptin can directly regulate FGF21 levels, both in 
vitro and in vivo (883). However, it was also documented that mice with induced 
lipodystrophy, and patients with congenital or acquired lipodystrophy, who are characterised 
by nearly complete absence of adipose tissue and negligible leptin levels, insulin resistance, 
lipodystrophy and hepatic steatosis, have increased circulating FGF21 levels (884,885). This 
might at first be counterintuitive, however both lipodystrophy and obesity are characterised by 
diminished leptin action and comparable metabolic complications. Thus, increased circulating 
levels of FGF21 in both pathological conditions might be a physiological mechanism trying 
to restore metabolic homeostasis.  In support of this view is the finding by Veniant et al., 
demonstrating that lipodystrophic mice were refractory to the effects of recombinant FGF21 
treatment however, treatment with leptin, or transplantation of adipose tissue, fully restored 
FGF21 responsiveness in those lipodystrophic mice (886). Therefore, these results indicate 
that leptin potentiates the action of FGF21, and that fully functional adipose tissue is a 
requirement for FGF21 efficacy. Adolescent PCOS-like sheep had only mildly decreased 
adiposity and clearly did not display as severe metabolic phenotype as subjects with 
lipodystrophy, it is therefore possible, that decreased circulating leptin levels, which 
corresponded with low volume of omental fat and diminished adipogenesis in SAT, underlined 
decreased hepatic and circulating FGF21 levels in those animals. 
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FGF21 plays an important role in adipose tissue biology. It has been shown that FGF21 binds 
preferentially to FGFR1 and its β-klotho co-receptor, which are abundantly expressed in WAT, 
and regulate variety of metabolic processes including lipogenesis, lipolysis, and fatty acid 
oxidation (817,887). In addition, detectable expression of FGF21 in murine and human 
adipocyte cultures were reported, and further shown to be induced by in vitro treatment with 
TZDs (812,825,888). The TZDs, rosiglitazone and pioglitazone, represent a class of insulin-
sensitising drugs that activate PPARG, a master regulator of adipocyte differentiation (889). 
However, it was demonstrated that treatment of mice with rosiglitazone upregulated FGF21 
mRNA and protein expression in WAT, but it did not result in a corresponding increase in 
circulating FGF21, whereas treatment with a PPARA agonist, induced hepatic expression of 
FGF21 with a corresponding increase in plasma levels, suggesting an autocrine and paracrine 
role of FGF21 in WAT and an endocrine role for hepatic FGF21 (812). Here, we report 
undetectable levels of FGF21 in ovine WAT. Likewise, some studies have reported that there 
is no detectable expression of FGF21 in human WAT samples (820,823). Considering that 
FGF21 expression in murine WAT has been found to be maximal four hours after feeding, as 
opposite to hepatic FGF21, which is highest during the fasting state, these discrepancies could 
be attributed to different nutritional status of subjects during sample dissection (812). 
Subsequently, our ovine adipose tissue samples were excised after overnight fast followed by 
15 min of a IVGGT test, which could potentially explain why FGF21 expression in WAT was 
undetectable. Alternatively, these results might suggest that WAT plays an insignificant role 
in contributing to circulating FGF21 levels in humans and sheep. However, WAT has been 
demonstrated to be an important target of FGF21 action in both, mice and humans. Mice with 
reduced body fat, unlike wild-type mice, are refractory to anti-diabetic treatment with 
recombinant murine FGF21, while transplantation of WAT into these lipodystrophic mice 
restores FGF21 responsiveness, thus confirming a significant role of WAT in FGF21 biology 
(886). It was reported that FGF21-KO mice had increased adipocyte size in subcutaneous and 
epidydimal WAT, increased lipid stores in BAT, accompanied by decreased mRNA 
expression of the lipolytic enzymes, ATGL and HSL (834,890). In addition, there was reduced 
mRNA expression of PLIN1, PPARA, PPARD, PPARG, PPARGC1A and PPARGC1B in 
WAT of FGF21-KO mice (834). Correspondingly, FGF21 transgenic mice have reduced 
adipocyte size and increased mRNA expression of lipolytic enzymes ATGL and HSL (891). 
However, conflicting results were reported by Dutchak et al., where lean FGF21-KO mice 
were described to have mild lipodystrophy with a significant decrease of total fat mass and 
reduced amounts of epididymal, subcutaneous, mesenteric, retroperitoneal and interscapular 
WAT as well as BAT, independent of body mass and calorie intake (812). The authors reported 
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that decreased adiposity in those FGF21-KO mice was a consequence of decreased adipocyte 
size rather than a reduction in number of adipocyte (812). Interestingly, Dutchak et al. 
examined the differentiation of preadipocytes derived from FGF21-KO mice and found that 
were was no difference in the expression of CEBPB, CEBPD and FGFR1 however, PPARG, 
CEBPA and KLB mRNA levels were significantly decreased in adipocytes from FGF21-KO 
mice (812). The results from this study matches our findings, where adolescent PCOS-like 
sheep had reduced hepatic and circulating FGF21 levels, diminished mRNA expression of 
FGF21 co-receptor KLB, as well as decreased PPARG, CEBPA and CEBPB expression, with 
no difference in the expression of FGFR1 and CEBPD, in SAT. KLB has been found to be a 
crucial component of FGF21 signalling, as when fed a high fat diet, mice with total knockout 
of β-klotho (KLB-KO) are refractory to exogenous FGF21 treatment, and show no changes in 
energy homeostasis, glucose and lipid control, as opposite to control mice (806). Ding et al. 
demonstrated that a selective reduction of KLB mRNA  in adipose tissue by 70% resulted in a 
corresponding decrease in the KLB protein and complete absence of FGF21-stimulated 
insulin-sensitising effect in obese mice (892). Correspondingly, overexpression of β-klotho in 
adipose tissue in mice sensitised those animals to endogenous FGF21 treatment, reduced 
plasma FFA and provided protection from diet-induced obesity (893). In addition, it was 
demonstrated that overexpression of β-klotho in adipose tissue, resulted in upregulated 
expression of SLC2A4, PPARGC1A, DIO2 and UCP1 in BAT, and after treatment with 
exogenous FGF21, mice overexpressing KLB in adipose tissue, had increased magnitude of 
caloric expenditure and increased expression of genes associated with enhanced thermogenic 
capacity (COX7A, COX7B and UCP1) in WAT, when compared with control mice (893). 
Interestingly, it was demonstrated that TNF-α inhibited β-klotho expression, but did not impact 
FGFR1 expression, in vitro in murine and human adipocytes, and impaired FGF21 action 
(894). Therefore, the increased TNF mRNA expression in SAT of adolescent PCOS-like 
sheep, as reported in chapter 3, could potentially result in decreased KLB expression. This in 
turn, could indicate that decreased circulating FGF21 levels, together with reduced signalling 
in SAT, due to decreased expression of KLB, in 11 months old prenatally androgenised sheep, 
might further contribute to decreased adipogenesis in SAT, as reported in chapter 3. In support 
of this hypothesis are the findings by Dutchak and colleagues, who reported that PPARG and 
KLB mRNA in adipocytes from FGF21-KO mice were restored by the addition of recombinant 
FGF21 in the differentiation medium in vitro. Furthermore, it was demonstrated that lipid 
accumulation, together with the expression of fatty acid binding protein, aP2, and various 
lipogenic proteins, were reduced in FGF21-KO adipocytes, and again partially restored when 
treated with FGF21 (812). In addition, in vitro and in vivo experiments demonstrated that 
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FGF21 increases PPARG transcriptional activity by suppressing its sumoylation, a type of 
post-translational modification (812). Interestingly however, when those FGF21-KO mice 
were fed a 10 week high-fat diet, they had significantly elevated levels of plasma FFA, 
increased hepatic TG and increased adipocyte size when compared with control mice fed the 
same high-fat diet (812). This indicates that FGF21-KO mice might have a decreased capacity 
for storage in adipose tissue, and as a consequence, when fed a high fat diet, develop adipocyte 
hypertrophy and dyslipidaemia. This metabolic phenotype parallels our ovine model of PCOS, 
where adolescent sheep have decreased FGF21 levels with decreased adipogenesis in SAT, 
whereas adult prenatally androgenised sheep, despite being on normal diet, present with 
obesity, increased FFA and adipocyte hypertrophy in SAT. Therefore, this notion supports a 
potential role of FGF21 in the metabolic dysregulation of the ovine model of PCOS.  
In chapter 3, we provided evidence that in adolescent PCOS-like sheep, ADIPOQ mRNA 
expression was significantly decreased in SAT, which was further reflected in low circulating 
level of adiponectin. Adiponectin, like FGF21, regulates glucose and lipid metabolism, and 
insulin sensitivity, however, while the liver is the main source of serum FGF21, adiponectin 
is produced and secreted entirely by adipose tissue, but acts mostly on liver and muscles (895). 
Interestingly, adiponectin is also a downstream effector of PPARG and is crucial in mediating 
some of the therapeutic benefits of TZDs (896,897). In addition, in vitro studies demonstrated 
that human and murine adipocyte treatment with FGF21 results in increased ADIPOQ mRNA 
expression and adiponectin secretion however, pre-treatment with PPARG antagonists 
partially reduced FGF21-induced adiponectin secretion (815). Correspondingly, the 
circulating levels of adiponectin were lower in FGF21 KO mice, and treatment with 
recombinant FGF21 resulted in a significant increase in serum adiponectin (815), while 
rosiglitazone administration induced adiponectin levels in control mice but this response was 
significantly attenuated in FGF21-KO mice (812). In addition, it was shown that a single 
administration of recombinant FGF21 acutely reduced circulating glucose, insulin and 
triglyceride levels in diet induced obese mice and db/db diabetic mice however, in adiponectin 
knockout mice (ADNKO), the magnitude of the beneficial effects of FGF21 treatment was 
significantly reduced (815,816). Holland et al. demonstrated that one week of FGF21 
treatment is able to promote weight loss in both control and ADNKO mice, however ADNKO 
mice, lost significantly less body weight than control mice, with 39% of fat mass in control 
mice versus 6.7% in ADNKO mice (816). These differences in fat mass reduction were 
accompanied by decreased energy expenditure in ADNKO mice (816).  In addition, in contrast 
to control mice with high fat diet-induced hepatic steatosis, ADNKO mice were refractory to 
chronic FGF21 treatment and showed no improvement in hepatic steatosis, no decrease of 
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hepatic inflammation, and no reduction in the expression of genes involved in lipogenesis 
(815). Similarly, chronic administration of FGF21 decreased intramuscular TG accumulation 
and increased insulin sensitivity in muscles in control mice, however these muscular effects 
of FGF21 treatment were abrogated in ADNKO mice (815). The link between FGF21 and 
adiponectin is further emphasised by a randomised, double-blinded clinical trial, where 
administration of a FGF21 analogue, to overweight and obese patients and non-human 
primates with T2DM, resulted in significantly increased circulating adiponectin levels in dose-
dependent manner (898,899). Moreover, it has been demonstrated that KLB-KO mice, when 
treated with exogenous FGF21, show no increase in plasma adiponectin as opposite to control 
mice (806). In addition, we have found a strong correlation between expression of KLB with 
PPARG and ADIPOQ in WAT of both adolescent and adult animals. Surprisingly, despite a 
comparable expression pattern of FGF21 and adiponectin in adolescent and adult animals, we 
did not find a direct correlation between circulating FGF21 and adiponectin levels. However, 
regardless of the plausible genetic and pharmacological evidence supporting the strong 
metabolic link between FGF21 and adiponectin, the interrelationship between these two 
metabolic regulators under pathological conditions is less straightforward. As documented in 
numerous studies, in overweight and obese subjects, and in metabolic syndrome, adiponectin 
levels are decreased while FGF21 increased (101,820,823,880,900,901). Few potential 
mechanisms can be proposed to explain this discrepancy. Adiponectin expression is 
suppressed by inflammation, oxidative and ER stress, which are elevated during the 
progression of obesity (902,903). In contrast, FGF21 has been shown to be upregulated during 
metabolic stress, however, the protective mechanism induced by FGF21 might be insufficient 
to counteract the suppressive factors on adiponectin synthesis, such as increased local 
inflammation in adipose tissue (838). In addition, obesity has been found to be a FGF21 
resistant state, with decreased β-klotho expression in WAT documented in diet-induced obese 
rodents, non- human primates and obese humans (822,823,894,904). Therefore, this could 
potentially explain why synthesis of adiponectin is diminished despite increased levels of 
FGF21 in obesity.   
Circulating FGF21 levels were reported to be increased in patients with hyperinsulinemia and 
insulin-resistant states, such as impaired glucose tolerance (IGT) and T2DM, and to correlate 
inversely with whole-body insulin sensitivity (905-909). Numerous studies reported that 
FGF21 is detectable in murine and human muscles and might be directly regulated by insulin 
(907,909,910), and that FGF21 mRNA is increased in skeletal muscles of IGT and T2DM 
patients (908). It was shown that FGF21 mRNA expression in muscle biopsies significantly 
increased after four hours of insulin infusion in healthy young men during hyperinsulinemic-
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euglycemic clamp studies, and that there was a positive relationship between fasting insulin 
and muscle FGF21 levels (907). In addition, some authors reported that FGF21 secreted from 
muscles might be a source of increased plasma FGF21 in states of insulin resistance. Although 
we detected FGF21 mRNA expression in ovine muscles, levels were low and there was no 
difference in the expression of muscle FGF21 between adolescent control and PCOS-like 
animals, despite evident hyperinsulinemia in prenatally androgenised sheep. Similar results 
were reported by Mashili et al. showing that expression of FGF21 mRNA in muscles were 
low and there was no difference in mRNA levels between normoglycemic subjects and 
patients with T2DM, suggesting that elevated plasma FGF21 in insulin resistant humans is 
unrelated to skeletal muscle expression (909). In addition, the authors demonstrated that BMI 
was the strongest independent variable that was positively correlated with plasma FGF21 
levels in patients with T2DM (909). We did not find a correlation between fasting insulin and 
plasma FGF21 in adolescent and adult animals, which indicates that adiposity might be the 
strongest predictor of levels of circulating FGF21 in the ovine model of PCOS. In addition, 
there was no correlation between muscle FGF21 and plasma FGF21 levels. Similar results 
were reported by Hojman et al., who suggested that FGF21 expression in muscles is more 
likely to have a paracrine role (907). It was demonstrated that FGF21 treatment of cultured 
myotubes resulted in glucose uptake and increased mRNA expression protein abundance of 
SLC2A1, but not SLC2A4, and that insulin and FGF21 treatment had additive effects on 
glucose transport in myotubes in vitro (909). These results suggest that FGF21 resistance, even 
with normal insulin signalling could contribute to decreased insulin sensitivity in muscles, 
therefore we also investigated insulin and FGF21 receptivity in muscle tissue and found that 
there was no difference in the expression of INSR, but both KLB and FGFR1 tended to be 
lower in 11 months old PCOS-like sheep, although this did not reach statistical significance. 
Interestingly, impaired FGF21 signalling in muscles of patients with impaired glucose 
tolerance and T2DM was reported (908). In addition, similar findings were confirmed in 
muscle biopsies from DIO mice, including decreased β-klotho and phosphorylated FGFR 
levels (908). We also noticed that expression of PPARG was significantly downregulated and, 
as in WAT, there was a significant positive correlation between KLB and PPARG expression 
in adolescent animals. Furthermore, there was no difference in the expression of IRS1 and 
IRS2 and selected ER stress markers, potentially suggesting that insulin signalling is not 
disturbed in muscles of adolescent prenatally androgenised animals however, this should be 
further investigated at protein level. Nevertheless, decreased PPARG expression might 
indicate a degree of insulin resistance, since PPARG has an important role in the maintenance 
of skeletal muscle insulin action, despite overall low PPARG expression in that tissue (911). 
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It was demonstrated that mice with a targeted deletion of PPARG in skeletal muscle developed 
glucose intolerance and progressive insulin resistance, with secondary insulin resistance in 
liver and adipose tissue (912,913). In addition, mice with disrupted muscle PPARG expression 
had impaired glucose uptake with altered IRS1 and protein kinase B (PKB) phosphorylation, 
but normal gene and protein expression of IRS1, PKB and GLUT4 (913). 
It was demonstrated that FGF21 can act directly on liver, and regulate hepatic oxidation of 
fatty acids and gluconeogenesis in an autocrine and paracrine manner (810). It was reported 
that expression of hepatic KLB in children with NAFLD was decreased, and this was directly 
correlated with circulating levels of FGF21. Therefore, expression of FGF21 receptors in a 
liver might be a limiting factor for FGF21 expression. Mice treated with exogenous FGF21 
had increased hepatic phosphorylation of MAPK1/3 and fibroblast growth factor receptor 
substrate 2 (FRS2) (810). In addition, it was found that in the liver FGF21 treatment induced 
expression of genes regulating gluconeogenesis and fatty acid oxidation, G6PC, PEPCK and 
PPARGC1A and reduced levels of circulating insulin and FFA however, only at 
pharmacological doses, whereas low doses of FGF21 had only effect on expression of PGC1-
α and plasma FFA (810). Therefore, to further investigate the potential causes and 
consequences of decreased hepatic and circulating FGF21 in adolescent PCOS-like sheep, we 
have studied hepatic expression of the four isoforms of FGFR receptors (FGFR1-4) and the β-
klotho co-receptor. No differences in the expression of KLB, FGFR2, FGFR3 and FGFR4 
were found, however, there was a trend towards decreased expression of FGFR1 in the liver 
of adolescent prenatally androgenised sheep. Interestingly, it was postulated that decreased 
expression of FGFR1 in the liver is the limiting factor for the FGF21 signalling within this 
tissue (822). It was found that, DIO mice had normal expression of KLB, FGFR2, FGFR3 and 
FGFR4 but decreased expression of hepatic FGFR1, and this was associated with impaired 
response to low-dose FGF21 treatment and diminished MAPK1/3 phosphorylation (822). 
Although, we did not investigate phosphorylation of MAPK1/3, we found no difference in the 
expression of G6PC and PEPCK in the livers of adolescent PCOS-like sheep however, there 
was a non-significant decrease in PPARGC1A expression indicating that there might be limited 
FGF21 signalling within liver of adolescent PCOS-like animals. Based on our results we are 
unable to determine whether potentially decreased expression of FGFR1 in liver of adolescent 
PCOS-like sheep is a cause or the consequence of diminished hepatic and circulating FGF21, 
but it remains possible that decreased expression of hepatic FGFR1 might contribute to 
decreased expression of FGF21. Nevertheless, decreased expression of FGFR1 in the liver and 
KLB in SAT might indicate some degree of FGF21 resistance in adolescent PCOS-like sheep. 
This is a noteworthy finding as studies in mice fed a high-fat diet for 4 weeks demonstrated 
Chapter 6 Role of FGF21 and irisin in the metabolic phenotype 
205 
that FGF21 resistance precedes obesity and FGF21 overexpression (822), whereas FGF21 KO 
mice fed a normal chow diet displayed mild late-onset obesity. Taken together, these results 
indicate that decreased FGF21 levels in adolescent PCOS-like sheep, together with potential 
FGF21 resistance in liver, muscle and SAT might contribute to the onset of obesity and 
metabolic phenotype in adult PCOS-like sheep.  
There is a lot of confounding data regarding FGF21 expression in paediatric population. Some 
studies reported that, as in adults, in children and adolescents, FGF21 correlated with BMI, 
adiposity and leptin levels (871,874,914), but others did not (915,916). Interestingly, the 
largest study to date, evaluating the role of FGF21 in nearly 20,000 school children aged 6-18, 
found that FGF21 levels were reduced in association with obesity and correlated negatively 
with insulin resistance, HOMA-IR scores and components of metabolic syndrome, and 
positively with adiponectin levels, independent of BMI, age and gender (917). In addition, the 
authors reported that children with increased FGF21 had a healthier metabolic profile, 
including lower systolic pressure, fasting insulin and HOMA-IR scores, and higher HDL 
cholesterol, whereas children with diminished FGF21 had highest proportion of insulin 
resistance and metabolic syndrome (917). These results suggest that in the paediatric 
population, a relative FGF21 deficiency, rather than resistance, may play a role in the 
pathogenesis of insulin resistance, components of metabolic syndrome and low levels of 
adiponectin, independent of obesity (917). This is in agreement with study by Alisi et al. 
showing that paediatric NAFLD is associated with FGF21 deficiency, independent of BMI 
(872). Moreover, it was demonstrated that FGF21 levels differed by gender in puberty, with 
circulating FGF21 levels declining during puberty in boys, but not girls, and being lower than 
in girls throughout puberty (917). Corresponding results were reported in the study on FGF21 
expression in Danish children and adolescents, showing that boys had significantly decreased 
levels of circulating FGF21 (915), and in the study by Reinehr et al., although the difference 
in FGF21 levels between boys and girls did not reach statistical significance in this report 
(874). Moreover, similar finding were reported in adults, showing that females have increased 
circulating FGF21, when compared to males (918). Therefore, it is possible that sex hormones 
might have a role in regulation of FGF21 expression. However, to our knowledge, there are 
no investigations directly addressing the effect of sex hormones on FGF21 expression or 
potential sexual dimorphism in FGF21 concentration in either adults or children. To date only 
one study has investigated the role of FGF21 in reproduction. It was reported that female, but 
not male, transgenic mice overexpressing FGF21 were infertile (891). Further investigation 
revealed that FGF21 overexpression in female mice resulted in delayed puberty, anovulatory 
hypogonadism with normal FSH and decreased LH levels, suggesting that abnormal FGF21 
Chapter 6 Role of FGF21 and irisin in the metabolic phenotype 
206 
levels might contribute to reproductive aberrations (919). Unfortunately, there are no studies 
investigating FGF21 levels in adolescent girls with PCOS. The only comparable study was 
conducted on lean adolescent girls with hyperinsulinemic androgen excess and reported that 
those girls have normal levels of circulating FGF21 as compared to BMI- and age- matched 
controls (920). Interestingly, the authors also reported that plasma FGF21 inversely correlated 
with BMI and adiposity in those girls (920), again demonstrating that association between 
FGF21 and body composition might be different in paediatric and adult populations. Adult 
women with PCOS were reported to have comparable FGF21 levels with BMI-matched 
controls (921,922). However, one study noted that although lean PCOS had comparable 
circulating FGF21 levels to BMI-matched controls, obese patients with PCOS had elevated 
plasma FGF21 as compared with obese controls (923). Nonetheless, the same study also 
reported that plasma FGF21 levels were correlated with BMI, body fat mass and percentage, 
waist circumference and plasma insulin but did not with estradiol and FAI (923). Therefore, 
authors concluded that increased plasma FGF21 levels, as observed in obese women with 
PCOS were associated with metabolic but not hormonal disturbances (923).  
Interestingly, comparable to women with PCOS, in adulthood, there was no statistical 
difference in the levels of hepatic and circulating FGF21 between controls and PCOS-like 
sheep. However, whereas levels of FGF21 in control animals remained stable across 
adolescence and adulthood, there was an increase in hepatic and serum FGF21 in adult PCOS-
like animals as compared with levels during puberty, although this was not statistically 
significant. These changes perhaps reflect more rapid changes in body mass and adiposity in 
PCOS-like animals as compared with controls, during the transition from adolescence to 
adulthood. As stated earlier, adult PCOS-like sheep were obese with a non-significant increase 
in omental fat when compared with controls. However, since we investigated the levels of 
FGF21 at the early onset of obesity in adult PCOS-like animals, based on the published data 
regarding FGF21 and obesity, it can be speculated that with the predicted progress of obesity 
in those sheep there would be a corresponding increase in FGF21 levels, potentially resulting 
in FGF21 resistance. Although, there was no correlation between levels of circulating leptin 
with hepatic and plasma FGF21, as observed in adolescent animals, there was a negative 
relationship between volume of omental fat and circulating FGF21, indicating that animals 
with the lowest levels of FGF21 had the highest levels of omental fat, and suggesting that that 
decreased levels of FGF21 in adolescent might predispose to obesity in adulthood. 
Alternatively, the increase in FGF21 level in adult PCOS-like sheep could be a homeostatic 
response to progressing metabolic distress observed in those animals. Interestingly, we have 
not found evidence of FGF21 resistance in adult prenatally androgenised sheep, despite 
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obesity, again supporting the hypothesis that this might be a transition window with an early 
stage of obesity. In contrast to adolescent PCOS-like animals, adult sheep had normal levels 
of KLB and FGFR1 expression in SAT, inguinal and neck adipose tissue, and significantly 
increased expression in VAT. In addition, as described in chapter 3, adult prenatally 
androgenised sheep, had comparable levels of PPARG and ADIPOQ expression in both SAT 
and VAT. However, like in adolescent animals, there was still a significant correlation in 
expression of KLB with PPARG and ADIPOQ, indicating a potential regulatory feed forward 
loop in expression of those gens.  
Normalised plasma FGF21 levels together with improved FGF21 sensitivity in the adipose 
tissue of adult PCOS-like animals was an unexpected finding. Especially considering the 
obesity and decreased expression of thermogenic genes in adipose tissue, reported in chapter 
4. Several studies reported that FGF21 plays an important role in the regulation of 
thermogenesis and expression of thermogenic genes, and that treatment with FGF21 can 
induce browning of WAT in vitro and in vivo (818,841,918,924). It was found that circulating 
FGF21 correlated positively with cold-induced non-shivering thermogenesis and BAT activity 
in humans (819,918). In addition, it was demonstrated that thermogenic activation induces 
FGF21 expression and release in BAT (925). However, the majority of those studies were 
conducted during cold exposure, whereas our study was conducted at thermoneutrality. 
Notably, Hanssen et al. reported that adult females had a trend toward increased circulating 
FGF21 compared to males at thermoneutrality, however, this difference become statistically 
significant during cold exposure (918). In addition, a study by Veniant et al. documented that 
FGF21 induced weight loss only in lean mice, but not in DIO obese mice, kept at standard 
housing temperatures, however, it was inefficient at thermoneutrality and was independent of 
WAT browning and UCP1, suggesting that FGF21 may only play a significant role at lower 
temperatures (926). The authors also noted that the beneficial effects of FGF21 treatment on 
body weight and energy expenditure were related to significant induction of PPARGC1A 
(926). This finding was also reported by others, showing that FGF21 regulates energy 
metabolism by activating the AMPK-SIRT1-PPARGC1A pathway, and that the role of FGF21 
during cold exposure is to enhance PGC-1α protein levels within thermogenically active fat 
depots (818,927,928). Interestingly, in chapter 4, it was reported that in IAT of adult PCOS-
like animals there was decreased expression of UCP1, UCP2 and UCP3 but significantly 
increased expression of PPARGC1A and normal SIRT1, which could be a compensatory 
mechanism stimulated by FGF21. However, in SAT of adult prenatally androgenised sheep 
there was decreased expression of UCP1 together with PPARGC1A and SIRT1, which could 
suggest that this depot might be less sensitive to FGF21 action. Alternatively, since we did not 
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investigate expression of FGF21 in IAT, it is possible that that FGF21 was expressed and 
secreted from that fat depot, which might subsequently stimulate thermogenic genes in a 
paracrine fashion. Interestingly, it was reported that the expression of FGF21 in BAT is 
stimulated by noradrenaline (925), and in the in vitro study of human neck adipocytes it was 
demonstrated that FGF21 can induce heat production only after noradrenaline exposure (841). 
In chapter 4, we provided evidence that noradrenaline levels were significantly decreased in 
all fat depots studied, apart from IAT, where noradrenaline levels were comparable between 
controls and adult PCOS-like animals. This cross-talk of noradrenaline and FGF21, could 
perhaps explain why adult PCOS-like animals have decreased postprandial thermogenesis and 
decreased expression of thermogenic genes despite normal FGF21 levels and sensitivity. Of 
note, more recent studies reported that FGF21 acts centrally to induce energy expenditure and 
that signalling to adipose tissue is not required to decease body weight, therefore, to fully 
understand the role of FGF21 in thermogenesis FGF21 signalling in the brain should be also 
investigated (929,930). 
In the liver of adult PCOS-like animals, there were no significant differences in the expression 
of KLB and FGF receptors when compared with controls, although a trend for increased 
expression of FGFR1, FGFR4 together with PPARGC1A (chapter 5) was observed, however, 
likely due to large variation and small number of PCOS-animals, this did not reach statistical 
significance. Interestingly, it has been demonstrated that FGF21 induces the expression of 
PPARGC1A and causes corresponding increases in FFA oxidation and gluconeogenesis (931). 
This association of FGF21, PPARGC1A and FFA oxidation could contribute to increased 
levels of hepatic triglycerides in adolescent PCOS-like animals, but comparable levels of 
hepatic fat with control animals in adult PCOS-like sheep, as demonstrated in chapter 5.  
Interestingly, in muscles there was increased expression of both FGF21 and FGFR1, together 
with trend for increased PPARG expression. Since, FGF21 in skeletal muscles has been shown 
to be upregulated by insulin, and to be elevated in humans with hyperisnulinaemia (907), it is 
possible that persistent hyperisulinaemia in PCOS-like animals, might be a driving factor for 
increased expression of FGF21 in muscles of adult prenatally androgenised sheep. Moreover, 
increased FGF21 in skeletal muscles was documented in patients with IR and T2DM (908), 
however, there was normal expression of INSR, IRS1 and IRS2, together with trend for 
increased expression of PPARG in skeletal muscle of adult PCOS-like animals. These results 
could indicate normal insulin sensitivity in that tissue although this should be further 
investigated at a protein level. In addition, it seems that compared to adolescent PCOS-like 
animals, adult sheep have improved insulin and FGF21 sensitivity in skeletal muscle. 
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Paradoxically, this could be attributed to increased body weight and adiposity in those adult 
PCOS-like animals. It is possible that, in adolescent PCOS-like animals, due to decreased 
storage capacity in SAT, there was increased concentration of TG in skeletal muscles and 
hence decreased insulin sensitivity, but hypertrophic expansion of SAT and increasing volume 
of omental fat in adult animals could lead to redistribution of intramuscular fat back to adipose 
tissue, and as a consequence, improved insulin sensitivity. Unfortunately, we did examine 
distribution of intramuscular triglycerides in adolescent or adult animals and this requires 
further investigation. Alternatively, since PPARG in skeletal muscles mediates upregulation 
of lipid use in skeletal muscle (912), the trend towards increased expression of PPARG in 
skeletal muscle of PCOS-like animals could indicate an improved use of fatty acids in skeletal 
muscles, and subsequently this could lead to improved insulin and FGF21 sensitivity. 
Interestingly, it was demonstrated that mice with muscle specific PPARG deficiency were 
insulin resistant and developed increased adiposity (912). Therefore, it is possible that 
decreased PPARG expression in adolescent PCOS-like sheep, resulting in lower utilisation of 
FFA, could promote insulin resistance in adolescent animals, and in addition, could contribute 
to increased adiposity in adult animals. This in turn, could restore insulin sensitivity in skeletal 
muscles and as a consequence lead to increased expression of PPARG, as observed in adult 
PCOS-like animals. Overall, these data provide evidence that adult PCOS-like sheep, in 
contrast to adolescent prenatally androgenised animals, have an increased sensitivity for 
FGF21. This might be a homeostatic mechanism in response to obesity, hyperinsulinemia and 
increased FFA in those animals. However, there were no correlations in the levels of 
circulating FGF21 with FFA, insulin or adiponectin. In summary, adolescent PCOS-like sheep 
have decreased plasma FGF21 together with decreased sensitivity for this hepatokine in SAT, 
liver and muscle, whereas adult prenatally androgenised sheep have opposite profile, with 
normalised levels of circulating FGF21 and increased sensitivity for this hormone in VAT, 
muscles and liver, which might be physiologic response trying to reverse deteriorating 
metabolic phenotype in those animals.  
In this chapter, we also analysed the role of irisin in metabolic profile of adolescent and adult 
sheep. Irisin, a myokine, is a cleaved and secreted product of the FNDC5 protein, induced by 
physical exercise, that was recently implicated in regulating browning of WAT, increasing 
thermogenesis, reducing insulin resistance and improving glucose homeostasis (840,841,850). 
In DIO mice, FNDC5 overexpression in skeletal muscle and increased circulating irisin levels 
enhanced energy expenditure, increased weight loss, improved insulin sensitivity and reduced 
hyperlipidaemia, hyperglycaemia and blood pressure (840,932). Overexpression of FNDC5 in 
skeletal muscles, significantly increased UCP1 and PPARGC1A levels and reduced adipocyte 
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diameter in the SAT, but not in the VAT or BAT, in both control and DIO mice, perhaps 
indicating a adipose depot-specific sensitivity to the metabolic action of irisin (932). However, 
it was also reported that FNDC5 mRNA, FNDC5 protein and irisin levels in skeletal muscle, 
but not in the circulation, were higher in obese mice than those in control mice (932). In 
addition, results in humans are inconsistent concerning the potential beneficial role of irisin in 
metabolism and energy expenditure. Circulating irisin levels were reported to be higher 
(859,933), and lower (850,852), in subjects with metabolic syndrome and patients with insulin 
resistance and T2DM. Furthermore, similar level of circulating irisin were found in people 
with active and non-active BAT (934). Our results showed that there were no differences in 
the expression of FNDC5 in skeletal muscle or circulating irisin between control and PCOS-
like sheep, in adolescence and adulthood. This finding could simply indicate that control and 
PCOS-like animals had same level of activity, since majority of the studies confirmed that 
irisin is an exercise stimulated myokine (933,935,936). However, there was a significant 
increase in levels of circulating irisin, but not the expression of FNDC5 in skeletal muscle, in 
adult PCOS-like animals when compared with adolescent prenatally androgenised sheep, and 
this change was not present in control animals. This sharp increase in levels of irisin in PCOS-
like animals could reflect increasing adiposity associated with significantly increased body 
weight in those animals, since adipose tissue might be an additional source of irisin, which 
could also explain why irisin correlates with BMI, adipose tissue mass, and is elevated in 
obesity (858,861,862,937). Alternatively, this could be a homeostatic response to counteract 
obesity, as irisin was also demonstrated to increase energy expenditure and browning of WAT, 
and to enhance lipolysis and correct glucose and lipid metabolic derangements associated with 
obesity (840,932). However, it should be noted that irisin plays important role in shivering 
induced thermogenesis as it is secreted from muscles during cold exposure (841). Therefore, 
the potential role of irisin in postprandial thermogenesis of adult animals, investigated in this 
thesis, might not be relevant. Conversely, comparable levels of circulating irisin in control and 
PCOS-like animals might indicate that animals were exposed to the same environmental 
temperatures. Nevertheless, it was demonstrated that irisin induced glucose and FFA uptake, 
and SLC2A4 expression in adipocytes and myocytes (938), therefore, a significant change in 
circulating irisin may well be an adaptive response in an attempt to improve insulin sensitivity 
in adult PCOS-like animals. However, we did not find a correlation between levels of fasting 
insulin and irisin, in adolescent and adult animals. This was a surprising finding since, majority 
of previous studies reported positive correlation between irisin and fasting insulin, HOMA-IR 
and other parameters of the metabolic syndrome, indicating a regulatory feedback mechanism 
or possibly suggesting a degree of irisin resistance (938-940). 
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We also did not find a correlation between mRNA expression of FNDC5 in skeletal muscles 
and circulating irisin. This could be due post-translational modification and proteolytic 
cleavage of FNDC5 protein before releasing it into circulation therefore, as noted by some 
researchers, FNDC5 mRNA does not always correlate with levels of irisin and mRNA 
expression alone should be interpreted very cautiously (857). Alternatively, difference in the 
expression in muscle FNDC5 mRNA and circulating irisin could be attributed to other tissues 
secreting this factor. As reported by others, adipose tissue might also secrete irisin. 
Interestingly, it was demonstrated that in rats irisin is released from mature adipocytes mainly 
in SAT, and to lesser extent in VAT, but not BAT (863). Therefore, the increased irisin levels 
in adult PCOS-like animals, compared with adolescents, could reflect decreased number of 
mature adipocytes in SAT in adolescent sheep and the progressive hypertrophy in SAT in adult 
animals. Unfortunately, we did not investigate expression of FNDC5 in adipose tissue. 
Nevertheless, we found a positive correlation between levels of circulating irisin with omental 
fat and leptin, but only in adolescent, not adult animals. Perhaps this observation could be 
attributed to dysfunctional adipose tissue in obesity, or this could suggest that irisin levels are 
modified by additional factors in adult animals. Similar findings were reported by Sanchis-
Gomar et al., where no correlation of irisin with BMI, or other metabolic parameters in obese 
and diabetic patients were found (941). We also found a negative relationship of irisin with 
fasting FFA in adolescent, but not in adult animals. Comparable findings were reported by 
Volzke et al., showing that there was a negative correlation of irisin with LDL cholesterol and 
TG in general population (942). Interestingly, it was recently reported that FNDC5 mRNA 
was expressed in the brain and in the reproductive neuroendocrine axis, and that circulating 
irisin could be modified by diet and hormonal status (943). In addition, a sexual dimorphism 
in the concentrations of irisin in children, adolescents and adults was reported, with females 
having higher levels than men (844,944,945). It was therefore suggested that sex hormones 
may play a role in regulating irisin concentration (844).  
In women with PCOS, just like in general population, the findings regarding levels of 
circulating irisin are inconsistent. Serum irisin has been demonstrated to be increased (946-
949), decreased (950), or no difference was found (951,952). In addition, some reported an 
association of irisin in patients with PCOS with BMI, obesity and hyperinsulinemia 
(946,947,951,953), whereas others found no association with these metabolic factors 
(950,952). In addition, few studies documented association of irisin with hormonal status of 
women with PCOS, including hyperandrogenemia and levels of LH (946,947,950,953). 
Evidently there are a lot of discrepancies between the above studies. It is likely that differences 
in clinical characteristics of study cohort, such as age, BMI, degree of insulin resistance, and 
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variations in sex hormones, may explain some of them. Furthermore, medication commonly 
prescribed to women with PCOS could also alter the results. For example, it was demonstrated 
that metformin promotes irisin release from skeletal muscles (954). In addition, as recently 
reviewed by Perakakis et al. some of the ELISA kits used for the measurement of irisin 
concentrations had low accuracy with cross-reactivity with non-specific serum proteins (938). 
Therefore, further research is needed to provide comprehensive understanding of the potential 
role of irisin in PCOS.  
In summary, our study provide evidence that there is no difference in the concentration of 
irisin between control and PCOS-like animals in adolescence and adulthood, it is therefore 
unlikely that irisin might play an important role in metabolic profile of the ovine model of 
PCOS. However, it should be noted, that due to small number of animals and large result 
variation, our results might not be fully representative.
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Prenatal programming can be defined as the ability of the intrauterine environment to induce 
phenotypic alterations in the developing fetus. Hormonal imbalance during this crucial 
developmental window may programme permanent changes in the differentiating tissues of 
the individual that will determine further development but also its reproductive and metabolic 
capacity as well as predisposition for health and disease. It has been proposed that the adult 
PCOS phenotype is likely to be programmed by exposure of female fetuses to increased 
androgens in utero. Results documented in this thesis present further evidence to support this 
hypothesis and provide better understanding into the some of the mechanisms underlying the 
metabolic problems associated with the syndrome 
It has been documented that some aspects of metabolism are sexually dimorphic. Differences 
between males and females in glucose and lipid metabolism, peripheral insulin sensitivity and 
liver metabolism have been described (955-957). Furthermore, males have been reported to 
have increased prevalence of dyslipidaemia (958), NAFLD (959), IR (960), T2DM (961), 
CVD (962), and lower concentration of adiponectin than females (499). Body fat distribution 
patterns are also sexually dimorphic. In general, women are characterised by a higher body fat 
percentage than men, with a greater proportion of adipose tissue in gluteal and femoral regions, 
while men tend to have more adipose tissue accumulated in the VAT and decreased volume 
of SAT (125,142). Since visceral obesity is considered a significant risk for metabolic 
complications (123,124) while preferential gynoid fat distribution is believed to be protective, 
those differences in adipose tissue distribution have been postulated as one of the main causes 
underlying those sex-specific differences in aforementioned metabolic problems (960,961).  
What induces adipose tissue differences between males and females? Sex hormones play an 
important role in the regulation of body fat distribution. This may be particular important with 
regards to androgens, which inhibit preadipocyte differentiation, modulate adipocyte function 
and affect the size and distribution of adipose tissue (142). Women with PCOS have been 
reported to have increased central and decreased gynoidal adipose tissue, thus displaying an 
android pattern of adipose tissue distribution (145,963). In addition, adipose tissue 
dysfunction, independent of obesity, have been described in PCOS (964). Furthermore, there 
is evidence showing link between partial lipodystrophy and PCOS (221-226). Moreover, 
women with PCOS have been found to have higher prevalence of IR, T2DM, NAFLD, 
dyslipidaemia, and lower concentration of adiponectin than BMI-matched women in general 
population. These observations raise several questions: are women with PCOS programmed 
to have male-like adipose tissue distribution and function and therefore increased prevalence 
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of male-like metabolic problems? If so, what are potential mechanisms underlying this? When 
do these changes occur? Is this an androgenic effect? 
Animal models of PCOS provide great opportunity to answer some of those questions. 
Numerous studies documented that exposure of ovine female fetuses to increased levels of 
androgens in utero result in many reproductive, neuroendocrine and metabolic characteristics 
that mirror those of PCOS women. Previous data generated in our lab demonstrated that 
adolescent prenatally androgenised sheep display some of the PCOS features, including 
enhanced capacity for androgen synthesis in theca cells and adrenal glands, accompanied by 
global upregulation of steroidogenic genes, fatty liver, hyperinsulinemia, however, without 
confounding factors such as hyperandrogenemia or obesity. Likewise, pre-pubertal and early-
pubertal daughters of PCOS mothers have been shown to have some of metabolic 
characteristic of adult PCOS, including hyperinsulinemia and decreased adiponectin however,  
independent of obesity and without increased androgen levels, therefore indicating that 
metabolic changes might precede development of hyperandrogenism (286,965). 
Our results demonstrate that adolescent sheep that were exposed to increased androgens in 
utero through maternal injections had decreased expression of markers of adipogenesis in 
SAT. Further, we provide evidence that perturbed adipogenesis in SAT is likely to be a 
consequence of prenatal androgen exposure, as in the model of direct fetal injections with 
steroids, only adolescent sheep that were exposed to androgens in fetal life, but not those 
treated with estrogen or glucocorticoids, displayed perturbed adipogenesis in SAT. Moreover, 
we show that altered adipogenesis correlates with onset of puberty, as changes in expression 
of adipogenic markers were not evident during fetal and early life, neither in adulthood. So 
why these changes are only apparent during puberty?  
Studies demonstrated that throughout life there are two main waves of adipocyte 
differentiation, fetal life and puberty. Adipocyte proliferation tends to decline by the end of 
the gestation, and adiposity is increased primarily by filling of predetermined adipocytes until 
puberty, after which another intensified proliferation and maturation of adipocytes occurs (68). 
Therefore, the total number of adipocytes that the individual will have as an adult is set during 
puberty, although, the differentiation potential of preadipocytes into mature adipocytes is 
present throughout life, and depends on the body energy status and the storage needs. 
However, in adult life, the capacity of preadipocytes to become fully functional mature 
adipocytes declines (69,70). Consequently, diminished adipogenesis results in decreased 
storage capacity of adipose tissue, which might cause accumulation of lipids in non-adipose 
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tissues, such as liver and muscles, and subsequently leads to lipotoxicity, insulin resistance 
and metabolic perturbations (72,73). Therefore, inability of an individual to increase adipose 
cell number results in the development of hypertrophic adipocytes, which might increase risk 
of metabolic diseases (74). And although, adipogenesis in PCOS patients has not been 
investigated, there is growing evidence of decreased adipogenesis in SAT from insulin 
resistant individuals and subjects with abdominal obesity (473-475). Therefore, what are the 
potential mechanisms underlying decreased adipogenesis in adolescent PCOS-like sheep? 
Insulin and androgens, both suggested to be important contributors to the PCOS phenotype, 
affect adipose tissue function, however, insulin and androgens have opposing regulatory 
effects on the differentiation of preadipocytes to adipocytes. There is evidence that insulin 
stimulate adipogenesis (227), while androgens inhibit preadipocyte differentiation (228), thus 
hormonal and metabolic derangements are likely to play an important role in adipose tissue 
function in PCOS. However, since adolescent prenatally androgenised sheep were not 
hyperandrogenemic, this raises a question whether androgens prime SAT in fetal life to be a 
male-like and whether there are any additional factors contributing to that? Wang et al. 
documented that in subcutaneous adipocytes from PCOS patients, expression of testosterone 
synthesising enzymes was higher, while expression of aromatase was decreased, suggesting 
increased local androgen action (229). In addition, PCOS women and daughters of women 
with PCOS were reported to have increased 5α-reductase activity (966,967), therefore there is 
possibility that adolescent PCOS-like sheep might have increased peripheral androgen 
metabolism. In addition, as discussed throughout this thesis adolescent PCOS-like sheep were 
hyperinsulinemic with some features of insulin resistance and had decreased gene expression 
of proteins associated with insulin signalling in SAT, although insulin sensitivity was not 
assessed in those animals. Nevertheless, puberty is associated with decreased insulin 
sensitivity (968). Insulin has a stimulatory effect on adipogenesis, therefore it is likely that 
mixture of androgenic programming combined with a degree of insulin resistance, so prevalent 
in PCOS girls and adult women might lead to decreased adipogenesis in SAT. Furthermore, 
adolescent PCOS sheep, like adolescent and adult women with PCOS had decreased 
adiponectin, which as discussed in chapter 3 is likely due to dysfunctional SAT. In turn, low 
levels of adiponectin, an insulin sensitising adipokine might lead to further deterioration of 
insulin sensitivity. Therefore, what are the potential consequences of decreased adipogenesis 
in SAT during puberty? 
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Decreased adipogenesis indicates lower capacity of SAT to safely store fat. Adolescent 
prenatally androgenised animals had increased circulating fasting FFA, most likely due to 
decreased adipogenesis and perturbed insulin signalling in SAT, but independent of body 
weight and central adiposity, as reviewed in chapter 3. Circulating FFA comprise majority of 
hepatic lipids in NAFLD. Chapter 5 provide evidence that these adolescent PCOS-like sheep 
had upregulated expression of genes involved in hepatic FA uptake and de novo lipogenesis, 
but normal expression of genes associated with FA oxidation, which might elucidate the 
mechanisms involved in increased hepatic lipid accumulation in those animals and perhaps 
explaining increased prevalence of NAFLD in adolescent and adult women with PCOS, which 
is again independent of obesity. Moreover, since increased FFA have been demonstrated to 
directly stimulate pancreatic insulin secretion (269), this delivers an additional link between 
perturbed adipogenesis in SAT and hyperinsulinemia PCOS-like animals and potentially 
women with PCOS. Further, as discussed in chapter 3, SAT represents about 80% of total 
body adipose tissue and given set adipocyte number in adulthood, decreased SAT adipogenesis 
in adolescents would result in decreased storage capacity in adulthood and increased lipid 
storage in already developed adipocytes, resulting in hypertrophy. Indeed, adult PCOS-like 
sheep have decreased total number of adipocytes in SAT with a corresponding increase in 
large, hypertrophic adipocytes. Enlarged adipocytes are less insulin sensitive and individuals 
with hypertrophic adipocytes in SAT are more insulin resistant than people with comparable 
adiposity but smaller adipocytes (469-471). Moreover, there are reports documenting 
adipocyte hypertrophy in women with PCOS (230), thus potentially explaining high 
prevalence of insulin resistance, independent of obesity (189). Conversely, adipocyte 
hypertrophy is not only strongly associated with increased release of lipid content and insulin 
resistance but also with increased inflammation, which might further impair insulin sensitivity 
and dysregulate adipokine secretion. Again, results documented in chapter 3, show increased 
expression of pro-inflammatory genes in that fat depot. In addition, it can be speculated that 
due to the combination of diminished storage capacity and adipocyte hypertrophy in SAT of 
adult PCOS-like sheep, there is a physiological response to increase buffering capacity of other 
adipose tissue depots, represented by increased omental fat volume in those animals, although 
not statistically significant, as discussed in chapter 3. This in turn however, might explain 
normalised hepatic fat content in those adult PCOS-like ewes, which was paralleled by normal 
levels of hepatic FA uptake, as demonstrated in chapter 5, suggesting that fat from the liver 
might be redirected back to adipose tissue. In addition, the early increase in volume of VAT, 
likely paralleled by increased adipokines secretion, might contribute to normalised levels of 
leptin and adiponectin in those young adult sheep, as demonstrated in chapter 3. Although it 
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is tempting to speculate that once the capacity of visceral adipose tissue would become 
saturated, there would be an increase in inflammation in that depot paralleled by dysregulated 
adipokine secretion, while FA would be shunt back to the liver, resulting in NAFLD once 
again. This in turn would result in progressive deterioration of insulin sensitivity and overall 
metabolic profile, as it is normally observed in adult women with PCOS. In addition, due to 
decreased capacity of SAT, even normal caloric intake could be relatively excessive, resulting 
in SAT hypertrophy, subsequent increase in central obesity and insulin resistance.  
Decreased adiponectin and leptin in adolescent prenatally androgenised sheep are likely to be 
additional consequences of decreased adipogenesis in SAT. As discussed throughout this 
thesis, these adipokines regulate broad spectrum of metabolic aspects, including insulin 
sensitivity, FFA oxidation, energy expenditure and appetite, therefore dysregulated secretion 
of those adipokines is likely to contribute to perturbed metabolic profile in adolescent PCOS-
sheep. In addition, there is evidence showing that adiponectin can suppress theca cell androgen 
synthesis, and therefore decreased levels of adiponectin in PCOS may contribute to enhanced 
capacity of ovarian androgen production, as previously demonstrated in our ovine model of 
PCOS and typically seen in women with PCOS. 
Moreover, decreased leptin levels in adolescent prenatally androgenised sheep might, at least 
partially, be responsible for decreased expression of hepatic FGF21 in those animals, as 
discussed in chapter 6. FGF21 regulates a broad spectrum of metabolism, including insulin 
sensitivity, lipid homeostasis and energy balance. Therefore, it is likely that changes in its 
expression might contribute to the perturbed metabolic phenotype, as observed in adolescent 
prenatally androgenised sheep. In addition, adolescent PCOS-like sheep displayed decreased 
FGF21 sensitivity in SAT and liver, which could in turn, contribute to decreased adipogenesis 
paralleled by reduced adiponectin, and decreased FA oxidation, respectively. Conversely, 
adult prenatally androgenised sheep display an opposite FGF21 profile, with normalised levels 
of circulating FGF21 and increased sensitivity for this hormone in VAT, muscles and liver, 
which might represent a homeostatic mechanism trying to reverse deteriorating metabolic 
phenotype in those adult animals. 
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Figure 7.1 An adolescent PCOS-like model of prenatally androgenized sheep. Adolescent PCOS-like 
sheep have decreased adipogenesis in SAT, likely due to combination of increased androgens and 
insulin resistance, accompanied by decreased circulating concentrations of leptin and adiponectin. 
Decreased storage capacity of SAT results in increased concentration of FFA in circulation, which is 
countered by increased FFA uptake into liver resulting in hepatic fat accumulation. In addition, 
adolescent prenatally androgenized sheep have decreased concentration of FGF21, likely due to 
decreased leptin levels, and decreased expression of KLB in SAT further augmenting expression of 
PPARG and adiponectin. Decreased adiponectin levels might result in decreased insulin sensitivity and 
increased ovarian androgen synthesis while reduced leptin concentration might lead to increased 
appetite resulting in an increased body weight in future.  
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Does perturbed adipogenesis only affect white adipose tissue? In chapter 3, we provide 
evidence of reduced expression of PRDM16 in adolescent SAT, which is associated with 
programming of brown/beige adipocyte development. Further, in chapter 4 we show that there 
is significantly reduced thermogenic potential of adipocytes in three different adipose tissue 
depots of adult PCOS-like animals, further paralleled by decreased noradrenaline 
concentration. Is there evidence for a role of sex hormones in programming brown and beige 
adipose tissue function?  
Besides the well-known impact of sex hormones on WAT distribution, there is some evidence 
that there is also sexual dimorphism in distribution and function of BAT. Women have been 
found to have greater volume of BAT, than men (146,147). Further, studies on rodents 
demonstrated that, there is sex-specific composition of lipids in BAT (148), mitochondrial 
function and sensitivity of BAT to adrenergic stimulation (149). Female mice are more 
responsive to browning of WAT during β-adrenergic stimulation than males (150), and have 
higher UCP1 expression in BAT (151). 
What are potential consequences of diminished thermogenic potential of brown/beige 
adipocytes in an ovine model of PCOS? Epidemiological studies provide a clear evidence for 
the close link between PCOS and obesity, showing that 38%–88% women with PCOS are 
overweight or obese (207), and conversely, that the prevalence of PCOS is high in unselected 
obese female population, with up to 28% of all cases (208,209). Therefore, considering the 
high prevalence of obesity in PCOS, some authors postulated that women with PCOS might 
have a unique predisposition to obesity, and that these women might face additional barriers 
to effective weight management (210). Indeed, decreased basal BMR (211) and postprandial 
thermogenesis (212) have been reported in women with PCOS. In addition, Wright et al. 
reported that PCOS patients with a normal BMI consumed significantly lower number of 
calories (≥250 kcal/day) than BMI-matched controls, hypothesising that this might be 
necessary to prevent weight gain in those women (547). Moreover, obesity exacerbates 
symptoms of PCOS. It has been demonstrated that obesity can further increase prevalence of 
irregular menstrual cycles, amplify androgen concentrations and elevate risk for pregnancy 
complications (213). Obesity is also linked to a reduced response to infertility treatment (213). 
Conversely, even modest weight loss in obese PCOS women can significantly improve 
reproductive and metabolic characteristics of the syndrome (207).  
  
Chapter 7 General Discussion 
221 
What are the potential mechanism underlying increased prevalence of obesity in women with 
PCOS? In chapter 5 we have provided evidence that adult PCOS-like sheep have a decreased 
amplitude of PPT when compared with controls, measured through direct calorimetry, without 
a difference in basal body temperature, despite receiving the same caloric intake, and 
independent of obesity. What is more, we also reported that these PCOS-like sheep have 
increased time to reach their maximal postprandial temperature, again independent of obesity. 
These findings suggest that prenatally androgenised sheep have reduced capacity for energy 
expenditure, which may explain propensity for obesity in these animals, and potentially PCOS 
women. Interestingly, it has been shown that obese individuals, with a childhood history of 
obesity, have lower PPT, before and after weight loss, suggesting that thermogenic defect may 
be a cause rather than a consequence of obesity (578). 
Is decreased thermogenic potential of adipose tissue solely responsible for decreased PPT in 
adult PCOS-like sheep? This is unlikely. As discussed in chapter 5, there are possible 
additional factors, including potential peripheral, and/or central insulin resistance. As 
reviewed in chapter 5, a study on intranasal insulin administration reported that administration 
of intranasal insulin increased PPT by 17% when compared to placebo, thus showing that 
efficient brain insulin signalling is necessary for whole-body energy flux (604). Since 
peripheral insulin resistance and obesity has been shown to be associated with reduced insulin 
sensitivity in central nervous system (605-607), it can be speculated that prenatally 
androgenised sheep and women with PCOS might also have decreased central insulin 
sensitivity, which in turn might be accountable for reduced sympathetic outflow, decreased 
noradrenaline and consequently diminished PPT, although currently there is no data to support 
this hypothesis.  
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Figure 7.2 An adult PCOS-like model of prenatally androgenized sheep. Adult PCOS-like sheep have 
increased body weight, adipocyte hypertrophy in SAT, which is further associated with increased 
expression of inflammatory markers and elevated concentration of circulating FFA, likely due to 
saturation of SAT storage capacity. Further, due to combination of reduced SAT storage capacity and 
adipocyte hypertrophy there is a physiological response to increase buffering capacity of VAT volume, 
potentially explaining normalised hepatic fat content in those adult PCOS-like animals. Adult prenatally 
androgenized animals have decreased PPT independent of obesity and further associated with 
hyperinsulinemia and decreased thermogenic potential of brown/beige adipocytes represented by 
diminished expression of UCP1.  
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Are there any advantages of decreased subcutaneous and increased visceral adiposity, as well 
as diminished energy expenditure in women with PCOS? It is highly speculative however, 
some authors postulated that women with PCOS might have reproductive advantage during 
the times of food deprivation. It has been suggested, that although women with PCOS have 
increased likelihood of being obese and anovulatory during times of normal or excess food 
availability however, they start to ovulate after body weight loss, therefore displaying a 
selective advantage by being able to reproduce during periods of food shortage when other 
women become anovulatory (969,970). Therefore, considering this hypothesis, it can be 
suggested, that since adipocytes in the VAT depot exhibit increased rate of lipolysis during 
adrenergic stimulation, thus being more metabolically active, having increased visceral 
adiposity during times of food deprivation would provide more accessible energy stores, while 
decreased PPT would offer improved energy utilisation during those adverse conditions. 
Can we potentially prevent some of the metabolic problems associated with PCOS? As 
discussed, pre-puberty or early puberty in girls at high risk of developing PCOS, such as 
daughters of PCOS mothers, would be an ideal time for early clinical intervention to 
ameliorate the metabolic phenotype of adult PCOS. Adiponectin could be used as an early 
marker of metabolic perturbations while treatment with FGF21 analogs or TZDs could be used 
as preventative measure. Although, FGF21 therapeutics represents an attractive opportunity 
for novel drug development treating metabolic disorders, these drugs are still under scrutiny 
(971), while TZDs, a class of antidiabetic drugs, which are also potent stimulators of adipose 
tissue differentiation, have been already successfully used as therapeutic measure in adult 
women with PCOS (972), therefore suggesting a more realistic approach.  
Can findings described in this thesis be extrapolated to our understanding of PCOS in human? 
As discussed throughout this thesis, midgestational exposure of fetal sheep to increased levels 
of androgens results in clinically realistic model of PCOS. In sheep, fetal development, 
metabolism, thermogenesis, histological location of WAT and BAT as well as adult body 
weight parallel humans. Adolescent daughters of PCOS mothers have increased levels of 
insulin and reduced levels of adiponectin as compared with age and BMI-matched controls 
(482). Moreover, it was found that metabolic perturbations often precede reproductive 
compilations in adolescent PCOS (448). Further, adult women with PCOS were reported to 
have hypertrophic adipocytes in SAT (472), increased insulin and decreased adiponectin 
levels, independent of obesity when compared with control women (489). In addition, women 
with PCOS are often overweight or obese, and were reported to have reduced PPT, which 
further correlated with insulin resistance. We now provide further evidence that ovine model 
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of PCOS mirrors metabolic complications of adolescent and adult women with PCOS, 
including increased insulin, decreased adiponectin and hepatic fat accumulation that precede 
obesity and reproductive problems in adolescents as well as obesity, decreased PPT and 
adipose tissue dysfunction in adulthood. Moreover, we deliver mechanistic understanding into 
the aforementioned metabolic pathophysiology of PCOS from puberty to adulthood and 
therefore, we believe that findings documented in this thesis can be extrapolated to our 
understanding of PCOS in human. 
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7.1 Future work 
The studies demonstrated in this thesis investigated the effects of prenatal androgens on 
metabolism of adolescent and adult PCOS-like sheep. However, to fully understand and 
characterise an adult ovine model of PCOS further studies are required. Especially, a 
reproductive phenotype of those adult PCOS sheep should be studied, including ovarian 
morphology, but also hormonal profile. Although, we have undertaken a several attempts to 
measure androgens in those animals, these were unsuccessful, due to very low concentration 
of those hormones in adult ewes.   
Further, to fully characterise metabolic profile in adolescent and adult sheep, a study of insulin 
signalling on protein and phosphorylation level should be carried, especially in muscle, liver 
and adipose tissue. In addition, performing a hyperinsulinemic-euglycemic clamp to assess 
overall insulin sensitivity in those animals would be highly recommended. Moreover, to fully 
understand consequences of perturbed adipogenesis, quantification a fat deposits in skeletal 
muscle should be performed. Preferably, morphological analysis of SAT and VAT should be 
also conducted in future. Finally, to fully understand impact of steroids on adipogenesis a 
peripheral steroid metabolism should be assessed, through analysis of gene and protein 
expression of steroidogenic enzymes in WAT. 
Regarding postprandial thermogenesis study, a protein expression of brown/beige adipocyte 
markers in different adipose tissue depots should be validated by western blotting. In addition, 
an impact of muscle thermogenesis on overall energy expenditure should be assessed in our 
model. Finally, an effect of intranasal insulin administration on energy expenditure in adult 
control and PCOS-like animals should be studied. 
Lastly, since a period of possible intervention has been established, this could be utilised to 
study an effect of potential treatments, FGF21 analogs and TZDs, on adolescent PCOS-like 
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